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(i)   
Abstract  
 
Changes in the microenvironment have been implicated in the transition of pre-
invasive ductal carcinoma in-situ (DCIS) to invasive breast cancer. Normal 
myoepithelial cells have a tumour suppressor phenotype but they are altered in 
DCIS and ultimately lost with transition to invasive cancer. A consistent 
change in DCIS is up-regulation of the integrin αvβ6 in myoepithelial cells. 
Preliminary observations identified a correlation between myopeithelial αvβ6 
and an increased peri-ductal inflammatory infiltrate.  
The hypothesis of this study is that the altered myoepithelial phenotype 
influences the peri-ductal inflammatory environment, which in turn mediates a 
pro-apoptotic effect on myoepithelial cells contributing to their loss. 
To investigate this, the inflammatory infiltrate was characterised in a series of 
DCIS tissue in relation to αvβ6 status. This demonstrated significantly higher 
levels of CD4+ve and FOXP3+ve T cells around αvβ6+ve DCIS ducts 
compared to αvβ6-ve ducts (P=<0.01), suggesting an increase in Treg cells. In-
vivo, Matrigel plugs containing injected into the flanks of female C57/Blk6 
normal mice generated influx of higher levels of CD4+ve cells (p=0.005) and 
FOXP3+ T cells (p=0.007) in the presence of αvβ6+ve myoepithelial cells 
compared to αvβ6-ve cells, supporting the findings in human tissue samples.  
Since Treg cells produce TRAIL that can induce apoptosis, we investigated the 
influence of αvβ6 on myoepithelial cells on the levels of TRAIL in T cells and  
the hypothesis that αvβ6-positive myoepithelial ells may be more susceptible to 
TRAIL-induced apoptosis, leading to loss of the myoepithelial barrier. Firstly, 
levels of TRAIL in Jurkat and primary T cell populations co-cultured with β4 
                                                                                                             
 
(ii)   
or β6 myoepithelial cells were measured. This demonstrated a higher level of 
TRAIL in primary T cells co-cultured β6 myoepithelial cells compared to those 
co-cultured with β4 myoepithelial cells. β6+ve and β6-ve myoepithelial cells 
were exposed to TRAIL, and this demonstrated that TRAIL enhanced 
apoptosis, measured by cleaved PARP, in β6+ve cells. Furthermore, these cells 
showed loss of the anti-apoptotic protein Galectin-7, and knockdown of 
Galectin-7 in normal β6-ve myoepithelial cells rendered them more susceptible 
to TRAIL-induced apoptosis. In DCIS tissues, an inverse relationship between 
αvβ6 and Galectin-7 in myoepithelial cells was demonstrated, and Cytokine 
Array analysis showed that αvβ6+ve myoepithelial cells express higher levels 
of IL-16, which has a role in Treg cell recruitment. 
Taken together these results suggest that expression of αvβ6 by myoepithelial 
cells in DCIS generates a tumour-promoter peri-ductal inflammatory infiltrate 
through altered cytokine release, is associated with reduced galectin-7 
expression and enhances myoepithelial cell apoptosis in response to TRAIL. 
This provides a potential mechanism by which myoepithelial cells may be lost 
during evolution of DCIS and so contribute to progression to invasive disease. 
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Introduction  
1.1 The Breast  
 
In simple terms the breast is a modified sweat gland, comprised of a lobular 
cluster of bilayered glands, known as acini, which have the potential to express 
milk, draining into bilayered ducts, distributed within a fibro-adipose stroma. 
The ducts branch repeatedly and ultimately give rise to the terminal ductal 
lobular units (TDLU) (Bissell, Radisky et al. 2002). Six to ten major ductal 
systems originate at the nipple. These ductal systems form independent but 
overlapping breast lobes, the size of which is variable. The terminal duct 
branches into a grapelike cluster of small acini to form a lobule. Each ductal 
system typically occupies over a quarter of the breast, and the systems 
extensively overlap each other.  
In cross section, mammary ducts and lobules have a similar structure, with a 
lining of a single layer of epithelial cells, surrounded by a low, flattened 
discontinuous layer of contractile cells containing myofilaments  
(myoepithelial cells), which are separated from stroma by the basement 
membrane (Figure 1.1) (Ross 2006). In the larger ducts the luminal cells are 
columnar whereas in the smaller ducts the luminal cells are cuboidal. The 
luminal cells produce milk and myoepithelial cells assist in milk ejection 
during lactation (Ross 2006). The lobules are separated by moderately dense 
collagenous interlobular stroma, whilst the intralobular stroma surrounding the 
ducts within each lobule is less collagenous and more vascular. The amount of 
glandular tissue is controlled by progesterone and oestrogen secretion during 
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the menstrual cycle (Ferguson and Anderson 1981), pregnancy, lactation 
(Salazar, Tobon et al. 1975) and menopause (Huseby 1954).  
         
 
    
 Figure 1.1Normal Breast Histology H&E Stain (Ross 2006) 
1.2 Cancer 
 
Cancer is a disease in which a group of cells show uncontrolled growth, 
invasion of surrounding tissue and sometimes spread to other organs in the 
body, primarily through lymphatics or the blood stream. The hallmarks of 
cancer were described many years ago by Hanahan and his colleagues and they 
characterised cancer development by six features (Figure 1.2) (Hanahan and 
Weinberg 2000) . These processes are apoptosis evasion, self-sufficiency in 
growth signals, insensitivity to antigrowth signals, sustained angiogenesis, 
tissue invasion and metastasis, and limitless replicative potential. Several years 
later, other hallmarks have been added to describe the cancer cell state 
including DNA damage, oxidative stress, proteotoxic stress, mitotic stress, 
metabolic stress and immune surveillance evasion (Hanahan and Weinberg 
2000). Recently, in 2010, instability of genes was presented by Negrini and his 
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colleagues as a further major factor involved in tumourogenesis (Negrini, 
Gorgoulis et al. 2010). 
 
 
Figure 1. 2 The cancer hallmarks 
 
The hallmarks that are involved in development of cancer (Hanahan and Weinberg 2000). 
1.3Breast cancer  
 
Breast cancer is the most frequent malignancy among women in Western 
countries and its incidence is still increasing. A number of factors are thought 
to contribute to this increase. Mammographic screening temporarily increased 
frequency by discovering incident, as well as prevalent cases. Higher exposure 
to risk factors for breast cancer, such as low and late parity, alcohol intake and 
use of hormonal replacement therapy could also contribute towards this 
increased incidence (MacMahon 2006). Depending on histological features, 
breast cancer can be classified into many subtypes. The first sub-classification 
is into pre-invasive versus invasive disease. Pre- invasive disease refers to a 
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neoplastic population that remains within the ductal-lobular framework and 
does not penetrate the surrounding stroma. This will be discussed in more 
detail below. Invasive disease is where the neoplastic population penetrates the 
basement membrane surrounding the ducts and lobules. Infiltrating ductal 
carcinoma (IDC) is the most common invasive breast cancer subtype, 
accounting for 70-80% of cases in most series (Kumar 2005). Infiltrating 
lobular carcinoma (ILC) is the second most common subtype accounting for 
~10% of cases, with the so-called “special types” making up the remaining 
10% of cases (Table 1.1). The importance of the morphological classification is 
that it impacts on patient prognosis, with IDC having poorest prognosis and the 
special types having a much better prognosis (Kumar 2005). More recently 
there has been an emerging molecular classification of breast cancer. This was 
first established by the report from Perou and his group (Perou, Sorlie et al. 
2000), which used gene expression arrays to define an intrinsic molecular 
subtype classification of breast cancer. This identified four major classes, later 
expanded to six subtypes, shown to have a significant impact on prognosis. 
Most recently, this complexity has been further increased, with the description 
of 10 “integrated subtypes” of breast cancer with differing clinical behaviour 
emphasising the enormous heterogeneity of the disease (Curtis, Shah et al. 
2012).  
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Table 1.1 Distribution of histological types of breast disease (Kumar 2005). 
 
Total cancers                                                                                           % 
In situ carcinomas                                                                               15-30 
Ductal carcinomas in situ                                                                         80 
Lobular carcinomas in situ                                                                       20 
 
Invasive carcinomas                                                                             70-85 
Infiltrating ductal carcinoma                                                                    79 
Infiltrating Lobular carcinomas                                                                10 
Tubular/cribriform carcinomas                                                                 6 
Mucinous (colloid)                                                                                    2 
Medullary carcinomas                                                                                2  
Papillary carcinomas                                                                                  1 
Metaplastic carcinomas                                                                            <1  
 
1.3.1 History of breast cancer  
The story of breast cancer is illustrated in the acts and artefacts of the human 
fight against illness. It is an epic tale that describes the concepts of disease 
from the work of evil spirits to the results of specific physical factors, and the 
healing arts from mysticism to modern science tools. The first reference to 
breast cancer was possibly written by Imhotep, the physician –architect in 
Egypt in the 30
th
 century and is included in The Edwin Smith Surgical Papyrus 
as an incomplete and fragmented copy of the original document (figure 1.3) 
(Breasted JH 1930). This text provides the earliest references to suturing of 
wounds and cauterization with fire drills. Moreover, it includes the diagnosis 
and treatment of eight cases of breast cancer.  Between 460-375 BC, 
Hippocrates describes some cases of breast cancer in detail. One of these cases 
was a woman who had breast carcinoma associated with bloody nipple 
discharge. He noted that when the discharge stopped the patient died so he 
concluded that there was a beneficial effect of the bloody discharge. Also he 
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linked menstrual cessation with breast cancer and sought to restore the 
menstrual cycle in young sufferers. His description of the course of advancing 
breast cancer sounds true today (De Moulin 1983). The invention of the 
microscope led to significant progress in breast histopathology. Johannes 
Muller (1801-1859) is the first one who reported that cancers are composed of 
living cells. Also, he noted the similarity of cells of primary breast cancer and 
its metastasis to the ribs, and that cancer cells had lost the characteristics of the 
normal cells. William S. Halsted, Professor of Surgery at Johns Hopkins 
Hospital in Baltimore (1852-1922), performed an operation which later became 
known as the radical mastectomy to treat breast cancer (Banks 1882). As the 
nineteenth century came to a close, the mastectomy seemed better than no 
treatment (Donegan 2002). Modified radical mastectomy was applied in the 
late 1940s (Patey and Dyson 1948).  Moreover, in the 1970s, a more limited 
surgical option came into use, focusing on removal of the tumor and a small 
amount of surrounding tissue known as lumpectomy. In 1985, the lumpectomy 
combined with radiation therapy became the accepted surgical approach 
(Cotlar, Dubose et al. 2003). Landmark advances in the diagnostic fields 
include the use of ultrasound started in the late 1970’s to aid differentiation 
between solid lesions and fluid-filled cysts.  More recently, Magnetic 
Resonance Imaging (MRI) was optimized and annual MRI is now 
recommended by the American Cancer Society for women at high risk for 
breast cancer, but it is an expensive procedure and only available in larger 
cities (Saslow, Boetes et al. 2007).  In addition, in 1895, discovery of X-ray led 
to mammography and formed the basis of radiotherapy for breast cancer. 
Radiotherapy was applied by Herman Goeth in Hamburg and Emile Herman 
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Grubbe in Chicago to treat cancer (De Moulin 1983). Endocrine surgery was 
replaced by hormonal treatment by Henry Starling in 1905, then by 
pharmacological methods of decreasing oestrogen secretion or its effects.  
Discovery of the oestrogen receptor (ER) in breast cancers by Elwood Jensen 
in Chicago in 1967 was another landmark in hormone therapy, differentiating 
the patients who could respond to this treatment from those could not (Jensen . 
1967). However, as medicine and science reach the third millennium, breast 
cancer remains a daunting problem, but it is becoming more clearly defined 
than ever before as the tools of the modern science are used to gain better 
understanding of the disease.  
 
 
Figure  1.3  Column VIII of The Edwin Smith Surgical Papyrus, a copy of the first 
document believed to describe cancer of the breast, circa 3000 BC. (Breasted, 1930). 
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1.3.2 Geographic variation 
 
Worldwide, every year more than a million people  are diagnosed with breast 
cancer which accounts for 23% of all new cases of cancer in women and  10% 
of all new cases of cancers overall (Ferlay, Parkin et al. 2010). The incidence 
varies considerably worldwide with the highest rate in North America. 
Conversely, Africa and Asia show the lowest rates of breast cancer (Ferlay, 
Parkin et al. 2010). Around 332,670 of new cases of breast cancer occur each 
year in Europe and 182,460 in the USA (Ferlay, Parkin et al. 2010). The risk of 
breast cancer increases in women who migrate from low to high risk countries 
suggesting a strong role for environmental or lifestyle factors (Ziegler, Hoover 
et al. 1993, Deapen, Liu et al. 2002). 
1.3.3 Risk factors 
 
There are many factors that influence the risk of breast cancer such as age, 
hormones, alcohol, obesity, physical activity and reproductive history. 
1.3.4 Age 
 
Age is the strongest risk factor for breast cancer development in which the risk 
is increased with advancing age (Table 1.2). This estimate is based on data for 
2008 in the UK (Sasieni, Shelton et al. 2011). 
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Table.1. 2 Estimated risk of developing breast cancer by age (Sasieni, Shelton et al. 2011) 
 
Estimated risk at birth up to and 
including: 
             UK (2008) 
Age 29 1 in 2,000 
Age 39 1 in 215 
Age 49 1 in 50 
Age 59 1 in 22 
Age 69 1 in 13  
Lifetime risk  1 in 8 
  
1.3.5 Reproductive history 
 
The rise in breast cancer in developed countries is partly explained by the fact 
that women in these countries have, on average, fewer children and limit the 
period of lactation. A study suggested that breast cancer can be reduced by 
more than half from 6.3% to 2.7% by increasing duration of breast feeding 
from 8 months  to 24 months  for each child (Collaborative Group on 
Hormonal Factors in Breast 2002).  
A meta-analysis study showed that the risk of breast cancer is 4% lower for 
every 12 months of breastfeeding (Collaborative Group on Hormonal Factors 
in Breast 2002). An estimated 3% of female breast cancers in the UK are 
linked to women breastfeeding each of their children for fewer than 6 months 
(Parkin 2011). Among BRCA1 mutation carriers, meta-analysis study showed 
that breast cancer risk may be lower in those breastfeeding for at least 12-24 
months. This study also demonstrated that the risk of breast cancer in BRCA2 
mutation carriers is not associated with breastfeeding (Pan, He et al. 2014).  
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1.3.6 Age of menarche 
 
The risk of breast cancer has consistently been associated with younger age at 
menarche. Estimates show the risk is decreased by 22% per five years delay in 
menarche (Garcia-Closas, Brinton et al. 2006).  
1.3.7 Age at menopause 
 
Early menopause reduces the risk of breast cancer.  Pre-menopausal women 
have a higher risk of breast cancer than women who have undergone 
menopause at the same age and with the same childbearing pattern. Risk rises 
by 3% for each year older at menopause (natural or induced by surgery) 
(Collaborative Group on Hormonal Factors in Breast 2012). 
1.3.8 Hormones 
 
I. Endogenous 
 
 The risk of breast cancer increases with higher level of endogenous hormones. 
Many studies have demonstrated that post-menopausal women with the highest 
levels of oestrogen and testosterone have 2-3 times the risk of women with the 
lowest levels (Key, Appleby et al. 2002). However, the relation between 
hormones levels and pre-menopausal breast cancer risk is less defined (Kaaks, 
Berrino et al. 2005, Eliassen, Missmer et al. 2006). Also higher levels of 
prolactin hormone are associated with an increased risk, especially for 
oestrogen-receptor-positive tumours (Tworoger, Eliassen et al. 2007). 
Furthermore, higher levels of insulin have been connected to elevated risk of 
breast cancer in postmenopausal women not taking hormone replacement 
therapy (Gunter, Hoover et al. 2009). This link between breast cancer and 
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insulin level might clarify the 20% raised risk of breast cancer in diabetic 
women (Larsson, Mantzoros et al. 2007). Moreover, insulin-like growth factor 
1 level shows a positive correlation with breast cancer risk (Key, Appleby et al. 
2010). 
 
II. Exogenous  
a) Oral contraceptives 
Use of the oral contraceptive is associated with an increased risk of breast 
cancer (Rosenberg, Boggs et al. 2010).  
 
b) Hormone Replacement Therapy (HRT) 
There is a 66% increased risk of breast cancer in women currently taking HRT 
compared to non users. This elevated risk is seen with use of oestrogen-
progesterone therapy rather than oestrogen only. In 2003, a study demonstrated 
that 20,000 extra breast cancer cases had arisen in women aged 50-64 years  in 
the UK over the previous decade due to use of HRT and three-quarters of these 
cases were as  a result of oestrogen-progesterone HRT use (Beral 2003). 
1.3.9 Breast density 
 
Breast density is considered a strong and independent risk factor for breast 
cancer (Oza and Boyd 1993, Tamimi, Byrne et al. 2007). Normal breast is 
composed of fat, connective tissue and epithelial tissue. Low breast density is 
formed of a high proportion of fatty tissue. The risk of breast cancer is five 
times higher in women with >75% dense breast tissue compared to women 
with <10% dense tissue (McCormack and dos Santos Silva 2006). There are 
many factors that influence breast density such as menopausal status, weight 
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and number of children but the most important factor is inheritance (Boyd, Dite 
et al. 2002) .   
1.3.10 Family history 
 
 The risk of breast cancer is doubled in women with one affected first-degree 
relative (mother or sister) compared to a women with no family history of the 
disease (Pharoah, Day et al. 1997). The risk also is higher if the relative is 
diagnosed under the age of 50 years. Mutations in the breast cancer 
susceptibility genes BRCA1 and BRAC2 account for the majority of families 
that have four or more affected members and about 2% of all breast cancers 
(Peto 2001). Women carrying these mutations have a 45-65% chance of 
developing the disease by the age of 70 (Antoniou, Pharoah et al. 2003). A 
number of other high prevalence susceptibility genes have been described, 
(Table 1.3) and altogether account for ~ 20-25% of breast cancers. More 
recently, a series of low prevalence SNP’s conferring low-level risk for breast 
cancer also have been described (Table 1.4) (Mavaddat, Antoniou et al. 2010).   
Table 1.3 High penetrance mutations predisposing to the development of breast cancer 
(Mavaddat, Antoniou et al. 2010) 
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Table 1.4 Low penetrance SNPs predisposing to the development of breast cancer  
(Mavaddat, Antoniou et al. 2010) 
 
1.3.11 Physical activity 
 
Studies conclude that there is 15- 20% risk reduction among women with the 
highest category of physical activity (Monninkhof, Elias et al. 2007). The link 
is clearer for post-menopausal women. The influence of physical activity on 
breast cancer risk might be explained by how it affects hormone levels.  A 
recent European Prospective Investigation of Cancer (EPIC) research study 
illustrated lower levels of oestrogen and testosterone in post-menopausal   
women with high levels of physical activity (Chan, Dowsett et al. 2007).  
1.3.12 Alcohol consumption 
 
A significant association between alcohol consumption and breast cancer has 
been shown by epidemiological studies (Baan, Straif et al. 2007). Analyses 
included 58 515 women with invasive breast cancer and 95 067 controls from 
53 studies. These studies showed that daily consumption of about 50 g of 
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alcohol is associated with a relative risk of about 1.5 compared with that in 
non-drinkers (Hamajima, Hirose et al. 2002). The relationship between alcohol 
consumption and breast cancer was studied in 1.905 invasive breast cancer 
cases in related to different subtypes of breast cancer. This demonstrated that 
the risk increased steadily with increasing amount of alcohol consumption for 
ER+ and PR+ cancers but not for ER- and PR- cancer (Falk, Maas et al. 2014). 
 
1.4 Ductal carcinoma in situ (DCIS) 
 
Ductal carcinoma in situ (DCIS) is the earliest clinical diagnosis of breast 
cancer and is usually detected through mammographic screening that identifies 
areas of calcification in the breast. This type of breast cancer is considered to 
be a pre-invasive neoplastic proliferation of cells within the ductal-lobular 
structures of the breast that does not penetrate the myoepithelial- basement 
membrane interface (figure 1.4). In the symptomatic setting, it accounts for 3-
5% of cancers, but in the screening setting it accounts for up to 30% of cases 
(Ernster, Barclay et al. 2000).  
According to epidemiological, histopathological and genetic studies, there is 
evidence that supports the concept that DCIS represents the precursor of 
invasive carcinoma in the majority of cases (Bombonati and Sgroi 2011). This 
model of progression of breast cancer has been refined, with columnar cell 
lesions and atypical ductal hyperplasia now being recognised as precursor 
lesions of low grade of DCIS (Schnitt 2003).  
Because the aim of screening is to detect cancer as early as possible and treat 
so as to prevent life-threatening disease, it could be argued that DCIS 
represents the ideal stage to target to prevent invasive breast cancer. However, 
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the behaviour of DCIS is not clearly understood because opportunities to study 
its natural history are limited (Sanders, Schuyler et al. 2005), and it has been 
suggested that only 50% of cases will progress to invasive disease during the 
lifetime of a woman, though currently it is not possible to distinguish between 
those that will progress and those that will not (Collins, Tamimi et al. 2005). 
 
 
Figure 1.4 Progression of DCIS to invasive breast cancer (Allen, Thomas et al. 2014) 
 
1.5 Classification of DCIS  
 
DCIS is a heterogeneous disease that shows a variation in its clinical 
manifestation, morphology and biological behaviour. Many histological 
classification systems have been developed based on growth pattern, nuclear 
morphology and presence or absence of necrosis, in different combinations 
(van Dongen, Holland et al. 1992). In the UK, the National Coordinating 
Group for Breast Screening Pathology has proposed a classification system 
based on an assessment of nuclear pleomorphism and on the frequency of 
mitoses within the luminal cells. This classification defines low, intermediate 
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and high grade DCIS. Low grade DCIS is composed of small regular cells, 
usually with cribriform or micropapillary architecture and infrequent mitosis 
while high grade is composed of large, pleomorphic cells associated with 
frequent mitosis, also often showing a solid architecture with necrosis. The 
intermediate grade lesions present manifestations between low and high grade 
DCIS (Badve, A'Hern et al. 1998). Several studies have used biomarkers to 
identify different molecular subtypes of breast cancer (Perou, Sorlie et al. 2000, 
Curtis, Shah et al. 2012). Whilst mainly applied to invasive breast cancer, 
similar subtypes can be identified in DCIS, further supporting the 
heterogeneous nature of this disease (Tamimi, Baer et al. 2008, Clark, 
Warwick et al. 2011). Based on expression of oestrogen receptor (ER), 
progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2) 
and cytokeratins, DCIS can be classified as: Luminal A (ER+/PR+/HER-), 
Luminal B (ER+/ PR+or-/HER2+) , HER2 (ER-/PR-/HER2+), Triple Negative 
(ER-/PR-/HER2-) and basal (ER-/PR-/HER2-/CK5/6 and or CK14 and or 
EGFR-) so reflecting the major molecular subtypes of breast cancer (Clarke, 
Brunner et al. 1989, Livasy, Perou et al. 2007, Tamimi, Baer et al. 2008). There 
are some significant differences in the proportion of DCIS subtypes compared 
to invasive breast cancer (Clarke, Brunner et al. 1989), for example, according 
to some studies the basal-like phenotype is seen more frequently in invasive 
cancer than DCIS (Clarke, Brunner et al. 1989). Furthermore, HER-2 positive 
invasive breast cancer is less frequently identified than HER2 positive DCIS 
(Tamimi, Baer et al. 2008). The explanation for these differences is unclear but 
there is a proposal that either expression of HER2 is switched off during 
invasion or that HER2 positive DCIS cases frequently do not transform to 
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invasive cancer (Reis-Filho and Lakhani 2003). In current clinical practice, the 
molecular subtype classification is not applied to DCIS. In current clinical 
practice, treatment of DCIS is surgical with no routine adjuvant medical 
therapy. Indeed, most NHS units do not assess hormone receptor and Her2 
receptor status in DCIS outside clinical trials. Whether this is best practice 
remains uncertain. Chemopreventive trials such as international Breast Cancer 
Intervention Study IBIS-I, in which patients diagnosed with DCIS were 
randomized to 5yrs adjuvant tamoxifen or no tamoxifen indicates that 
tamoxifen does reduce the incidence of recurrent invasive and non-invasive (ie 
DCIS) breast cancer, so it could be argued that knowing the subtype of DCIS 
could influence treatment, however, this does not yet appear to have become 
accepted clinical practice (Sestak, Kealy et al. 2012). Whether trials such as 
LORIS, which aims to randomize patients with non-high grade DCIS to 
surgery or surveillance, will open the way to medical treatment of DCIS, 
dependent on the subtype characteristics, remains to be seen. 
1.6 Progression of DCIS to invasive cancer 
  
There are few opportunities to observe the natural history of DCIS but those 
limited studies that report on long-tem follow up of DCIS provide an 
interesting insight (Sanders, Schuyler et al. 2005). There are two different 
models that have been described to explain the transition of DCIS to invasive 
carcinomas. The first model suggests that the progression of DCIS to invasive 
breast cancer (IBC) is a multistep process in which tumour progression follows 
a linear pattern - known as the theory of linear progression (Bodian, Perzin et 
al. 1993, Dupont, Parl et al. 1993, Lakhani, Chaggar et al. 1999). In this model 
it is suggested that low-grade DCIS progresses to high-grade DCIS and then to 
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invasive breast carcinoma (Bodian, Perzin et al. 1993, Dupont, Parl et al. 1993, 
Lakhani, Chaggar et al. 1999). The second model, known as the theory of 
parallel disease, suggests that low grade-DCIS tends to develop into low-grade 
invasive breast cancer. This theory implies commitment of a subtype of DCIS 
to a specific subtype of invasive breast cancer.  The second model is supported 
by chromosomal-alteration studies along with data that shows that during the 
progression of DCIS to invasive disease, the grade of DCIS corresponds to the 
grade of the subsequent invasive breast cancer (Stratton, Collins et al. 1995, 
O'Connell, Pekkel et al. 1998, Hwang, DeVries et al. 2004, Irvine and 
Fentiman 2007). Clearly, the idea that both theories are mutually exclusive 
may represent an oversimplification (Wiechmann and Kuerer 2008). Several 
studies have compared gene expression and genetic profile between DCIS and 
its invasive counterpart (Krop, Sgroi et al. 2001, Ma, Salunga et al. 2003, 
Porter, Lahti-Domenici et al. 2003, Chin, de Solorzano et al. 2004).  In general, 
these studies have failed to show consistent changes between in-situ and 
invasive disease and suggest that all the genetic changes associated with 
invasive breast cancer are already present at the DCIS stage. This has focussed 
attention on potential changes in the microenvironment that may contribute to 
development of invasive disease. 
1.7 DCIS microenvironment 
 
The role of the microenvironment in invasive breast cancer has received much 
attention but there has been less focus on what role the microenvironment 
might play in DCIS. The DCIS microenvironment is complex, with 
contributions from myoepithelial cells, as well as stromal fibroblasts, blood 
vessels and the immune cells (Figure 1.5) (Polyak and Kalluri 2010). 
          Chapter 1 Introduction   
20 
 
 
Figure 1.5  Schematic diagram of microenvironmental alterations during breast cancer 
progression (Polyak and Kalluri 2010) 
 
Normal breast ducts are composed of the basement membrane (BM) and an inner layer of 
luminal epithelial cells in contact with an outer layer of myoepithelial cells. Cells composing 
the stroma include various leukocytes, fibroblasts, myofibroblasts, and endothelial cells. In 
DCIS, the myoepithelial cells are epigenetically and phenotypically altered. The number of 
stromal fibroblasts, myofibroblasts, lymphocytes, and endothelial cells increases as tumour 
progresses, although the degree of this is tumour subtype-specific. 
 
1.8 Myoepithelial cells  
 
In the normal breast the myoepithelial cells provide the major interface with 
basement membrane (BM).  They attach to the basement membrane via  
hemidesmosomes and to the adjacent luminal epithelial and myoepithelial cells  
by desmosomes (Glukhova, Koteliansky et al. 1995).  The myoepithelial cells 
are spindle-shaped cells oriented parallel to the long axis of mammary ducts as 
a continuous layer  (Adriance, Inman et al. 2005).   
1.8.1 Markers of myoepithelial cells  
 
The presence of myoepithelial cells is frequently used as a marker of benign 
disease in the breast and as such there are continued efforts to identify specific 
markers that differentiate between luminal epithelial cells and myoepithelial 
cells in the normal resting human breast using different techniques (Table 1.5). 
Microarray studies have indicated that 42 genes can distinguish luminal and 
myoepithelial cells in the breast tissue (Jones, Mackay et al. 2004). 
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Table 1.5  Examples of genes expressed by normal myoepithelial cells contributing to 
their tumour-suppressor phenotype. 
Myoepithelial markers  References  
                                                                                                                                                                                                                    
CK5 
 
Galectin-7 
 
CK14 
 
CK17 
 
BG3C8 
 
Vimentin 
 
GFA 
 
-Smooth muscle actin 
 
Smooth muscle-MHC 
 
Calponin 
 
CALLA 
 
Thy-1 
 
P-cadherin 
 
α1integrin 
 
α 6 integrin 
 
β4 integrin 
 
Connexin-43 
 
bFGF 
 
Laminin 
 
Maspin 
 
Methallothionein 
 
Calcium binding protein A2 
(S100A2) 
SPARC 
 
 
(Nagle, Bocker et al. 1986) 
 
(Jones, Mackay et al. 2004) 
 
(Dairkee, Blayney et al. 1985) 
 
(Guelstein, Tchypysheva et al. 1988) 
 
(Ronnov-Jessen, Van Deurs et al. 1992) 
 
(Mork, van Deurs et al. 1990) 
 
(Moll 1993) 
 
(Gordon, Mulligan et al. 2003) 
 
(Lazard, Sastre et al. 1993) 
 
(Lazard, Sastre et al. 1993) 
 
(Gusterson, Monaghan et al. 1986) 
 
(Gudjonsson, Ronnov-Jessen et al. 2002) 
 
(Rasbridge, Gillett et al. 1993) 
 
(Lazard, Sastre et al. 1993) 
 
(Natali, Nicotra et al. 1992) 
 
(Koukoulis, Howeedy et al. 1993) 
 
(Wilgenbus, Kirkpatrick et al. 1992) 
 
(Gomm, Smith et al. 1991) 
 
(Rudland, Hughes et al. 1989) 
 
(Zou, Anisowicz et al. 1994) 
 
(Schmid, Ellis et al. 1993) 
 
(Jones, Mackay et al. 2004) 
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1.8.2 Function of myoepithelial cells in normal breast 
 
During development, myoepithelial cells act to induce luminal cell polarity 
(Runswick, O'Hare et al. 2001, Gudjonsson, Ronnov-Jessen et al. 2002), and to 
regulate ductal morphogenesis (Niranjan, Buluwela et al. 1995); here, 
connection to the BM and the desmosomal interactions with epithelial cells 
facilitate paracrine regulatory functions.  
During lactation, myoepithelial cells contract in response to oxytocin and push 
milk to the ducts (Hamperl 1970), and gap junctions and cadherin-based 
interactions connecting myoepithelial cells function to coordinate the ejection 
of milk smoothly (Monaghan, Clarke et al. 1996).  In addition, myoepithelial 
cells play a key role in synthesis of BM components such as collagen IV, 
laminin-1, laminin-5 and fibronectin that regulate ductal growth (Warburton, 
Mitchell et al. 1982). They further facilitate the remodeling of   BM through 
the production of matrix metalloproteinases (MMPs), including MMP2 and 
MMP3 (Dickson and Warburton 1992).  
Normal myoepithelial cells have been shown to exhibit a tumour suppressor 
action. For example, they express many ECM structural proteins, proteinase 
inhibitors and angiogenic inhibitors (Sternlicht, Safarians et al. 1996, Barsky 
2003). Myoepithelial cell also express a number of type II tumour suppressor 
genes such as CK5, maspin, α6 integrin and α smooth muscle actin (α SMA) 
(Sager 1997, Bissell and Radisky 2001). The first functional assays were 
carried out by Barsky and co-workers and demonstrated that myoepithelial 
cells exhibit many anti-tumourigenic properties, such as the ability to inhibit 
tumour cell invasion and angiogenesis (Sternlicht, Safarians et al. 1996, 
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Nguyen, Lee et al. 2000). Further studies using myoepithelial cell lines derived 
from canine tumours revealed that myoepithelial conditioned media inhibited 
the growth of breast cancer cells (Shao, Nguyen et al. 1998). 
1.8.3 Role of myoepithelial cells in breast cancer  
 
In general, it is believed that myoepithelial cells rarely become malignant 
(Lakhani and O'Hare 2001). Luminal and myoepithelial cells are different in 
their capacity for DNA repair, and this contributes to the lower rate of 
transformation in myoepithelial cells (Angele, Jones et al. 2004). Moreover, 
when myoepithelial cells do undergo transformation, they usually form benign 
or low-grade neoplasms. They express many ECM structural proteins, 
proteinase inhibitors and angiogenic inhibitors, which may explain in part why 
these lesions are generally not invasive (Sternlicht, Safarians et al. 1996, 
Barsky 2003). However, there is growing evidence that myoepithelial cells 
change in DCIS. 
Despite the fact that the myoepithelial layer remains largely intact in DCIS, the 
cells appear to differ from normal myoepithelial cells in gene expression 
(figure 1.6). Polyak and her team used SAGE (serial analysis of gene 
expression) to identify differences between normal myoepithelial cells and 
DCIS myoepithelial cells.  They found that DCIS-associated myoepithelial 
cells exhibited the greatest change in gene expression of all cells in DCIS, 
including up-regulation of certain chemokines such as CXCL14 (Allinen, 
Beroukhim et al. 2004). This suggests that although myoepithelial cells are 
present, they may no longer send the correct signals to epithelial cells. One 
study found that myoepithelial cells derived from breast carcinoma express no 
or low level of laminin-1, and that these  purified myoepithelial cells were 
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unable to polarize epithelial cells in three-dimensional collagen assays. This 
suggests that cancer associated myoepithelial cells may fail to transmit the 
necessary signals to produce proper epithelial cell polarity due to their inability 
to induce laminin-1 (Gudjonsson, Ronnov-Jessen et al. 2002).  
A study carried out by Man et al (2007) aimed to identify the steps involved in 
development from normal breast through hyperplasia, in-situ disease to 
invasive cancer; they suggest that breast cancer invasion is triggered by a 
multi-step process of events targeting the microenvironment. They proposed 
that internal or external injuries such as trauma, inflammation or exposure to 
some chemicals result in disruption of the myoepithelial cell layer with 
subsequent infiltration of inflammatory cells. These inflammatory cells lead to 
further degeneration of the myoepithelial cells and basement membrane 
resulting in a gap that allows direct contact between the tumour cells and 
stromal cells. This gap in the myoepithelial cell layer is proposed to lead to a 
localized loss of tumour suppressors and paracrine inhibitory function, a local 
increase in oxygen level, nutrients and growth factors, and a focal increase of 
inflammatory cell infiltration, resulting in substantial changes in the micro-
environment that ultimately facilitate cell proliferation.  
Furthermore, direct contact between the luminal cell clusters and stromal cells 
stimulates the production of tenascin and other invasion-associated molecules 
that lead to  tissue remodelling, angiogenesis and epithelial mesenchymal 
transition (EMT), offering a favourable micro-environment for invasion and 
proliferation (Man 2007). Work in our lab has shown that one of the most 
consistent changes in myoepithelial cells in DCIS is up-regulation of the 
integrin αvβ6. Normal myoepithelial cells do not express this integrin, but it is 
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induced in ~60% of DCIS cases with no evidence of invasion, and in >90% of 
cases of DCIS which is associated with established invasion. 69% of high 
grade DCIS cases were positive for αvβ6 expression, while 52% of non-high 
grade DCIS showed positivity for αvβ6 expression (Allen, Thomas et al. 2014). 
αvβ6 integrin is an epithelial-specific integrin and is a receptor for the 
extracellular matrix (ECM) proteins fibronectin (Weinacker, Chen et al. 1994), 
vitronectin (Huang, Wu et al. 1998), and tenascin (Yokosaki, Monis et al. 
1996). It also binds to latency-associated peptide 1 (LAP-1), a protein which 
maintains TGFβ in its inactive form. On binding to αvβ6, latent TGFβ becomes 
activated (Munger, Huang et al. 1999). αvβ6 integrin expression levels are low 
in normal healthy epithelia but are up-regulated in association with wound 
healing and inflammation. Suppression of the β6 integrin in mice has 
demonstrated its role in down-regulation of inflammation in skin and the 
respiratory tract (Huang, Wu et al. 1996).  
In addition, αvβ6 plays a significant role in the migration of keratinocytes 
(Huang, Wu et al. 1996). Moreover, it has been reported that αvβ6 is up 
regulated in several invasive cancers such as oral squamous cell carcinoma and 
colonic cancer (Bates, Bellovin et al. 2005, Thomas, Nystrom et al. 2006). 
Many studies have indicated that αvβ6 integrin may promote cancer 
progression by regulating expression of matrix metalloproteinases (MMPs) and 
activation of TGF-β1 (Agrez, Chen et al. 1994, Dixit, Chen et al. 1996, Li, 
Yang et al. 2003, Janes and Watt 2004, Morgan, Thomas et al. 2004, Thomas, 
Nystrom et al. 2006). It also is suggested to play a role in inducing tumour 
tolerance as a recent study has shown that there is a positive correlation 
between the number of Treg cells and the levels of αvβ6 in colorectal cancer 
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(Yang, Du et al. 2012) . In addition, αvβ6 integrin converts the precursor TGFβ 
to active TGF-β in dendritic cells (DCs), which converts immature DCs to 
tolerogenic DCs (Chen, Yao et al. 2011). Tolerogenic DCs generates Treg cells 
(Li, Guo et al. 2008).  Loss of αvβ6 leads to inflammation by impairing the 
immune-suppressive activity of Treg cells (Munger, Huang et al. 1999). Thus, 
there is a body of evidence linking expression of αvβ6 to a shift in the 
inflammatory microenvironment towards a more pro-tumourigenic phenotype.  
The role of the myoepithelial cell in the process of tumour progression and 
invasion is still incompletely understood, but there is emerging evidnce, as 
cited above, to indicate that their phenotype becomes altered in DCIS, and this 
may lead to acquisition of a pro-invasive phenotype. When invasive carcinoma 
is established there are few myopeithelial cells detectable, a characteristic that 
is sometimes used in clinical practice to confirm invasive phenotype. What 
happens to the myoepithelial population is unknown: it is possible the 
population is simple overgrown by the expanding tumour population, however, 
it may be that loss of the myoepithelial population is achieved through other 
mechanisms such as apoptosis, and factors leading to myoepithelial cell 
apoptosis may be contributory to the transition on in-situ to invasive disease. 
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Figure 1.6 Myoepithelial cells in normal and DCIS ducts (Adriance, Inman et al. 2005) .  
 
In DCIS, the myoepithelial cell layer remains intact, however, they exhibit an altered 
phenotype, including down-regulation of CD10 and laminin-1, and up-regulation of v 
integrin. 
 
 
1.9 Immune system   
Structurally, the immune system is a collection of tissue, organs, circulatory 
cells and molecules (Charles 2001). Immune cells are produced and mature in 
primary lymphoid organs such as the bone marrow and thymus. They are 
transported via lymphatic and blood vessels to peripheral tissues or secondary 
lymphoid organs such as the lymph nodes or spleen. Functionally, the immune 
system is responsible for the location and removal of pathogens from the body. 
This system is divided into two categories; the innate system and adaptive 
system.  
The innate immune system functions as a host defence in the early stages 
through nonspecific recognition of pathogens, induction of adaptive immune 
responses and determination of the type of adaptive response (Janeway 1998). 
The main function of adaptive system is specific recognition of pathogen 
resulting in induction of pathogen- specific long-term memory (Charles 2001). 
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The adaptive system includes two types of cells: T cells and B cells. The innate 
system includes macrophages, natural killer cells (NK) and dendritic cells 
(DCs). 
1.10 Overview of immune cell function in cancer  
In general, the relationship between cancer and inflammation can be classified 
into two categories: an intrinsic pathway and an extrinsic pathway. The 
intrinsic pathway is mediated by genetic events that induce inflammation and 
neoplasia (Mantovani, Allavena et al. 2008). These events include the 
activation of different types of oncogenes by mutation, rearrangement or 
amplification of genes and inactivation of tumour-suppressor genes. Cells that 
are altered in this manner induce inflammatory mediators resulting in 
generation of an inflammatory microenvironment in tumours without an 
underlying inflammatory condition, such as in breast cancer (Mantovani, 
Allavena et al. 2008). In contrast, in the extrinsic pathway, inflammatory or 
infectious conditions enhance the risk of cancer development. Both pathways 
lead to activation of transcription factors, mainly Nuclear Factor Kappa B (NF-
kB), signal transducer and activation of transcription 3 (STAT3) and hypoxia- 
inducible factor 1 α (HIF-1α), in tumour cells. These transcription factors 
coordinate the production of inflammatory mediators including cytokines, 
chemokines and cyclooxygenase 2 (COX2). Moreover, these factors are 
responsible for the recruitment and activation of various leukocyte populations 
(Mantovani, Allavena et al. 2008). The cytokines activate transcription factors 
in inflammatory cells, stromal cells and tumour cells leading to more 
inflammatory mediators being induced and the cancer-inflammatory 
microenvironment is generated (Mantovani, Allavena et al. 2008). 
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1.11 Inflammation and cancer: progression 
versus elimination 
 
The immune system has a dual role in cancer. It has the ability to inhibit 
tumour growth by killing cancer cells, for example, through the cytotoxic 
effect of CD8 T cells (Nosho, Baba et al. 2010). It also can promote tumour 
growth via proliferation of T regulatory cells (Treg) in the cancer 
microenvironment that can suppress the cytotoxic activity of CD8 T cells 
(Wang and Wang 2007).  
1.11.1 Anti-tumour response of immune cells 
 
In colorectal cancer, tumour- infiltrating CD8 T cells are thought to have an 
important role in the elimination of cancer cells, and CD8 T cells are associated 
with good prognosis for colorectal cancer patients (Nosho, Baba et al. 2010). 
Activated CD4 T helper cells are classified into Th1 or Th2. Th 1 cells secrete 
IFNγ, TGFβ, TNFα and IL-2. These cytokines collaborate with CD8 cytotoxic 
functions (Romagnani 1997). Moreover, Th1 CD4 cells can enhance the 
antitumor immune response via secretion of IFNγ, which in turn induces 
cytotoxic activity of macrophages (Stout and Bottomly 1989).  
1.11.2 Pro-tumour response of immune cells  
 
Th2 CD4 T cells and T regulatory cells function together to repress CD8 
cytotoxicity and to induce pro-tumoural polarization of innate immune 
responses such as polarization of tumour associated macrophages (TAMS) 
through secretion of cytokine such as IL-4, IL-3, IL-6, IL-10 and IL-13 (Parker 
1993). T regulatory cells normally function to protect tissue from autoimmune 
disease and express CD4, CD25 and FOXP3 molecules (DeNardo and 
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Coussens 2007). Dendritic cells (DCs) influence the function of other immune 
cell functions by expression of transforming growth factor beta (TGFβ) which 
has the ability to convert naıve CD4 T cells to FOXP3 CD4 CD25 + Treg cells 
(Coombes, Siddiqui et al. 2007). Moreover, DCs express retinoic acid, which 
plays a critical role in the induction of Treg cells (Salagianni, Lekka et al. 
2011). A recent study showed that interleukin (IL) - 10 produced by DCs is 
involved in tumour tolerance by promoting Treg cell development (Augier, 
Ciucci et al. 2010). CD25+CD4+ Treg cells have been used to suppress 
autoimmune reactions (Suri-Payer, Amar et al. 1998) and inflammatory bowel 
disease (Coombes, Robinson et al. 2005), while removal of CD25+CD4+ Treg 
cells results in enhanced resistance to tumours (Ko, Yamazaki et al. 2005), and 
increases the response to foreign antigens (Pasare and Medzhitov 2004). In 
fact, it has been proposed that depletion of Treg cells could be used as a 
therapeutic strategy for cancer (Salagianni, Lekka et al. 2011). 
 
1.12 The role of the immune system in breast 
cancer  
 
In breast cancer, the role of the immune system is also paradoxical, being 
described both as pro-tumour and anti-tumor. Activation of different pathways 
results in a complex cascade of signalling which can affect the inflammatory 
response. Also these pathways are affected by environmental factors and other 
tumour derived stimuli. Immunohistochemical studies have shown that T 
lymphocyte infiltration is more extensive in higher grade DCIS and invasive 
carcinoma (Wong, Staren et al. 1998), while B cells were the dominant 
lymphocyte population in non-malignant breast lesions and in DCIS, 
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suggesting that a B-cell response may occur early in tumor development. 
(Coronella-Wood and Hersh 2003). In breast cancer the percentage of Treg 
cells, as evaluated by the presence of FOXP3, increases in parallel with cancer 
stage, from normal to DCIS and from DCIS to invasive carcinoma (Bates, 
Bellovin et al. 2005). The presence of large numbers of FOXP3 positive cells 
in invasive carcinoma is associated with poor relapse-free survival. The CD4+ 
CD25+ FOXP3+ Treg has the ability to inhibit CD4+ CD25- T cells, CD8+T 
cells, natural killer cells and B cells in a cell-cell contact dependent manner 
(Chen 2006).  
Infiltrating inflammatory cells are also involved in later stages of tumour 
progression where they are thought to play a role in promoting progression to 
invasion and metastasis. One mechanism by which this can occur is the 
induction of epithelial to mesenchymal transition (EMT) in breast cancer cells 
by infiltrating T lymphocytes (Santisteban, Reiman et al. 2009).  A recent 
study has demonstrated a direct link between inflammation and breast 
tumourgenesis including an epigenetic switch induced by NF-kB and IL6 in 
tumour epithelial cells leading to an increasingly malignant phenotype 
(Iliopoulos, Hirsch et al. 2009). The study has shown the link between these 
molecules using MCF-10A cells as a model, and then subsequently 
demonstrating that the activation signature is also present in primary human 
breast tumours so implicating IL6-STAT3 signalling in breast cancer 
(Iliopoulos, Hirsch et al. 2009).  
B-lymphocytes are recognized as contributing to anticancer immune responses 
via their secretion of antigen-specific immunoglobulin. Chronic activation of B 
cells may, paradoxically, play a role in potentiating carcinoma development. 
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During breast carcinogenesis, mature B cells (including naive cells and 
activated cells) can be found in secondary lymphoid tissues as well as in 
tumour-associated stroma. Furthermore, data from retrospective studies 
examining the percentage of B cells present in sentinel and axillary lymph 
nodes of breast cancer patients reveal that their presence and/or maturation 
immunoglobulin (IgG+) correlates with advanced disease stage and total 
tumour burden (Wernicke 1975, Morton, Ramey et al. 1986) . A study 
conducted by Uridiales- Viedma and his colleagues report the 
immunohistochemical detection of IgA, IgG and IgM in axillary lymph nodes 
from 50 unselected ductal breast carcinomas, and found that lymph nodes with 
IgG+ lymphoid follicles and/or metastatic lymph nodes with IgM+ lymphoid 
cells were significantly related to breast tumours of high histological grade and 
with more than three lymph node metastases (Urdiales-Viedma, Nogales-
Fernandez et al. 1986). Also B cells present in breast tumour-associated stroma 
may have a role in disease progression. Approximately 20% of invasive breast 
cancers contain high numbers of B cells, and when present, these cells can 
comprise up to 60% of the neoplasia- associated lymphocyte population 
(Coronella, Telleman et al. 2001). 
1.13 T lymphocytes 
 
T cells are a sub-group of lymphocytes involved in the immune response (Hahn 
and Kaufmann 1981). Their production begins in fetal life, and is maintained 
throughout adult life by the bone marrow, and they are mobilized to the thymus 
for differentiation (Guidos 2006, Schwarz and Bhandoola 2006). The 
differentiation process is continued in peripheral tissues and results in 
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production of various sub-groups of T lymphocytes that have different 
functions (Miller 1961) . 
1.13.1 CD69 T cells 
 
CD69 is an early membrane receptor transiently expressed on activated T cells, 
not detected in resting lymphocytes, and selectively expressed in chronic 
inflammatory infiltrates (Sancho, Gomez et al. 2005). Its expression is 
associated with production of Th1 T cell cytokines, including IL-2, TNF-α and 
interferon-γ (IFNγ) (Ziegler, Ramsdell et al. 1994, Rutella, Rumi et al. 1999).  
It also has been shown that CD69 cells can promote Transforming growth 
factor beta (TGF-β) production in CD4 and CD8 T cells, NK cells and 
macrophages (Esplugues, Sancho et al. 2003, Sancho, Gomez et al. 2003). 
Moreover, TGF-β synthesis is dependent on extracellular-signal-regulated 
kinases (ERK) activation (Grewal, Mukhin et al. 1999), and CD69 mediates 
ERK activation (Zingoni, Palmieri et al. 2000). 
1.13.1.1 The role of CD69 T cells in malignancy 
 
CD69 antibody increases the cytotoxic activity of host NK cells, mediated by 
reduction of TGFβ (Esplugues, Vega-Ramos et al. 2005).  
Moreover, CD69 antibody can stimulate the production of interleukin-2 (IL-2), 
which leads to T-cell proliferation (Cebrian, Yague et al. 1988, Testi, Phillips 
et al. 1989), and tumour necrosis factor-a (TNF-a) synthesis (Santis, 
Campanero et al. 1992, Sancho, Santis et al. 2000). Anti-CD69 increases 
secretion of nitric oxide (NO) by monocytes (De Maria, Cifone et al. 1994). 
CD69 also can trigger apoptosis in different types of cells including monocytes 
and eosinophils (Ramirez, Carracedo et al. 1996, Walsh, Williamson et al. 
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1996), and might mediate inhibitory signals to the IL-1 receptor (IL-1R) or on 
CD3 T cells proliferation (Cosulich, Rubartelli et al. 1987).  
In lung cancer, a study has shown that accumulation of CD69+ve T cells is 
associated with the metastatic phenotype. (Wald, Izhar et al. 2006, Han, Guo et 
al. 2009). Thus, immune activation in tumour microenvironments may result in 
immune tolerance (Zhao, Kuang et al. 2012). 
In contrast, lower numbers of CD69+ T cells are retrieved from the tumour-
associated colonic mucosa compared to unaffected mucosa (Svensson, 
Olofsson et al. 2012). In addition, in ovarian cancer, the presence of CD69+ve 
cells is associated with an increase in survival (Yacyshyn, Poppema et al. 
1995), and a study has shown that tumour-infiltrating activated CD4+CD69+ T 
cells are associated with a good prognosis in head and neck squamous cell 
carcinoma (Badoual, Hans et al. 2006). 
1.13.1.2 Role of CD69+ cells in breast cancer 
Little is known about the role of CD69+ve cells in breast cancer, however, a 
positive correlation has been found between the presence of CD69+ cells and 
survival in patients with invasive breast cancer (Yacyshyn, Poppema et al. 
1995).  
1.13.2 CD4 T cells 
 
CD4 cells are a sub-group of T lymphocytes that are important for maintaining 
self-tolerance (Tai, Cowan et al. 2005).  CD4 T cells are divided into two main 
categories: T helper 1 (Th1) and Th2 depending on the cytokines they produce 
in response to antigen activation. Th1 cells produce IL-2, IL-12 and IFN-γ and  
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Th2 cells produce IL-4 and IL-5 (Swain, Bradley et al. 1991, O'Garra and 
Murphy 1994).   
1.13.2.1 Role of CD4 T cells in immunity 
 
CD4 T cells play a key role in orchestrating the beginning and maintenance of 
the adaptive immune response (Gerloni and Zanetti 2005). They have the 
ability to help antibody responses (Mitchison 1971) and they also help 
activation and expansion of CD8 cytotoxic cells (Keene and Forman 1982). 
CD4 T cells also regulate DCs to increase their ability to stimulate CD8 T cells 
(Bennett, Carbone et al. 1998, Ridge, Di Rosa et al. 1998, Schoenberger, Toes 
et al. 1998, Smith, Wilson et al. 2004): CD4 T cells  release IL-2 that is critical 
to  elicit the full response of CD8 T cells (Lai, Lin et al. 2009) . Cytokines 
released by Th1 T cells regulate M1 macrophages, and subsequently enhance 
the cytotoxic activity of macrophages, whereas,  Th2 cytokines stimulate the  
M2 macrophage phenotype is more frequently associated with solid tumors and 
thought to mediate an immunosuppressive effect  (Leek, Hunt et al. 2000, 
Mantovani, Sica et al. 2007). 
1.13.2.2 Role of CD4 T cells in cancer 
CD4 T cells play a dual role in tumour development and progression dependent 
on their phenotype, which is regulated both by the tumour and the tumour 
microenvironment (DeNardo, Barreto et al. 2009). They can act as tumour 
suppressive cells. Th1 cells repress tumour growth by release of IFNγ and 
support cytotoxic T cells function, or as tumour promoting cells, including the 
function of  Treg cells , that enhance tumour expansion by suppressing CD8 T 
cell and NK cell  functions (Trzonkowski, Szmit et al. 2006). In sarcomas, one 
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study demonstrated that deficiency of CD4 T cells leads to enhanced tumour 
development (Koebel, Vermi et al. 2007).  
In contrast, CD4 cells that express IL-17 regulate chronic inflammation and 
promote tumour progression when activated in the presence of TGF-β and IL- 
6 or IL-23 (Dong 2008). Furthermore, a direct correlation has been 
demonstrated between the number of infiltrating CD4 T cells and shorter 
survival in renal cell carcinomas patients (Nakano, Sato et al. 2001).  
 
1.13.2.3 Role of CD4 T cells in breast cancer 
In breast cancer, CD4 lymphocytes can directly enhance early tumour 
development by their expression of IL-13 (Aspord, Pedroza-Gonzalez et al. 
2007).  In addition, the extent of CD4 T cell infiltration in primary tumours has 
been shown to be associated with lymph node metastasis (Macchetti, Marana et 
al. 2006), and an unfavourable prognosis (Matkowski, Gisterek et al. 2009).  
Studies in mice have shown that IL-4 expression CD4 T cells promote invasion 
and metastasis of mammary adenocarcinoma to lung by regulating the 
phenotype and effector function of tumour-associated CD11b+ Gr1-F4/80+ 
macrophages, that in turn enhance metastasis through activation of epidermal 
growth factor receptor signalling in malignant mammary epithelial cells 
(DeNardo, Barreto et al. 2009) .  
This study also demonstrated that CD4 T cell in primary mammary carcinoma 
expressed Th2 cytokines such as IL-4 and IL-13 (DeNardo, Barreto et al. 
2009).  This  is  consistent  with results of studies that  have shown that  CD4 T 
cells isolated from primary  human breast cancer tissue  produce high levels of 
cytokines of Th2 cell type  including IL-4 and IL-13 (Aspord, Pedroza-
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Gonzalez et al. 2007, Pedroza-Gonzalez, Xu et al. 2011). Tissue microarray 
analysis of primary breast cancer showed that high CD4 T cell density is 
associated with reduce overall survival of patients (DeNardo, Brennan et al. 
2011).  
1.13.3 FOXP3+ cells  
 
 Forkhead box protein 3 (FOXP3) is a member of the forkhead family of 
transcriptional regulators and expressed by regulatory T cells (Treg cells) and 
plays a key role in regulating their immunosuppressive function (Fontenot, 
Gavin et al. 2003, Sakaguchi, Ono et al. 2006).  FOXP3 is the only   definitive 
marker of CD4+ CD25+ Treg cells (Hori, Nomura et al. 2003, Fontenot, 
Rasmussen et al. 2005).  However, FOXP3 is not entirely specific for Treg 
cells since it can also be detected on tumour cells such as colorectal cancer 
(Kim, Grimmig et al. 2013), pancreatic cancer (Hinz, Pagerols-Raluy et al. 
2007) and melanoma (Ebert, Tan et al. 2008).  
1.13.3.1 Role of FOXP3 T cells in cancer   
FOXP3-positive Treg cells have been identified in peripheral blood and in the 
tumours of patients with different types of cancer, including ovarian (Curiel, 
Coukos et al. 2004, Leffers, Gooden et al. 2009), pancreatic (Liyanage, Moore 
et al. 2002), gastric (Ichihara, Kono et al. 2003) and breast cancer (Bates, Fox 
et al. 2006). The abundance of FOXP3-positive Tregs in tumours has been 
positively correlated with poor prognosis (Curiel, Coukos et al. 2004, Bates, 
Fox et al. 2006).  For example, Treg cells have been shown to be increased in 
tumour sites in non- small lung cancer and ovarian cancer and demonstrated to 
release TGF- β leading to inhibition of CD8 T cells in vitro (Woo, Chu et al. 
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2001). The presence of Treg cells in ovarian cancer is associated with reduced 
patient survival (Curiel, Coukos et al. 2004). However, some studies have 
reported that higher infiltration of Treg cells  in tumour sites are a marker  of 
good clinical outcome such as in colon (Correale, Rotundo et al. 2010) and 
ovarian (Leffers, Gooden et al. 2009) carcinomas. This contradictory evidence 
may be explained by differences in the size of the studies, with the latter being 
significantly larger.  
 
1.13.3.2 Role of FOXP3+ cells in breast cancer 
 
High density of FOXP3 positive Treg cells in DCIS has been  associated with 
increased risk of relapse, and in invasive breast cancer associated with both 
shorter relapse-free and overall survival (Bates, Fox et al. 2006). Furthermore, 
abundant FOXP3 positive cells in breast cancer were significantly correlated 
with high grade and large tumour size (Bohling and Allison 2008). In addition 
to their potential value in predicting tumour progression, FOXP3 expressing 
cells have been identified as a marker to monitor therapeutic response. For 
example, response to neoadjuvant chemotherapy in breast cancer is associated 
with the disappearance of tumour-infiltrating FOXP3 positive Treg cells 
(Ladoire, Arnould et al. 2008). Moreover, FOXP3 has been investigated as a 
therapeutic target, and it has been demonstrated that vaccination to eradicate 
FOXP3 positive cells in mice enhances tumour immunity (Nair, Boczkowski et 
al. 2007).  Recently, tissue microarrays study has investigated the density of 
FOXP3+ve cells in tumour nests, in tumour-adjacent stroma, and in distant 
stroma of 1445 cases of well-characterised primary invasive breast carcinoma 
with long-term follow up.  This demonstrated that the total number of 
FOXP3
+
 cells was significantly correlated with higher tumour grade and ER 
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negativity. In addition, it showed that FOXP3 infiltration positively correlated 
with HER2 expression and basal phenotype subclass (Mahmoud, Paish et al. 
2011). 
1.13.4 CD8 T cells 
 
CD8 T lymphocytes mediate a central role of the immune system in protection 
against infection (Olson, McDonald-Hyman et al. 2013).  The major cytokine 
pattern secreted by CD8 T cells is similar to Th1 set of cytokines (Kelso and 
Glasebrook 1984, Fong and Mosmann 1990). However, not all CD8 
lymphocytes express Th1 like cytokines with some CD8 cells expressing both 
Th1 and Th2 cytokines (Paliard, de Waal Malefijt et al. 1988). 
 
1.13.4.1 Role of CD8 T cells in cancer  
Cytotoxic CD8 T cells have an important role in tumour specific cellular 
adaptive immunity that attacks tumour cells. They produce IFNγ following 
interaction with their target tumour cells resulting in cell cycle inhibition, 
apoptosis, angiostasis and induction of macrophage tumouricidal activity 
(Dunn, Old et al. 2004, Smyth, Dunn et al. 2006).  
 Imuunohistochemistry studies have shown that infiltration of  CD8 T cell in 
the tumour microenvironment appears to have an anti-tumour effect as they are 
associated with good prognosis  in tumours such as  ovarian (Zhang, Conejo-
Garcia et al. 2003, Sato, Olson et al. 2005) ,  colon (Galon, Costes et al. 2006, 
Pages, Kirilovsky et al. 2009) , oesophageal (Ashida, Boku et al. 2006), renal 
(Nakano, Sato et al. 2001), lung (Kawai, Ishii et al. 2008) and pancreatic 
(Fukunaga, Miyamoto et al. 2004) cancer.  
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1.13.4.2 Role of CD8 T cells in breast cancer 
The infiltration of CD8 T cells has also been investigated in breast cancer.  A 
retrospective cohort study of 1,334 patients with primary breast cancer 
diagnosed from 1987 to 1998 in the UK found that infiltration of CD8+ T cells 
was independently correlated with better survival (Mahmoud, Paish et al. 
2011). Another study from Switzerland between 1985 and 1996 also reported 
an independent favorable prognostic effect of CD8 T cells, shown only with 
ER-negative breast cancer, while in ER-positive cases, CD8 T cells were 
associated with an unfavourable effect on outcome (Baker, Lachapelle et al. 
2011). Furthermore, among 3403 breast cancer cases for which 
immunohistochemical results were obtained, CD8 T cells have shown to be  an 
independent prognostic factor associated with better patients survival in basal-
like breast cancer, but not in non-basal triple negative breast cancer or in other 
intrinsic molecular subtypes (Liu, Lachapelle et al. 2012). 
1.13.5 CD45RO+ cells 
 
CD45 leukocyte common antigen is a family of 180-220 KD transmembrane 
glycoproteins present in high abundance on the surface of all leukocytes 
(Thomas 1989). CD45 isoforms modulate lymphocyte activation, function and 
signal transduction in a variety of cell types, including NK cells (Mittler, 
Greenfield et al. 1987, Starling, Davidson et al. 1987), B cells (Mittler, 
Greenfield et al. 1987, Lin, Brown et al. 1992) and T cells (Ledbetter, Rose et 
al. 1985, Martorell, Vilella et al. 1987). The CD45RA and CD45RO isoforms 
identify functionally distinct “naive" and "memory" T cell subsets (Akbar, 
Salmon et al. 1991, Beverley 1992, Clement 1992). 
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T cells that express the RA phenotype are small, resting cells that release a 
limited repertoire of cytokines (Salmon, Kitas et al. 1989, Akbar, Salmon et al. 
1991, Kristensson, Borrebaeck et al. 1992). 
In contrast, T cells that express RO phenotype are larger, activated cells that 
express activation markers such as CD25 and secrete a wide repertoire of 
cytokines such as IL-2, IL-4, IL-5, IL-6, TNF and IFN-γ (Akbar, Terry et al. 
1988, Sanders, Makgoba et al. 1988, Salmon, Kitas et al. 1989, Wallace and 
Beverley 1990, Akbar, Salmon et al. 1991, Mackay 1991, Beverley 1992, 
Clement 1992, Kristensson, Borrebaeck et al. 1992, Plebanski, Saunders et al. 
1992). CD45RO is considered as the most suitable single marker for memory 
T-cell populations in humans, which could represent the activation status of the 
T cells (Hotta, Sho et al. 2011).  CD45RO T cells predominate in inflammation 
sites (Sterry, Bruhn et al. 1990), mucosal tissues (Harvey, Jones et al. 1989, 
Marathias, Preffer et al. 1991), and among the population of tumor infiltrating 
lymphocytes (Bukowski, Sharfman et al. 1991, Nguyen, Moy et al. 1993). 
1.13.5.1 Role of CD45RO+ cells in cancer  
 In gastric and colorectal cancers, high density of  CD45RO cells has been 
associated with  an increased survival rate and acted as an independent 
prognostic factor (Pages, Berger et al. 2005, Galon, Costes et al. 2006, Lee, 
Chae et al. 2008, Pages, Kirilovsky et al. 2009).  It also has been shown that 
the presence of CD45RO cells is significantly associated with improved 
prognosis, independent of pathologic and clinical parameters in colorectal 
cancer (Nosho, Baba et al. 2010).   
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1.13.5.2 Role of CD45RO+ cells in breast cancer  
 An immunohistochemistry study of 196 breast cancer cases has shown that the 
extent of CD45RO cells in invasive breast cancer is associated with an 
increased risk of recurrence and poor survival (Scholl, Pallud et al. 1994), and 
also has been shown to correlate with angiogenesis (Lee, Happerfield et al. 
1997). 
1.14 Macrophages  
 
Macrophages are released into the circulation as monocytes, and within a few 
days they seed throughout the body tissues, including the spleen, which acts as 
a storage reservoir for immature monocytes (Geissmann, Manz et al. 2010).  
Macrophages are located throughout the body, where they ingest and process 
foreign materials, dead cells and debris and recruit additional macrophages in 
response to inflammatory signals (Murray and Wynn 2011) . They are highly 
heterogeneous cells that can rapidly change their function in response to local 
microenvironmental signals (Murray and Wynn 2011).  
Macrophages have been sub-classified into two categories, M1 and M2, or 
classically-activated and alternatively-activated cells (Gordon 2003, 
Mantovani, Sica et al. 2004, Mantovani, Sica et al. 2005). Interferon-gamma 
(IFNγ) is involved in induction of classical macrophage activation, which 
refers to the pro-inflammatory phenotype (M1), and is produced by activated 
Th1 T cells and NK cells (Schroder, Hertzog et al. 2004). The IL-12 produced 
by M1 macrophages can promote the differentiation of Th1 cells, which can in 
turn improve antigen phagocytosis (Benoit, Desnues et al. 2008, Cassol, 
Cassetta et al. 2010). M1 macrophages are strongly positive for Major 
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histocompatibility complex class  II  (MHC class II) and present antigen to T 
cells, and contribute to the killing of microorganisms and of tumour cells 
(Mantovani, Sica et al. 2004, Hao, Lu et al. 2012).  This type is characterized 
by production of nitric oxide (Ho and Sly 2009), high level of IL-12 and IL-23 
release but low levels of IL-10 (Gordon and Taylor 2005, Mantovani, Sica et 
al. 2005, Benoit, Desnues et al. 2008, Solinas, Germano et al. 2009).. 
In contrast to M1 macrophages, the alternatively-activated phenotype releases 
anti-inflammatory molecules such as high levels of IL-10, with low levels of 
IL-12 and IL-23 (Condeelis and Pollard 2006, Solinas, Germano et al. 2009).  
In addition, IL-10 expressed by M2 macrophages can promote production of 
IL-4 and IL-13 by Th2 (Mantovani, Sica et al. 2009), and IL-4 is a major 
promoter of wound healing because it can activate arginase, which contributes 
to production of the extracellular matrix (ECM ) (Hao, Lu et al. 2012).  
 
1.14.1 Macrophages in cancer  
Macrophages dominate tumour microenvironments where they play a key play 
role in tumour growth (Balkwill, Charles et al. 2005). A body of research 
suggests that tumour associated macrophages (TAMs) are biased towards the 
M2 phenotype and exhibit pro-tumour functions, promoting tumour cell 
proliferation and survival (Mantovani, Sozzani et al. 2002, Biswas and 
Mantovani 2010). 
The distribution of TAMs in most tumours such as breast, prostate, ovarian, 
cervical, lung carcinoma, and cutaneous melanoma is considered to be anti-
inflammatory and is associated with poor prognosis (Hao, Lu et al. 2012).  
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Epidemiological studies have suggested that a macrophage-rich 
microenvironment will promote an aggressive tumour behaviour with a high 
metastatic potential (Nardin and Abastado 2008). 
 1.14.2 Macrophages in breast cancer 
Several studies, mainly focusing on invasive ductal breast carcinomas, have 
investigated the correlation between level of macrophage infiltration in the 
tumour microenvironment and disease progression. Clinical studies have 
reported a correlation between density of TAMs and poor prognosis for breast 
cancer (Goede, Brogelli et al. 1999, Leek, Landers et al. 1999, Leek, Hunt et al. 
2000). High level of TAM infiltration is associated with a high tumour vascular 
density, suggesting a pro-angiogenic activity for TAM in invasive breast 
cancer (Leek, Lewis et al. 1996, Tsutsui, Yasuda et al. 2005). In addition, a 
high density of macrophage infiltration is positively correlated with poor 
prognostic features such as high tumor grade, low estrogen and progesterone 
receptor status and high mitotic activity (Volodko N 1998).  
1.14.3 CD68+ macrophages 
 
 CD68 expression increases markedly during differentiation of monocytes into 
macrophages (van der Kooij, von der Mark et al. 1997). CD68 is also 
expressed in cancer tissue such as melanoma and predicts a poor prognosis 
(Jensen, Schmidt et al. 2009).  
1.14.3.1 CD68 + macrophages in cancer 
In Hodgkin's lymphoma, high numbers of CD68+ macrophages have been 
correlated with a shortened progression-free survival and with increased 
disease relapse (Steidl, Lee et al. 2010). In addition, CD68+ macrophages 
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infiltration in melanoma is associated poor prognosis (Brocker, Zwadlo et al. 
1988, Bernengo, Quaglino et al. 2000, Makitie, Summanen et al. 2001, Varney, 
Johansson et al. 2005).  
1.14.3.2 CD68+ macrophages in breast cancer  
In breast cancers, high infiltration with CD68+ macrophages has been 
associated with higher tumour histological grade (Naukkarinen and Syrjanen 
1990, Lee, Happerfield et al. 1997, Volodko N 1998), larger tumour size, 
necrosis and metastasis (Lee, Happerfield et al. 1997, Bolat, Kayaselcuk et al. 
2006) and shown to predicate reduced relapse-free and overall survival (Leek, 
Lewis et al. 1996). Immunohistochemistry and tissue microarray studies have 
investigated the number, density and localization of CD68+ve macrophages in 
1322 breast tumours. This demonstrated that the distant stromal macrophage 
count (infiltrating stroma away from the carcinoma, median count 14 cells) was 
higher than the intratumoural (median zero cells) and adjacent stromal 
macrophage count (median three cells). It also showed a significant association 
between the total number of macrophages and tumour grade, ER and PR 
negativity, HER-2 positivity and basal phenotype. In univariate survival 
analysis, density of CD68 macrophages was significantly associated with 
worse breast cancer-specific survival and shorter disease-free interval. 
However in multivariate model analysis, the CD68 macrophage number cannot 
be considered as an independent prognostic marker (Mahmoud, Lee et al. 
2012). 
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1.14.4 CD74+ cells  
 
CD74 is a transmembrane glycoprotein that is associated with MHC class II 
and it regulates antigen presentation for the immune response (Zheng, Yang et 
al. 2012). It is expressed on antigen-presenting cells, including B cells, 
monocytes, dendritic cells and macrophages (Greenwood, Metodieva et al. 
2012).  CD74 acts as the high-affinity receptor for the pro-inflammatory 
cytokine macrophage migration inhibitory factor (MIF) (Leng, Metz et al. 
2003).   
1.14.4.1CD74+ cells in cancer  
CD74 expression has also been detected in some tumor cells.  Its expression 
has been reported on malignant B-cells and the majority of cell lines derived 
from these cancers (Burton, Ely et al. 2004, Stein, Qu et al. 2004).  It also has 
been observed in Multiple Myeloma plasma cells as well as multiple myeloma 
cell lines and it has been suggested that CD74 may be a novel and promising 
therapeutic target (Burton, Ely et al. 2004).  Up-regulation of CD74 expression 
in gastric cancer has been reported and is associated with increasing clinical 
stage and again is suggested to offer an opportunity as novel gastric cancer 
chemoprevention and treatment approach. In pancreatic cancer, it also has been 
demonstrated that over-expression of CD74 is clearly associated with 
perineural invasion of pancreatic cancer and may be a useful prognostic factor 
(Nagata, Jin et al. 2009).  CD74 expression also has been found in other 
tumours such as renal, thymic epithelial neoplasms and non-small lung cancer 
(Ioachim, Pambuccian et al. 1996, Young, Amin et al. 2001). 
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1.14.4.2 CD74+ cells in breast cancer 
In invasive breast cancer, CD74 has been detected predominantly in triple 
negative cancers. Interestingly, its expression was significantly correlated with 
lymph node metastasis. In addition, CD74 expression was significantly related 
to a poor chemotherapy response in patients undergoing neoadjuvant 
chemotherapy (Tian, Zhang et al. 2012). Moreover, a study has shown that 
Stat1/CD74 positive triple- negative tumors are more aggressive and suggests 
this may be a targeted therapy for triple-negative breast cancer (Tian, Zhang et 
al. 2012).  
1.14.5 Macrophage inhibitory factor (MIF)  
 
MIF is a product of activated macrophages, which sustains macrophage 
survival and function (Mitchell, Liao et al. 2002). It regulates the expression of 
proinflammatory mediators by macrophages, and also is involved in T cell 
activation (Calandra, Bernhagen et al. 1994, Bacher, Metz et al. 1996). It is a 
proinflammatory cytokine and is expressed by several  cells types such as T 
cells, B-lymphocytes, monocytes,  macrophages, lung  and gastrointestinal 
tissue  (Calandra and Roger 2003).  
1.14.5.1 Role of MIF in cancer  
Overexpression of MIF has been reported in many types of tumours, including 
hepatocellular (Ren, Tsui et al. 2003), lung (Meyer-Siegler and Hudson 1996, 
White, Flaherty et al. 2003), cervical cancer (Ishigami, Natsugoe et al. 2001, 
Xu, Wang et al. 2008, McClelland, Zhao et al. 2009, Hertlein, Triantafillou et 
al. 2010, Cheng, Deng et al. 2011) prostate (Meyer-Siegler and Hudson 1996),  
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colorectal (He, Chen et al. 2009) and breast (Hagemann, Wilson et al. 2005) 
cancer.  
Several studies have shown that MIF is linked to fundamental processes that 
control cell proliferation, differentiation, angiogenesis, tumor progression, and 
metastasis (Takahashi, Nishihira et al. 1998, Ogawa, Nishihira et al. 2000, 
Mitchell, Liao et al. 2002). For example, it has been reported that MIF can 
abolish the tumor suppressive activity of p53 (Hudson, Shoaibi et al. 1999). In 
colorectal cancer, the concentration of serum MIF was positively correlated 
with an increased risk of hepatic metastasis (He, Chen et al. 2009). In breast 
cancer, high MIF expression correlates with lager tumour size (Verjans, 
Noetzel et al. 2009). 
1.14.6 Arginase-positive macrophages 
 
The differential metabolism of L-arginine provides a means of distinguishing 
the two macrophage activation states (Hao, Lu et al. 2012) . In M1 cells, L-
arginine is catabolised to nitric oxide ( NO) by up-regulation of inducible nitric 
oxide synthesis (iNOS) (Odegaard and Chawla 2008) , which is used  to kill 
intracellular pathogens, while M2 macrophages produce arginase-1, which can 
metabolize arginine to ornithine and polyamines, which leads to collagen 
synthesis and cellular proliferation (Odegaard and Chawla 2008).   
Interestingly, in an animal tumor model, the increase in NOS activity has been 
observed during tumor rejection, whereas the increase in arginase activity 
occurs during tumor growth (Mills, Shearer et al. 1992). These results suggest 
that L-arginine metabolism in macrophages at the tumor site, through the iNOS 
or arginase pathways, may have either pro-tumour or anti-tumour effects, based 
on which pathway is prevailing (Chang, Liao et al. 2001). This contention is 
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supported by the findings that the tumoricidal activity of macrophages is 
increased when transfected with the iNOS gene (Lorsbach, Murphy et al. 1993, 
Lala 1998, Xie and Fidler 1998). In addition, it was reported that arginase 
induction in macrophages can enhance tumor cell growth by providing them 
with polyamines and suppress tumor cytotoxicity by reducing NO production 
(Chang, Liao et al. 2001). 
1.15 Apoptosis (programmed cell death) 
Cell death is a critical cellular process that has an important role in shaping 
tissues and organs during development and in regulating tissue homeostasis by 
eliminating unwanted or damaged cells. Cell death can be classified into 
regulated or un-regulated processes (Degterev and Yuan 2008). Regulated cell 
death is called apoptosis and reflects an active programme of cell death as 
result of specific cues and is executed by intrinsic cellular mechanisms 
(Degterev and Yuan 2008). The concept of apoptosis was described by plant 
biologists working on Caenorhabitis elegans in the early 1990s (Yuan and 
Horvitz 2004). In contrast, necrosis is a form of unregulated cell death that is 
caused by overwhelming stress that is incompatible with cell survival 
(Degterev and Yuan 2008).  These two mechanisms have classically been 
considered as independent process (Zeiss 2003).  
Apoptosis is an important phenomenon within biological systems and is the 
most common form of physiological cell death that can be initiated by 
exogenous and endogenous stimuli such as radiation, chemicals and oxidative 
stress, and defects in apoptosis have been implicated in diseases such as cancer, 
neurodegenerative and autoimmune disorders (figure 1.7) (Rastogi, Richa et al. 
2009). It is an energy- dependent process that includes the activation of a set of 
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cysteine proteases (caspases) in a complex cascade of events.  Apoptotic cells 
are morphologically characterised by cell shrinkage, nuclear fragmentation, 
chromatin and cytoplasmic condensation and cytoplasmic membrane blebbing 
with formation of apoptotic bodies (Majno and Joris 1995, Trump, Berezesky 
et al. 1997).  
                     
                         
Figure 1.7 Key morphological changes exhibited in apoptosis and necrosis (Rastogi et al. 
2009).  
 
 
 
 
 
 
          Chapter 1 Introduction   
51 
 
1.16 Mechanism of apoptosis 
Apoptotic cell death is triggered by two signalling pathways; intrinsic 
(mitochondria- mediated) or extrinsic (receptor-mediated), both of which 
involve a number of different proteins (Rastogi, Richa et al. 2009). 
I. Extrinsic pathway 
The extrinsic pathway is initiated by activation of cell surface death receptors 
such as TNF1 receptor, Fas, DR3, DR4 and DR5 (Haupt, Berger et al. 2003, 
Yan and Shi 2005, Elmore 2007). Ligands binding to these death receptors 
trigger the intra-cellular association of Fas associated death domain (FADD) 
with pro-caspase-8 forming the death-inducing signalling complex (DISC) 
(Boldin, Goncharov et al. 1996, Muzio, Chinnaiyan et al. 1996). This will 
result in activation of pro-caspase-8 (Walczak, Miller et al. 1999). Caspase-8 
then activates the executioner caspases-3, -6 and -7 which are responsible for 
widespread proteolytic activity leading to the removal of the apoptotic cell by 
the immune system (Hengartner 2000).  
II. Intrinsic pathway 
The signalling through this pathway of apoptosis is linked to permeabilization 
of the mitochondrial outer membrane (Green, Ferguson et al. 2009). The 
control and regulation of apoptotic mitochondrial events occurs through 
members of the Bcl-2 family of proteins (Cory and Adams 2002). The Bcl-2 
super family act as sentinels of cell well-being that detect stress signals such as 
DNA damage, cytokine/growth factor withdrawal and anoikis (detachment 
induced cell death) (Borner 2003). They also ensure the completion of 
apoptosis by irreversible mitochondrial membrane damage (Newmeyer and 
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Ferguson-Miller 2003). The Bcl-2 family is classified into three functionally 
distinct groups governed by the number of BH domains present (Huang and 
Strasser 2000). The Bcl-2-like anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-w, 
Mcl-1 and A1) contain BH 3 and 4 domains and protect cells from apoptosis by 
guarding the outer mitochondrial membrane (OMM) (Reed 1994)( Admas, 
2003,Reed 1994). The BH3-only proteins (Bim, Bad, Bid/tBid, Bmf, Bik, Hrk 
and Noxa Puma) contain a single BH domain and when activated engage with 
specific pro-survival Bcl-2 partners neutralizing their pro-survival activity 
(Bouillet and Strasser 2002, Chen, Willis et al. 2005). The last group comprises 
the BH1–3 proteins (Bax, Bak and Bok) that regulate mitochondrial membrane 
permeability (Willis and Adams 2005, Dewson and Kluck 2009). 
 Once the mitochondrial outer membrane is disrupted, several  proteins are 
released including cytochrome c, second mitochondrial activator of caspase 
(Smac), apoptosis inducing factor (AIF) and endonuclease G (Saelens, Festjens 
et al. 2005). Cytochrome c release is particularly important as it forms the 
apoptosome complex with apoptosis activating factor-1 (Apaf-1) and pro-
caspase-9.  Caspase- 9 can also activate caspases-3, -6 and -7 to further 
provoke the apoptosis response. These pathways and their interaction are 
summarised in Figure 1.8 (Desouza, Gunning et al.) . 
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Figure 1.8 The extrinsic and intrinsic apoptosis pathways (Desouza, Gunning et al. 2012) 
 
(1) The extrinsic pathway is initiated by the ligation of TNF members to the surface receptors. 
This result in formation of the death-inducing signalling complex (DISC) composed of FADD 
and pro-caspase 8. Caspase 8 activation also can activate the pro-apoptotic protein Bid which 
feeds into the intrinsic pathway. (2) The intrinsic pathway is chiefly mediated by the Bcl-2 
super family. Inactivation of Bcl-2 pro-survival partners by BH3 group (pro-apoptotic proteins) 
leads to release of Bax and Bak. Homo-oligomerization of Bax and Bak at the outer 
mitochondrial membrane results in the release of cytochrome c and activation of caspase-9. 
Both pathways converge to activate the executioner caspases leading to cell death. 
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1.17 Markers of apoptosis 
I. Cleavage of Poly (ADP-ribose) polymerase 
(PARP)  
 
PARP is a 116 KDa protein involved in the repair of DNA and in formation of 
chromatin structure (Lazebnik, Kaufmann et al. 1994). It also is important in 
maintaining cell viability, whilst the degradation of PARP facilitates 
disassembly of cells and is considered a marker of the apoptotic cell (Oliver, de 
la Rubia et al. 1998).  During apoptotic cell death, PARP cleavage into its 
characteristic 89KDa fragment is mediated by caspase-3 (Le Rhun, Kirkland et 
al. 1998).  
II. Cleavage of β – actin 
 
The actin cytoskeleton is a structural network of proteins that is involved in 
many  biological functions including cell contraction, cell motility, intracellular 
organization, vesicle trafficking,  cytokinesis, endocytosis and apoptosis 
(Pollard and Cooper 1986, Khaitlina 2001, Yarar, Waterman-Storer et al. 2005, 
Franklin-Tong and Gourlay 2008).  Actin is a 42 kDa globular protein (G-
actin) that reversibly polymerizes to form filaments (F-actin). In muscle cells 
actin is a core component of the sarcomere that interacts with myosin filaments 
to enable force generation needed during muscle contraction (Huxley, 1969). In 
non-muscle cells, actin isoforms (β and γ) perform a different range of 
functions that permit cell survival and adaptation to a changing environment 
(Cooper 1991, Hoock, Newcomb et al. 1991, Schevzov, Lloyd et al. 1992, Hill 
and Gunning 1993).  
The actin cytoskeleton has been shown to be essential during the apoptosis 
process, with extensive changes in the organization of actin filaments 
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accompanying different stages of apoptosis (Laster and Mackenzie 1996, 
Hacker 2000) . Cell rounding, which involves the loss of focal contacts with 
the extra-cellular environment, requires the formation of a contractile cortex of 
myosin II arranged actin filaments (Charras, Hu et al. 2006). Retraction of the 
actin-myosin II cortex considerably alters membrane dynamics leading to 
formation of membrane blebs (Coleman and Olson 2002, Charras, Hu et al. 
2006) .  
There are also several lines of evidence that suggest a role for actin in 
signalling apoptosis (Suria, Chau et al. 1999, Yamazaki, Tsuruga et al. 2000, 
White, Williams et al. 2001, Bando, Miyake et al. 2002, Kim, Schwabe et al. 
2002, Cabado, Leira et al. 2003). In some cells, induction of apoptosis is 
accompanied by caspase-dependent β-actin cleavage to 15 and 31 kDa 
fragments (Mashima, Naito et al. 1995, Kayalar, Ord et al. 1996, Mashima, 
Naito et al. 1997, Mashima, Naito et al. 1999, Nakazono-Kusaba, Takahashi-
Yanaga et al. 2002, Cabado, Leira et al. 2003).  Furthermore, ectopic 
expression of the 15 kDa actin fragment in HeLa and A431 cells has been 
shown to induce morphological changes resembling those in etoposide-induced 
apoptosis (Cabado, Leira et al. 2003). Exposing HeLa cells to etoposide 
treatment resulted in β-actin cleavage, but β-actin cleavage was not detected in 
TNF-treated L929 cells (Li, Li et al. 2004). Thus, it appears that at least in 
some cell systems, cleavage of β-actin may act as a marker of apoptosis.   
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1.18 Role of apoptosis in breast cancer  
 
The balance between proliferation, differentiation and cell death in the 
mammary gland is important in normal development and homeostasis (Parton, 
Dowsett et al. 2001).  Conditions that cause regulation of proliferation and 
downregulation of apoptosis may allow accumulation of mutations that can 
lead to development of breast cancer (Parton, Dowsett et al. 2001).  
Many studies have focused on understanding the mechanism by which 
apoptosis may be disrupted in tumours. In the context of the current study, 
however, the focus is whether induction of apoptosis in myoepithelial cells 
could contribute to the disruption of the limiting barrier in DCIS, allowing 
progression to invasive disease.  
1.19 TRAIL (APO-2L) 
Tumour necrosis factor-related apoptosis-induced ligand (TRAIL) belongs to 
the TNF ligand family that induces apoptosis in a variety of cancer cell lines 
including breast cell lines (Keane, Ettenberg et al. 1999, Chinnaiyan, Prasad et 
al. 2000, Wendling, Walczak et al. 2000). TRAIL protein is expressed by 
peripheral T lymphocytes (Salehi, Vodjgani et al. 2007), including CD4 T cell 
(Sato, Niessner et al. 2006).  TRAIL has been detected in a broad range of 
cells, in particular in activated T cells (Jeremias, Herr et al. 1998, Sato, Nuki et 
al. 2010)  Furthermore, activated Treg cells express TRAIL in vivo (Ren, 
Wagner et al. 2004, Ren, Ye et al. 2007).  Thus it is feasible that changes in the 
inflammatory microenvironment may expose both tumour cells and other host 
cell populations to a variety of pro-apoptotic signals. TRAIL binds to five 
different members of the TNF receptor family, TRAIL-R1/DR4, TRAILR-
2/DR5/TRICK2/Killer, TRAIL-R3/TRID/DcR1/LIT, TRAIL-
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R4/TRUNDD/DcR2 and osteoprotegerin (Locksley, Killeen et al. 2001).   
TRAIL-R1 and TRAIL-R2 mediate apoptosis and contain a death domain (Pan, 
Ni et al. 1997, Pan, O'Rourke et al. 1997, Walczak, Degli-Esposti et al. 1997) 
while TRAIL-R3, which lacks the death domain, is considered as a decoy 
receptor (Degli-Esposti, Smolak et al. 1997).  TRAIL-R4 has an incomplete 
death domain (Degli-Esposti, Dougall et al. 1997). Osteoprotegerin receptor 
inhibits TRAIL-induced apoptosis (Emery, McDonnell et al. 1998). NF-KB 
prevents TRAIL induced apoptosis in human hepatoma (Kim, Schwabe et al. 
2002). 
1.20 Galectin-7 expression in tissue  
Galectins, previously known as S-type lectins, constitute one of several 
families of endogenous lectins and are named for their ability to bind β-
galactosides (Barondes, Cooper et al. 1994).  All galectins display a  similar 
sequence in the carbohydrate recognition domain (CRD) which includes about 
130 amino acids, and a globular tertiary structure making a groove for the 
binding of carbohydrate (Leffler, Carlsson et al. 2004). There are 15 forms of 
galectins, 11 of them are expressed in humans, known as galectin 1-4, 7,10 and 
12-14 (Liu and Rabinovich 2005). In recent years, they have emerged as novel 
modulators in different aspects of cancer (Demers, Rose et al. 2010). 
Galectin-7 was isolated by Madsen and colleagues in their attempt to identify 
new markers involved in the maintenance of the normal human epidermal 
phenotype (Madsen, Rasmussen et al. 1995). Galectin-7 is expressed in 
stratified epithelia, including cornea, oral cavity, esophagus, anorectal 
epithelium and epidermis (Magnaldo, Bernerd et al. 1995). Galectin-7 
expression is up-regulated in mouse cornea during wound healing, and 
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recombinant galectin-7 stimulated re-epithelization of the cornea during 
healing (Cao, Said et al. 2003). Moreover, galectin-7 has been described both 
as pro-apoptotic and anti-apoptotic, in vivo and in vitro. An early report 
identified galectin-7 as one of the first genes responding to over-expression of 
the p53 tumour suppressor gene in human DLD-1 colon cancer cells (Polyak, 
Xia et al. 1997) . It also has been reported that galectin-7 expression is 
increased in apoptotic keratinocytes of human skin explants exposed to UVB 
light (Bernerd, Sarasin et al. 1999). In addition, ectopic expression of galectin-
7 in HeLa and DLD-1 cells renders them more susceptible to apoptosis induced 
by actinomycin D and UVB (Kuwabara, Kuwabara et al. 2002). In contrast, 
exposure of skin of wt and galectin-7-/- adult mice to UVB has demonstrated a 
twofold increase in apoptotic cells in galectin-7-/- compared with wt epidermis 
at 6 h (Gendronneau, Sidhu et al. 2008).  In the normal breast, Dermer and his 
colleagues (2010) have shown that galectin-7 is highly expressed by the 
myoepithelial cell population.  They also have shown that high-grade breast 
cancers express high levels of galectin-7 while low-grade cancers show none or 
minimal galectin-7 expression. Moreover, they found its over-expression to be 
associated with tumour metastasis to the lung and bone. It has been suggested 
that galectin-7 has the ability to render mammary epithelial cells more resistant 
to apoptosis (Demer et al 2010).   It also has been revealed that intracellular 
galectin-7 may have  a novel function as a transcriptional regulator whereby 
galectin -7 interacts with Smad3 to regulate its export from the nucleus, 
thereby inhibiting TGFβ signalling (Inagaki, Higashi et al. 2008). Given the 
privileged position of myoepithelial cells in DCIS, changes in the 
myoepithelial phenotype which may influence their response to apoptotic 
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stimuli may be of importance in defining the integrity of the myoepithelial- 
basement membrane interface and so disease progression. Changes in galectin-
7 by breast myoepithelial cells have not, to our knowledge, been previously 
investigated.   
1.21 Hypothesis  
 
The microenvironment in DCIS is complex and the myoepithelial cell, which 
forms the major barrier between the epithelial and stromal compartments, may 
play a key role in disease progression. We previously have shown that 
myoepithelial cells in DCIS display an altered phenotype, with up-regulation of 
the integrin αvβ6, switching myoepithelial function from tumour suppressor to 
tumour promoter. However, the relationship between myoepithelial phenotype 
and the peri-ductal inflammatory infiltrate, and the influence of it on 
myoepithelial integrity have not been investigated. 
Therefore, the hypothesis of the study is that changes in myoepithelial 
phenotype that occur during evolution of DCIS, including up regulation of 
integrin αvβ6, result in an altered peri-ductal inflammatory microenvironment 
contributing to a pro-tumour phenotype. A key step in progression of DCIS is 
loss of the myoepithelial cell layer. We hypothesise that one mechanism by 
which the inflammatory infiltrate may promote tumour progression is through 
induction of myoepithelial cell apoptosis, possibly through release of TRAIL. 
Since galectin-7, a molecule highly expressed by normal myoepithelial cells, 
has been shown in some situations to protect cells from apoptosis, we postulate 
that changes in galectin-7 in DCIS- associated myoepithelial cells may enhance 
their susceptibility to apoptosis: To investigate this hypothesis the aims are:  
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 To characterise the nature of the inflammatory cell infiltrate in the peri-
ductal environment of DCIS, and correlate this with myoepithelial 
phenotype as indicated by αvβ6 expression.  
 To investigate the impact of myoepithelial cells on the inflammatory 
cell phenotype using co-culture systems and in-vivo Matrigel plug 
assays. 
 To investigate the cytokine profile of normal and DCIS-modified 
myoepithelial cells, and whether this is influenced by inflammatory 
cells, using cytokine arrays. 
 To study the sensitivity of β4 and β6 myoepithelial cells to apoptosis 
generated through release of inflammatory cell mediators (such as T cell-
derived TRAIL) and investigate whether phenotypic alterations in 
myoepithelial cells, such as loss of Galectin-7, influenced their response. 
This will be done using knock-down and over-expression culture model 
systems. 
 
Together, this should elucidate the functional relationship between the 
altered myoepithelial phenotype observed in DCIS and the nature of the 
inflammatory infiltrate, and indicate whether these changes impact on loss 
of the myoepithelial cell layer through apoptosis. 
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Materials and Methods 
 
2.1 Clinical materials 
2.1.1 Tissue samples  
2.1.1.1 UK tissue samples  
Cases of DCIS were identified from The Barts Cancer Institute Breast Tissue 
Bank, covered by Research Tissue Bank Ethics Approval (10/H0308/49, 
Cambridge 2 Research Ethic Committee). These were sequential patients 
presenting to Barts Health Breast Unit during the period of 2007-2009 and who 
had consented for use of their tissues for research.Samples were linked-
anonymised prior to use in this study. Forty-seven cases of DCIS of different  
grades were used in the study.  Details of patient demographics and pathology 
are given in Table 2.1. 
Table 2.1 Details of patient demographics and pathology 
 
 
 
  
Age 
Size 
mm 
Invasive 
Number      
(%) 
Total     
number 
(%) 
DCIS grade  Mean Range Mean  Range  Present Absent 
Low  56 54-59 14.2 6-19 0 
(0%) 
3 
(100%) 
3 (6%) 
Intermediate  57 52-63 19.0 4-28 0 
(0%) 
8 
(100%) 
8 (17%) 
High  46 39-54 32.9 9-47      0 
(0%) 
    36 
(100%) 
36 (77%) 
  Chapter 2 Materials & Methods 
63 
 
2.1.1.2 Netherland tissue samples  
 
Through collaboration with Dr. Pieter Westenend (Labratorium voor 
Pathologie, Dordrecht), sections from patients with a diagnostic core biopsy of 
DCIS were obtained for study. A total of 294 cases were received, all 
anonymised. Following analysis, data were returned to Dr.Westenend to be 
collated with clinicopathological information and then returned for statistical 
analysis. Details of patient demographics and pathology are given in Table 2.2.  
 
Table 2.2 Details of patient demographics and pathology 
 
 
 
 
 
 
             
 Age  
Size 
mm 
Invasive 
Number 
(%) 
Total     
number 
   (%) 
DCIS grade  Mean Range Mean  Range  Present Absent 
Low  61.6 44-77 11.1  2-60 5 
(15%) 
   29 
(85%) 
    34 
(11.5%) 
Intermediate  59.1 27-83 19.8 1-100     18 
(27%) 
   48 
(73%) 
    66 
(22.5%) 
High  57.1 45-88 26.7 3-90     46 
(24%) 
  148 
(76%) 
   194 
(66%) 
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2.1.2 Tissue block selection 
 
For the Barts Cancer Institute samples, formalin-fixed paraffin embedded 
blocks were sectioned  for Haematoxylin and Eosin (H&E) staining and 
representative blocks selected for the study by Professor Louise Jones (JLJ).  
Then, 4 µM serial sections were obtained from these blocks for 
immunohistochemical staining for galectin-7, αvβ6 and inflammatory markers.  
2.2 Origin of primary cells and cell lines 
 
Details of cells lines and primary cells used are summarized in Table 2.3. 
Primary breast myoepithelial cells were isolated from donors undergoing 
reduction mammoplasty surgery (section 2.1.3.1).  Primary T lymphocytes 
were obtained from peripheral blood samples of healthy donors. 
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Table 2. 3 Source and Characteristics of cells used in in vitro experiments  
 
 Type of cells                    Characteristics  
 
 
Human Breast 
Myoepithelial 
cells 
  
β4  
Origin: immortalised line initially derived from 
breast reduction tissue (O'Hare, Bond et al. 2001).  
Features: immortalized line of normal mammary 
myoepithelial cells positively selected for β4 using 
magnetic beads.   
β6 Origin: β6 cell line was derived from β4 cells in our 
lab by stable over-expression of β6. 
Features: Virally transfected with PBabepuro- β6 to 
express high levels of β6 integrin. 
Primary 
myoepithelial  
Origin:  normal human breast   
Features: normal mammary myoepithelial cells 
isolated using CALLA-magnetic beads  
 
 
Human T 
lymphocytes 
 
 
Jurkat cell line Origin:  in 1970s isolated from the peripheral blood 
of a 14 year old boy with T cell leukemia. 
 
Features: immortalized line of T lymphocyte cells. 
Primary T 
lymphocytes 
 
Origin: peripheral blood from healthy donors. 
 
Features: CD4/ CD8 positive. 
 
 
2.2.1 Primary cells 
 
2.1.3.1 Breast myoepithelial cells  
 
 Primary breast myoepithelial cells were obtained from donors undergoing 
reduction mammaplasty surgery at Barts Health NHS Trust. All donors were 
consented prior to Surgery. Ethical approval was obtained from Barts Cancer 
Institute Breast Tissue Bank (10/H0308/49, Cambridge 2 Research Ethic 
Committee). Cell isolation was carried out by Dr. Jenny Gomm (Gomm, 
Browne et al. 1995). Normal Breast tissue was minced into small pieces 
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(0.5cm), and then incubated in RPMI medium containing 10 % FBS, 
collagenase and hyaluronidase overnight at 37 ºC. Following enzyme digestion 
the fat layer was removed and the remaining organoids and single cells 
centrifuged and washed 3 times in medium. To isolate the ductal elements from 
the stroma, sedimentation steps at 1g were employed for 30 minutes and 
repeated 3 times. Supernatant was removed and used for stromal cells. A loose 
pellet of the organoids was collected and used as the ductal fragment.  
Purification of myoepithelial cells was performed using anti-CALLA (common 
acute lymphocytic leukaemia antigen)-labelled magnetic beads, as a specific 
cell membrane marker of myoepithelial cells (figure 2.1). This process was 
performed using immunomagnetic isolation with Dynabeads as described 
(section 2.8.9).  
 
Figure 2.1 Scheme depicting preparation and purification of breast cell types  
(Gomm, Browne et al. 1995). 
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2.1.3.2 Primary T lymphocytes  
 
Primary T cells were obtained from peripheral blood samples from healthy 
donors at Barts Hospital. Cell isolation was undertaken in the Centre of 
Medical Oncology at   Barts Cancer Institute and was a gift from Dr. Alan 
Ramsey.  
2.3 Matrigel plug assays  
 
A group of 12 female C57/Blk6 normal mice, 4 weeks old were used in this 
study. β4 cells and β6 myoepithelial cells were suspended in Matrigel then 
injected separately into opposite flanks of the mice. B16 mouse melanoma cells 
were used as a positive control and Matrigel alone as a negative control. After 
9 days when the tumours became palpable, the mice were sacrificed, and 
Matrigel with the surrounding tissue was extracted. 
 These Matrigel plugs were formalin-fixed and paraffin- embedded then 
sections cut and stained for inflammatory markers CD4, FOXP3 (Treg), CD8 
(cytotoxic T cell), CD74 (macrophage inhibitory factor receptor) and  arginase 
(M2 macrophage) (figure 2.2).  
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Figure 2.2 Scheme depicting investigation of the interaction between myoepithelial cells 
and the inflammatory infiltrate in - vivo.  
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2.4 Immunohistochemistry  
2.4.1 Slide preparation  
Formalin-fixed, paraffin-embedded breast tissue blocks including different 
grades and subtypes of DCIS were used in the study. Serial sections of 4µm 
thickness were cut and placed on positively charged microscope slides for 
immunohistochemical analysis.  
2.4.2 Haematoxylin and eosin staining 
 
Sections were dewaxed through changes of xylene then rehydrated through 
graded alcohols (100%, 100%, 80%, 70%, and 50%). After washing in tap 
water, the sections were immersed in Haematoxylin for 90 seconds, washed in 
tap water, and then briefly dipped in Eosin. After washing in tap water the 
sections were dehydrated through graded alcohols (50%, 70%, 80%, 100%, 
100%) and finally dipped in xylene. Finally the slides were drained in a rack 
and a drop of DPX mountant was   spread over cover slips. All procedures that 
included xylene or alcohol-containing materials were carried out in a fume 
hood. 
2.4.3 Immunohistochemistry technique   
 
Immunohistochemical staining is accomplished with antibodies that detect the 
target protein. Since antibodies are highly specific, the antibodies will bind 
only to the protein of interest in the tissue section. Then the antibody-antigen 
reaction is visualized using fluorescent detection, in which a fluorophore is 
conjugated to the antibody and visualized using fluorescence microscopy or by 
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chromogenic detection, in which an enzyme conjugated to the antibody cleaves 
a substrate to produce a coloured precipitate at the site of the target protein. 
2.4.4 Slide preparation for staining 
 
Sections were dewaxed in xylene and then rehydrated through graded alcohols 
as described. Endogenous peroxidase was blocked using a solution of hydrogen 
peroxide and methanol 3:200 for 10 minutes, followed by dipping in graded 
alcohols again for 2 minutes per solution. 
2.4.5 Antigen retrieval 
 
Antigen retrieval is a technique used to enhance the binding of antibody to 
antigen in tissue through unmasking of the antigenic site.  It is usually used 
when a fixation or embedding method has caused changes which mask 
antibody binding.  
Most antigen retrieval methods are based on microwave or pressure cooker 
treatment to heat the tissue sections to temperatures at 100-120 °C in the 
presence of metal solutions. Three approaches were tested in this study: 
i. Heat-induced: sodium citrate 10 mM, pH 6.0 at 100-120°c for 10 
minutes   
ii. Heat-induced: Tris/EDTA pH 9.0 at 100-120°c for 10 minutes. 
iii. Enzymatic: trypsin, pepsin, or other protease. 
After establishing the optimal antigen retrieval method, the antibody 
concentration can then be further optimized. 
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2.4.6 Blocking 
 
Sections were washed in distilled water. The sections were outlined using a 
PAP pen. Background was blocked  for 10 minutes using 20% Normal Rabbit 
Serum (NRS) or 1.5% Normal Horse Serum, according to the nature of 
secondary antibody, made up in 0.2% bovine serum albumin (BSA)  dissolved 
in phosphate buffered saline (PBS/BSA 0.2%). 
2.4.7 Primary antibody 
 
Sections were drained and 200 µl of primary antibody, made up in 0.2% BSA 
to optimal concentration, was applied. The sections were incubated for 1 hour 
at RT. Details of antibodies used and optimal dilutions and antigen retrieval are 
provided below (Tables 2.4 and 2.5). FOXP3 and CD8 antibodies could not be 
optimized, therefore, in order to investigate expression of FOXP3 and CD8 in 
Matrigel plugs, they were replaced with alternative antibodies. 
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Table.2.4 Details of Antibodies for human tissue: working dilutions and antigen retrieval 
techniques 
 
 
 
 
Antibody  Dilution  Antigen 
retrieval  
Source   Positive 
control  
   CD4  
 
 
1:25  EDTA pH 8.0  Leica   Tonsil   
  CD68  1:50  0.1M Tri-
sodium citrate 
pH 6.0  
 
Dako 
  Tonsil   
   CD69  
 
 
1:100  EDTA pH 8.0  Leica   Tonsil   
  Arginase-1  
 
 
1:75  EDTA pH 8.0  Sigma    Liver  
  FOXP3  1:50  0.1M Tri-
sodium citrate 
pH 6.0  
Abcam    Tonsil   
  MHC-II  1:1000  0.1M Tri-
sodium citrate 
pH 6.0  
Abcam     Tonsil 
 CD8  
 
 
1: 300 0.1M Tri-
sodium citrate 
pH 6.0 
Dako    Tonsil  
CD45RO 
 
 
1:200 0.1M Tri-
sodium citrate 
pH 6.0 
Dako    Tonsil  
CD74  
 
 
1:200 0.1M Tri-
sodium citrate 
pH 6.0 
Leica   Tonsil  
 Galectin-7  
 
 
1:750 
 
 
0.1M Tri-
sodium citrate 
pH 6.0 
 
Epitomics 
 
Skin  
Normal 
breast  
Caspase-3  
 
 
1:300                     0.1M Tri-
sodium citrate 
pH 6.0 
Cell 
Signaling 
 
Internal  
β 6 integrin     1:300 Pepsin  
 
Calbiochem  Skin  
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Table 2.5Details of Antibodies for mouse tissue: working dilutions and antigen retrieval 
technique 
 
2.4.8 Secondary antibody 
 
Sections were washed twice in PBS for 5 minutes. 200 µl of biotinylated 
secondary antibody at the appropriate concentration in 0.2% BSA was applied 
to each section, and incubated for 40 minutes at RT. 
2.4.9 Avidin biotin complex (ABC) 
 
Sections were washed twice in PBS for 5 minutes each before adding ABC 
solution (1:50 A and 1:50 B in PBS) which was made 30 minutes prior to 
application.  The sections were incubated for 30 minutes at RT. 
2.4.10 Detection 
 
For light microscopy, horseradish peroxidise (HRP) is a commonly used label. 
Peroxide/DAB are the substrate and recommended chromogen for horseradish 
peroxidase. Sections were washed with PBS buffer twice for 5 minutes each 
before being developed with 3, 3-diaminobenzidine tetrahydrochloride (DAB) 
Antibody Dilution Antigen 
retrieval 
Source Positive 
control 
CD4 1:25 EDTA pH 8.0 Leica Spleen 
Arginase-1 1:75 EDTA pH 8.0 Sigma Liver 
FOXP3 1:200 0.1M Tri-
sodium citrate 
pH 6.0 
Novus Spleen 
CD74 1:200 0.1M Tri-
sodium citrate 
pH 6.0 
Lieca Spleen 
CD8 1:300 0.1M Tri-
sodium citrate 
pH 6.0 
Cell 
Signaling 
Spleen 
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for 2-5 minutes at RT and then washed with distilled water, counterstained 
with haematoxylin and finally washed with tap water. 
2.4.11 Dehydration  
 
After washing with distilled water the sections were passed through graded 
alcohols for 2 minutes each and xylene for 5minutes. They were mounted with 
a drop of DPX mountant.  
2.5 Scoring of Immunohistochemistry  
2.5.1 Scoring of αvβ6 IHC staining  
 
Whole sections of DCIS were stained for αvβ6 expression and the extent of 
staining on DCIS-associated myoepithelial cells was recorded by Professor 
Louise Jones (JLJ) and myself.  
Cases that showed homogenously positive or negative patterns of staining ie. 
where all DCIS ducts showed myoepithelial cells positive or negative for αvβ6, 
were selected to further analyze the characteristics of the peri-ductal 
inflammatory infiltrate in DCIS, and its relationship to αvβ6 expression.   
2.5.2 Relationship between αvβ6 and galectin-7 
expression  
The relationship between myoepithelial expression of αvβ6 and expression of 
galectin-7 was analysed in two cohorts: 
(i) A set of 40 cases from the Barts Cancer Institute Breast Bank Tissues were 
analysed on a duct- by- duct basis. The stained sections were scanned using 
NDP Nanozoomer scanner. Cases were scored duct by duct for positive or 
negative staining for Galectin-7 and αvβ6 in the myoepithelial cells 
independently by JLJ and myself, and the results compared. Where there 
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was disagreement, the images were viewed by both scorers and an agreed 
score made.   
(ii) A series of 294 core biopsies with a pre-operative diagnosis of DCIS were 
received from our collaborator Dr. Pieter Westenend, and stained for αvβ6 
and galectin-7. The biopsies were scoredby Professor Louise Jones (JLJ), 
Dr. Purnima Makhija and myself as the percentage of DCIS ducts showing 
myoepithelial positivity for each stain. Where there was discrepancy 
between the scorers, the cases were viewed on a double-headed 
microscope, and an agreed score made. The staining scores were returned 
to Dr. Pieter Westenend to reconcile with the clinical data, specifically 
whether the surgical excision showed pure DCIS, or had admixed invasive 
carcinoma.  
2.5.3 Scoring of inflammatory cell infiltrate in DCIS 
2.5.3.1 Photography 
 
The DCIS cases classified as homogenously positive or negative for αvβ6 were 
then stained with a series of antibodies to characterize the inflammatory cell 
infiltrate. The serial sections were scanned using an NDP Nanozoomer scanner, 
a minimum of 4 ducts from each case were captured. Each duct image was 
exported as a jpg at X5 or X10 magnification (figure 2.3).   
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Figure 2.3 NDP Image software 
 
A series of cases of DCIS homogenously positive or negative αvβ6 were stained for a panel of 
inflammatory markers and scanned using NDP Nanozoomer scanner. Each duct image was 
exported to jpg with X5 or X10 magnification.  
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2.5.3.2 Process Image program 
 
To assess the relationship between αvβ6 staining of myoepithelial cells and the 
peri-ductal inflammatory environment, images of ducts were uploaded to 
Process Image software in order to score them. This software is a program that 
allows conversion of graphic files to editable forms that can be scored in co-
operation with the freeware image manipulation program GNU image 
manipulation program (GIMP).  It enables an image to be edited to calculate 
areas, lengths and marker counts.  A region of 100μm from the edge of the duct 
was defined by this software and the number of cells positive for different 
inflammatory markers was counted in this area. The positive cells were 
manually highlighted, then the program was run to calculate them (figure 2.4).  
      
Figure 2.4 Process Image Software. 
 
This software was used to score the inflammatory cells around each of the DCIS ducts.  The 
number of inflammatory cells staining for each marker was counted in a region of 100μm from 
the edge of the duct. 
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2.5.4 Scoring of inflammatory cell infiltrate in Matrigel 
plugs  
2.5.4.1 Photography 
 
 Immunohistochemically stained sections of Matrigel plugs were scanned using 
NDP Nanozoomer scanner. The numbers of positive cells for inflammatory 
cells markers were scored using Imagescope software. 
2.5.4.2 Aperio Imagescope software  
 
Imagescope is a new image analysis solution for immunohistochemistry as part 
of the Aperio digital pathology system. Aperio’s IHC image analysis 
algorithms are designed to assess staining of cell features (nuclei and 
membrane).  
The scoring scheme parameters specify the staining intensity thresholds that 
determine the individual cell.  The program classifies the intensity of staining 
as 0, 1+, 2+ and 3+. Cell staining is classified 0 when there is no staining, 1+ 
when there is weak staining, 2+ for moderate staining and 3+ for strong 
staining. 
 
2.5.4.3 Quantitation of the inflammatory cell infiltrate in 
Matrigel plugs containing myoepithelial cells 
 
Whole sections of Matrigel plugs were scanned using NDP software and 
analysed using Imagescope software. Each section was opened in the 
Imagescope program, the scoring scheme parameters specifying the staining 
intensity threshold of each marker were set up based on intensity of staining, 
which is classified as 0 (negative), 1+ (weak), 2+ (positive) and 3+ (strong 
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positive), and the software was run to count the positive and negative cells for 
each inflammatory marker over the entire section. The result was exported to 
an Excel file and the number of positive cells per mm
2
 was calculated, and 
plotted on a graph using prism software. 
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Figure 2.5 Imagescope software 
 
The program enabled an image to be edited to score intensity, area and marker-positive cell counts (A). 
Parameters of each marker were set up to avoid scoring background and based on intensity, staining is 
classified as 0 (negative, blue), 1+ (weak, yellow), 2+ (positive, orange) and 3+ (strong positive, red) 
(B). The software then calculated the define area, number of positive cells according to their intensity 
and number of negative cells. Data was exported into an Excel spread sheet (C).   
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2.6 Measuring of DCIS duct size  
 
Differences in size of the DCIS ducts were observed whilst scoring the IHC 
staining for galectin-7 and αvβ6. Therefore I measured the duct size and related 
it to IHC pattern to assess whether there is a correlation between the size of 
ducts and myoepithelial cell phenotype. The measurement was applied using 
NDP software after scanning the sections.  Ducts were selected from 40 DCIS 
cases retrieved from the Barts Cancer Institute Tissue Bank. Ducts were 
measured in two diameters as they are not definitive spheres (Figure 2.6). The 
area of duct was calculated using using a mathematical formula derived by Dr. 
Michael Allen to measure the area of ellipse ( ). A total of 617 
ducts were analysed.  
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Figure 2.6 Measuring DCIS duct size  
 
Each photo is opened in NDP software, and linear measure selected from the annotate menu 
(A). As DCIS ducts are not definite circles, they were measured in two directions using the 
linear measure (B). 
  Chapter 2 Materials & Methods 
83 
 
2.7 Statistical analysis 
 
Data has been analysed using the Mann Whitney test and one way ANOVA, 
and p values less than 0.05 were identified as statistically significant. Graphs 
were generated using GraphPad Prism software. 
Data from the Netherland DCIS series were analysed by Professor Stephen 
Duffy, Wolfson Institute for Preventive Medicine, by Spearmans 
correlationusing STATA software.  
 
2.8 Cell culture 
 
Primary cells and cell lines were regularly assessed for contamination with 
mycoplasma using RT-PCR protocol (section 1.1, appendix 1). 
2.8.1 Myoepithelial cell line culture   
 
β4 myoepithelial cells (β4 myo) and its β6 over-expressing counterpart, termed 
β6 myo, were stored in liquid nitrogen in 10% Dimethyl sulphoxide (DMSO), 
20% fetal calf serum (FCS) (Life Technologies) and 70% Ham’s F12: DMEM 
(Dulbeccos MEM; Cancer Research UK). Cells were recovered quickly from 
liquid nitrogen storage by defrosting at 37ºC and re-suspending in pre- warmed 
complete myoepithelial medium. Complete myoepithelial medium consisted of 
Ham’s F12, 10% FCS (Life technologies), 2mM L-glutamine, 10 ng/ml 
epidermal growth factor (EGF), 5μg/ml insulin, 0.4 μg/ml hydrocortisone 
(Invitrogen). After centrifugation at 1,200 rpm for 3 minutes the cell pellet was 
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resuspended in culture medium and transferred to culture flasks. Cells were 
usually cultured in T75 or T175 tissue culture flasks under standard conditions 
(37ºC, 5% CO2), and the cells passaged on reaching 70% confluence (every 2-
3 days) by trypsinizing with 10x Trypsin-EDTA for 2-5 minutes at 37ºC. After 
the cells were detached from the flask surface, the trypsin is deactivated by   
adding 3 ml of culture medium followed by centrifugation at 1,200 rpm for 3 
minutes to collect the cell pellet and then re-cultured in 1:3 split ratio. 
2.8.2 Maintenance of myoepithelial cell line 
 
β4 and β6 cell lines show phenotypic drift over time, particularly down-
regulation of α6 β4 integrin, a key characteristic of myoepithelial cells.  
Therefore, myoepithelial cell lines were re-sorted for high expression of β4 
integrin expression, using magnetic beads (section 2.8.9). For the myo β4 cells, 
a population was positively selected using magnetic beads labeled withan 
antibody to β4 integrin. For β6 myos, cells were positively selected using beads 
labeled with β6 integrin.  
2.8.3 Primary myoepithelial cell culture 
 
Primary myoepithelial cells were grown routinely in mammary epithelial 
growth medium (MEGM) containing 50µl EGF, 25 µl insulin, 50µl 
hydrocortisone (HC) and 10 µl gentamycin.   
2.8.4 Jurkat cell line culture 
 
Jurkat cells were placed in suspension cultures at ∼1 × 105 cells/ml in RPMI 
1640 containing 2 mM L-glutamine and 10% FCS. Cells were split 1:4 every 3 
days after reaching a density of ∼1 × 107 cells/ml.  
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2.8.5 Primary T cell culture  
Primary T cells were recovered from liquid nitrogen storage by thawing at 
37ºC with 2 µl of DNAase added to avoid cell clustering.  The cells were then 
resuspended in pre- warmed RPMI 1640 media containing 10% FCS, then 
centrifuged at 1500rpm for 5 minutes. The pellet was resuspended in 4 ml of 
complete T cell media.  Cell counts were carried out as described in section 
2.8.6. The viability of cells was determined using trypan blue. The cells were 
incubated overnight at 37ºC to aid recovery, then counts and viability were 
assessed again ready for use in experiments.  
2.8.6 Counting of cells 
 
Cell pellets were resuspended in 10 mls of medium in preparation for counting 
using a haemocytometer. 10µl of suspension was removed and transferred to 
the haemocytometer. Cells in the haemocytometer grid were viewed using a 
Zeiss Axiovert microscope. The number of cells in four of 4 X 4 grids was 
counted (number of cells x10
4
/ ml of cell suspension) and an average taken. 
Total cell count was determined and multiplied by a dilution factor (X 2). 
Viability of cells was assessed by trypan blue.    
2.8.7 Cryopreservation of cells 
 
Freezing medium was prepared, comprising DMEM, 40% FCS and 10% 
dimethyl sulphoxide (DMSO). At 70-80% confluence, cells were washed with 
PBS, trypsinised when required, then centrifuged at 1200rpm for 3 minutes.
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The pellet was resuspended in 1ml of freezing medium, then slowly frozen in a 
-80°C freezer. The next day vials were transferred to liquid nitrogen. When 
needed, cells were thawed quickly in a water bath at 37
°
C and pipetted slowly 
into a 15ml falcon tube containing 4 mls of complete cell medium.   
2.8.8 Generation of condition medium  
 
To generate myoepithelial cell conditioned medium (CM), 7x 10
4 
myoepithelial cells were seeded into each well of a 6 well plate and grown in  
general cell medium for 24hrs, to establish the culture. The next day the 
medium was replaced by 2 ml of serum free medium (SFM) and incubated for 
48 hrs to generate condition medium (CM).  This was aspirated, centrifuged 
and the supernatant aliquoted into 15 ml falcon tubes before freezing at -20
°
C
.
 
2.8.9 Magnetic activated cell sorting  
 
A cell suspension was prepared and counted. An aliquot of cells at the desired 
concentration was added to 1ml of ice-cold SFM and transferred to an 
eppendorf tube and 5 µl of β6 antibody added and mixed gently. The eppendorf 
then was placed on a rotating wheel at 4
° 
C for 20 minutes. Cells were 
centrifuged at 1200rpm for 3 minutes and washed with ice-cold SFM. This 
process was repeated twice. Rabbit anti-mouse IgG Dyanbeads were added to 
1ml of the cell suspension at 1:1 bead to cell ratio.  This was incubated for 20 
minutes at 4
° 
C on a rotating wheel. The eppendorf was then placed into a 
magnetic bead concentrator to separate the labeled cells.  
For positive selection, medium was carefully aspirated, a further 1ml of SFM 
was added and the eppendorf gently shaken. This was placed again in the 
magnetic bead concentrator and repeated 3 times. For negative selection, the 
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aspirated medium was transferred to a separate eppendorf and placed in the 
magnetic bead concentrator. This process was repeated 5 times.  Sorted cells 
were resuspended in complete medium and plated out into a T25 flask or stored 
in liquid nitrogen to maintain cell stocks (section 2.8.7). 
2.8.10 Co-culture of myoepithelial cells with T cells  
 
Myoepithelial cells (7x10
4
) were plated in the wells of a 6 well plate and 
incubated overnight in complete myoepithelium medium (figure 2.7A). The 
following day, the medium was removed and replaced with 2ml of serum free 
medium (SFM) followed by incubation overnight (figure 2.7B).  Jurkat T cells 
or primary T cells were spun down and re-suspended in SFM. 3x10
5
 T cells per 
well were aliquoted, centrifuged and medium discarded. Then, these cells were 
in re-suspended in 2ml of the myoepithelial medium and seeded back into the 
plates containing myoepithelial cells (figure 2.7C). These co-cultures were 
incubated for 24, 48 and 72 hrs then the floating T cells (Jurkat or primary T 
cells) were collected for flow cytometery or harvested and protein isolated. The 
attached myoepithelial cells were harvested and protein isolated.  
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Figure 2.7 Co-culture of myoepithelial cells with Jurkat or Primary T cells 
 
7x10
4
 myoepithelial cell were plated into each well of a 6 well plate and incubated overnight 
(A). Then the myoepithelial cell medium was replaced with SFM (B). Jurkat/T cells were 
counted, suspended in the condition medium from the myoepithelial cells and placed back into 
the wells with the myoepithelial cells to form the co-culture (C).    
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2.9 Cell treatment  
 
5x 10
5
 myoepithelial cells, either β4 or β6 myoepithelial cell lines, were seeded 
into T25 flasks, with 5 ml of complete myoepithelial medium. The cells were 
allowed to attach overnight then the medium was replaced with medium 
containing 500ng/ml of recombinant TRAIL (Peprotech) and the cells cultured 
for 2, 4 and 8 hrs before protein was extracted for Western blot. In separate 
flasks, as a control, both cell lines were also exposed to etoposide 
chemotherapy (1μM/ml) (Sigma) for 4, 6, 8 and 48 hrs to induce apoptosis. A 
similar experiment was performed using the myoepithelial cell lines following 
knockdown of galectin-7 (section 2.11), and the cells were then treated with 
recombinant TRAIL or etoposide at the  same concentrations and incubated for 
the same time course before being harvested. All experiments were performed 
a minimum of 3 times in duplicate.  
 
2.10 Western blotting  
2.10.1 Preparation of whole cell lysates  
 
Cell pellets were washed with cold PBS and spun at 10,000 rpm, 4ºC for 2 
minutes twice. 200 μL of cold Radio Immune Precipitation Assay (RIPA) 
buffer (section 1.2, appendix 1) containing protease inhibitor cocktail 
(Calbiochem) at 1:100 was added to the cells and incubated for 15 minutes on 
ice. Cells were then centrifuged at 4ºC at 13000 rpm for 5 minutes. The cell 
lysate supernatants were collected and stored at -20° C.  
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2.10.2 Estimation of protein concentration  
 
Bovine serum albumin (BSA) standards (0.1mg/ml to 5mg/ml) were made up 
using serial dilutions of a 5mg BSA solution (diluted in PBS). Then, 5 μl of 
each sample and the BSA standards were loaded into a 96-well plate in 
triplicate. Measurement of protein concentration was performed using the 
BioRad Dc protein assay kit (Reagent A, Reagent B, Reagent S) according to 
manufacturer’s protocols. 20μl of A and S mixture (1000:25) was added to 
each well followed by 200μl of B reagent. After incubation at RT for 10 
minutes, the color change was assessed using an ELISA plate reader set up to 
read the protein assay at an absorbance of 630nm. A standard curve was 
generated, which was used to determine the protein concentration of the 
experimental samples. 
2.10.3 Immunoblotting  
 
A 1.5 ml acrylamide gel cassette was filled with 12% or 8% SDS-
polyacrylamide resolving gel (section 1.3, appendix 1).  1ml of distilled water 
was added to cover the gel, which was left to set for 30 minutes.   The distilled 
water was removed using filter paper and a stacking gel (section 1.4, appendix 
1) was pipetted on the top of the resolving gel. A tooth-comb was inserted and 
the gel left to set for 30 minutes. The gel cassette was placed in an 
electrophoresis apparatus and surrounded by running buffer (section 1.5, 
appendix 1).   10 µl of molecular weight marker (Thermo Fisher Scientific) 
was loaded into the first well of the gel.  Each sample (40μg protein) of the 
whole cell extract was mixed with 4 x Laemmli buffer containing 
Bromophenol Blue (Epigentic). 
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The samples were then denatured at 95
°
C for 5 minutes and vortexed before 
being loaded into the gel. The gels were run at 125V for one and half hours 
until adequate separation was obtained. The proteins were then transferred onto 
nitrocellulose membrane (Amersham), using a wet blotting system (Biorad) 
and transfer buffer (section 1.6, appendix1) was added. A constant voltage of 
30V was applied until sufficient transfer of proteins had been achieved.  The 
membrane was removed and stained with 0.1% Ponceau S solution to visualize 
the total protein bands.  
2.10.4 Antibody detection 
 
 The membrane was blocked with 5% milk in PBS with 0.1% Tween 20 for 20 
minutes at room temperature.  
Specific primary antibodies were diluted in 0.1% Tween –PBS with 5% milk. 
Details of the antibodies and optimal dilutions used in this study are 
summarized in Table 2.6. Incubation of the membranes with the primary 
antibodies was performed overnight with shaking at 4ºC. After that the 
membranes were washed 3 times with 0.1% Tween- PBS for 5 minutes each 
then incubated with mouse or rabbit secondary antibody conjugated to 
horseradish peroxide for 1hr at room temperature. To detect the bound 
antibody, the membranes were washed 3 times for 5 minutes each and 
incubated in ECL solution (Amersham) for 1 minute. Then they were placed in 
the film cassette boxes with an X-ray film and developed with an automated 
developing system.  
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 Table 2.4 Details of antibodies used in Western blot 
 
 
 
2.10.5 Blotting for β-actin/HSC70 
 
Detection of β-actin or HSC70 was used as a loading control to ensure that the 
samples were equally loaded. This involved stripping the membrane after 
detection of the antibody of interest, then washing with TBS/0.05Tween-20 
three times for 5 minutes each. The membrane was re-blotted with either β-
actin or HSC70 antibody at the appropriate concentration (section 2.10.4) for 1 
hr at RT on a rotator. The remainder of the procedure was as described for the 
primary antibodies (section 2.10.4).     
Antibody species  
 
Dilution  Source  
Primary antibody  
 
Galectin-7  
 
1:1000  Epitomics  
β- Actin  
 
1:5000  Santa Cruz  
Cleaved PARP  
 
1:1000  Santa Cruz  
 HSC70  
 
      1: 5000        Santa Cruz 
 β6 1:1000 Santa Cruz 
 CD3 1:1000 Novus 
Secondary antibody  
Anti-rabbit-HRP  
(Goat)  
1:1000  Dako  
Anti-mouse-HRP  
(Goat)  
1:1000  Dako  
Anti-Goat –HRP 
(Mouse) 
1:1000 Dako  
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2.11 siRNA Transfection  
 
Gene knock down of galectin-7 was conducted using DharmaFECT 
transfection reagent (Thermo Fisher Scientific) following the manufacturers 
protocols. For this experiment, 7x10
4
 cells per-well were plated into 6-well 
plates and cultured overnight in complete myoepithelial medium. Transfection 
mixture consisting of 3.3 μl of siRNA galectin-7 (L-001719-00, Dharmacon) or 
3.3 ml of siRNA non targeting (D-001206-14, Dharmacon), 24 μl of interferen 
(Bioscience) and 1200 μl of serum free medium was vortexed for 10 seconds. 
Cells were incubated with transfection mixture for 10 minutes at room 
temperature. Cells in each well were supplemented with 2 ml of complete 
medium and 200 μl of siRNA mixture then incubated at 37ºC for 48 hrs. 
Knockdown was confirmed by Western blotting as described in section 2.10. 
 
2.12 Detection of apoptosis  
 
Apoptosis was detected in TRAIL- treated cells by Western blot for cleaved 
PARP (89 KDa) as described in section 2.10. 
 
2.13 RNA extraction 
  
RNA extraction from primary cells and cell lines was performed using Quick 
RNA Miniprep kit (Zymo Research) according to the manufacturer’s protocol 
(section 1.7, Appendix 1).
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2.14 Quantitation of RNA 
 
All samples were diluted 1: 100 in PCR-grade water. The spectrophotometer 
was blanked with PCR-grade water and absorbance reading for each sample 
was recorded at 260nm and the amount of RNA in µg/µl calculated.   
 
2.15 Complementary DNA (cDNA) synthesis  
 
2 μg of isolated RNA was diluted with 12 μL of nuclease free water (NFW). 
Then, 2 μL of random hexamer primer was added and the mixture was heated 
at 70°C for 5 minutes and chilled on ice for 4 minutes. 5 μL of 5x first-strand 
buffer, 5 μL of 0.25 mM dNTP and 1 μL of Molony Murine Leukemia Virus 
Reverse Transcriptase (M-MLV-RT) were mixed with the RNA, and incubated 
at room temperature for 10 minutes, followed by 50 minutes at 40°C. Finally, 
the mix was adjusted with NFW to a final volume of 100 μL. cDNA samples 
were stored at -20°C until further use. All the chemicals used to generate the 
cDNA were obtained from Promega.  
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2.16 Polymerase chain reaction (PCR) 
  
Polymerase chain reaction was performed using 2 μl of cDNA in a 20μl 
reaction volume. The PCR mixture used is described in Table 2.7 
. 
Table 2.5 Recipe for the PCR mixture 
 
Components Volume (μl) Source 
Megamix 16.5 Sigma 
NFW 0.5 Sigma 
Forward primer 1 Sigma 
Reverse primer 1 Sigma 
cDNA 1  
Total 20  
 
PCR was carried out to determine the expression of galectin-7 in β4 and β6 
myoepithelial lines. Primary mammary myoepithelial and luminal epithelial 
cells (isolated by Dr. Jenny Gomm, section 2.1.3.1) were used as positive and 
negative controls respectively. The cDNA amplification programme used is 
outlined in Table 2.8. 
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Table 2.6 cDNA amplification programme  
 
Step  Temperature  Time  
Initial denaturation  95°C  5 min  
35 cycles  
Denaturation  95°C  45 sec  
Primer annealing   
 
       65°C  
 
 
45 sec  
 
Galectin-7  
    
 β6 
 
    64.3ºC 
   
DR4 
 
    56.8ºC 
 
DR5 
 
     557ºC 
 
Elongation  72°C  2 min  
Final elongation  72°C  10 min  
Chilling  4 °C  Infinite  
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Primer sequences were as follows:  
GAPDH forward: CAT CAT CCC TGC CTC TAC TG,  
GAPDH reverse: TTG GCA GGT TTT TCT AGA CG 
Galectin-7 forward primer: ATG TCC AAC GTC CCCCAC AAG 
Galectin-7 reverse primer: TGA CGC GAT GAT GAG CAC CTC  
DR4 forward primer:  ACAGCAATGGGAACATAGCC 
DR4 reverse primer, GTCACTCCAGGGCGTACAAT. 
DR5 forward primer, TGCAGCCGTAGTCTTGATTG 
DR5 reverse primer, GCACCAAGTCTGCAAAGTCA. 
The PCR product was detected by running the reaction product on a 1 % 
agarose gel in Tris-Acetate-EDTA (TAE) buffer and visualised using ethidium 
bromide staining. 
 
2.17 qPCR  
The reaction was performed using the ABI One Plus according to the 
manufacture’s protocol. Each reaction contained 7µl of Sybr Green PCR 
Master Mix, 300nM of each forward and reverse primer and the equivalent 1µl 
of cDNA. Conditions for the reaction were 2 minutes at 50°C, 10 minutes at 
95°C and then 40 cycles, each consisting of 15 seconds at 95°C, and 1 minute 
at 60°C.  
2.17.1 Relative expression level 
 
The threshold level (Ct) is the point at which the fluorescence can be detected. 
The average Ct value for the triplicates of the samples and GAPDH was 
calculated and the difference between the two values was determined (ΔCt). 
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The reference cell line (control) ΔCt was subtracted from the other samples 
(ΔΔCt). The values were put into the equation 2-ΔΔCt to give the fold change in 
expression. The fold change of the reference sample equals 1,   so any 
reduction in the gene expression will be <1 and any increase in the gene 
expression will be >1. 
                                
2.18 Proteome Profiler  
All reagents were prepared at room temperature. Array membranes (R&D 
System) contain 36 different cytokine antibodies were incubated in 2ml of 
buffer 4 (blocking buffer) for one hr on a rocking platform. 1ml of each sample 
was added to 0.5 ml of buffer 4 in separate tubes. Then, 15 µl of reconstituted 
Cytokine Array Panel A Detection Antibody Cocktail was added to each 
prepared sample. The samples were mixed and incubated at RT for one hr. The 
buffer 4 was aspirated from each membrane, and incubated with the mixture 
overnight at 2-8ºC on a rocking platform. The membrane was washed with 20 
ml of the washing buffer for 10 minutes x 2 on a rocking platform shaker. The 
membrane was then incubated with secondary antibody for 30 minutes, 
followed by three washes in buffer. The membrane was then incubated in ECL 
solution (Amersham) for 1 minute after which the membrane was placed in the 
film cassette boxes with an X-ray film and developed with an automated 
developing system. 
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2.19 Flow cytometry 
Cells were trypsinised and counted.  4x10
4 
cells were suspended in 1 ml of 
FACS buffer (DMEM + 1% BSA). An aliquot of 50µl of cell suspension was 
pipetted into each flow cytometry tube. 50µl of primary antibody at the 
optimized concentration (Table 2.9) was added and incubated for 45 minutes at 
4
°
C in the dark room.  
 
Table 2.7 Primary antibodies used for Flow cytometry 
 
 Primary antibody  Dilution  Source  
CD3 Alexa fluor
@ 
488 1:20 BD  
CD4 Alexa fluor
@ 
488 1:20 BD 
CD8a APC 1:20 BD  
 
Two wash steps with 2ml of FACS buffer were performed, centrifuging the 
samples at 1200rpm for 5 minutes between washes. Cells were resuspended in 
500µl of FACS buffer before being analyzed on the flow cytometry (BD FACS 
Caliber) using Cell quest program. A negative control, using matched isotype 
antibody instead of the primary antibody, was used in each run. 
When analyzing data, forward scatter and side scatter were plotted, to allow 
gating of the live cell population. Dead cells were gated out, based either on the 
appearance of the plot or using the viability stain, propidium iodide (PI), which 
was added prior to analysis. In order to quantify live cells, a dot plot was set up 
which plotted the fluorescence of the labeled cells against cell count.    
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2.20 TRAIL ELISA  
Both myoepithelial cell lines (β4 /β6) were co-cultured with Jurkat or primary 
T cells for 48 hrs as described in section 2.8.10. Lysates from Jurkat and 
primary T cells from 3 independent experiments were collected and assayed for 
TRAIL by ELISA (R & D Systems) according to the manufacturer’s protocol. 
 A protein assay was performed on each of the samples (section 2.10.2). 100 µl 
of protein from each sample was pipetted into an eppendorf and diluted to 400 
µl with buffer and vortexed. TRAIL standards were prepared with PBS using 
TRAIL supplied with the Quantikine immunoassay to make concentrations: 
1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.2 pg/ml, 15.6 
pg/ml and distilled water only. The protocol supplied with each kit was then 
followed. 100 µl of assay diluent RD1S was added to each well of the supplied 
microplate, pre-coated with a monoclonal antibody specific for TRAIL.  
50 µl of either standard or Sample was added to each well. The sample wells 
were set up in duplicate and incubated at RT for 2 hours on a shaker.   Samples 
were then aspirated and the wells washed with 200 µL of the supplied washing 
buffer three times. 200 µL of Conjugate solution, containing an enzyme-linked 
polyclonal antibody specific for TRAIL was then added to the wells and 
incubated at RT for 2 hours on the shaker. Samples were then aspirated and the 
plate washed with the washing buffer three times.  200 µL Substrate Solution 
was added to each well and the plate covered with foil and incubated for 30 
minutes at RT.  
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The observed colour change is proportional to the amount of TRAIL in the 
initial sample.  50 µL of Stop Solution was the added to each well and intensity 
of the colour change read on an ELISA reader at 450nm with a wavelength 
correction at 540nm. A standard curve was generated from the TRAIL 
standards, plotting mean absorbance for each standard against concentration. 
This was used to derive the absolute values of TRAIL for the samples, which 
were corrected for the total number of cells in the flask. Throughout, pipette 
tips were used only once and plate sealers were used during incubation periods.  
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Chapter 3: Inflammatory cell   
infiltrate in DCIS 
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3.1 Introduction  
3.1.1 Role of Inflammatory cells in cancer  
 
The inflammatory tumour microenvironment (iTME) contributes significantly 
to the biological behaviour of cancer (Hanahan and Weinberg 2011). 
Accordingly, the inflammatory cell infiltrate in the cancer microenvironment 
can be negatively associated with prognosis, such as with CD68-positive 
macrophages in Hodgkin’s lymphoma (Steidl, Lee et al. 2010) and Ewing’s 
sarcoma (Fujiwara, Fukushi et al. 2011), or be associated with a favourable 
clinical course as shown for CD8-positive lymphocytes in colon cancer 
(Fridman, Galon et al. 2011, Galon, Pages et al. 2012). Accumulating evidence 
has emphasised that the development of cancer and its progression are 
dependent on a complex interaction of the tumour and the host inflammatory 
response (Coussens and Werb 2002, de Visser, Eichten et al. 2006, DeNardo 
and Coussens 2007, Colotta, Allavena et al. 2009, Hanahan and Weinberg 
2011), and better characterisation of this interaction should facilitate the use of 
the immune infiltrate as a prognostic factor and raise strategies for targeting 
immune cells in the treatment of cancer. A recent review of evidence for the 
role of inflammatory cells in breast cancer has concluded that despite the large 
number of published studies, the relationship between different aspects of the 
inflammatory cell infiltrate and outcome of primary operable breast cancer 
remains unclear  (Mohammed, Going et al. 2012). 
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Out of a total of 24 studies, 13 showed an association between the 
inflammatory cell infiltrate and improved survival, 4 studies showed no 
association and 7 studies concluded that the inflammatory cell infiltrate 
correlated with poor prognosis. The review suggests that the inconsistencies 
between published studies is, in large part, due to the absence of 
methodological validation, underpowered studies (small size  of the samples, 
heterogeneity  of tumour subtypes and insufficient follow-up) and the absence 
of independent validation (Mohammed, Going et al. 2012). Overall, published 
data on the prognostic value of the inflammatory cell infiltrate in  breast cancer 
remains unclear (Mohammed, Going et al. 2012), emphasising  the need for  
improved  analysis of the inflammatory cell infiltrate in stage-specific breast 
cancer (Kruger, Wemmert et al. 2013). 
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3.2 Rationale for investigation  
 
Work in our lab has shown that one of the most consistent changes in 
myoepithelial cells in DCIS is up-regulation of the integrin αvβ6. Normal 
myoepithelial cells do not express this integrin, but it is induced in ~60% of 
DCIS cases with no evidence of invasion, and in >90% of cases of DCIS 
associated with established invasion (Allen, Thomas et al. 2014).  Previous 
studies have suggested that the extent of inflammatory infiltrate is related to 
behaviour of DCIS (Lee, Happerfield et al. 1996). 
We hypothesised that the changes in myoepithelial phenotype that occur during 
evolution of DCIS, including up regulation of integrin αvβ6, result in an altered 
peri-ductal inflammatory microenvironment, the characteristics of which 
contribute to a pro-tumour phenotype.  
The aim of this chapter was to analyse human tissue samples to characterise the 
extent and nature of the inflammatory cell infiltrate in the DCIS 
microenvironment, and to relate this to the myoepithelial phenotype. A further 
aim was to use an in-vivo model to address more directly whether 
myoepithelial phenotype influences the nature of the inflammatory infiltrate.  
To address these aims, the approaches used were:   
 Immunohistochemical analysis of a series of DCIS cases of known 
αvβ6 status, using a range of antibodies to characterise and quantitate 
the peri-ductal inflammatory cell infiltrate.  
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 In-vivo Matrigel plug assays incorporating αvβ6+ve and αvβ6-ve 
myoepithelial cells then characterised for the nature of inflammatory 
infiltrate.  
3.3 Selection of inflammatory cell markers  
 
To determine the phenotype of infiltrating inflammatory cells, a series of 
markers was used to identify key immune cell populations. T cell markers used 
include CD4 and FOXP3 as markers of T regulatory cells, CD8 for cytotoxic T 
lymphocytes, CD69 expressed on activated T cells, CD45RO identifying 
activated T cells and  also expressed by Treg cells, macrophage markers 
including CD74 and MHCII, recognising M1 classically activated 
macrophages, and arginase recognising M2 alternatively activated 
macrophages.  
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3.4 Methods and Materials  
3.4.1 Immunohistochemistry 
 
Paraffin-embedded sections were stained for αvβ6 and inflammatory markers 
as described in section 2.4. 
3.4.2 Scoring of αvβ6 IHC staining 
 
Scoring of the extent of αvβ6 staining on DCIS-associated myoepithelial cells 
has showed that some cases were homogenous positive or negative for αvβ6 
and other were heterogenous. Cases that were homogenously positive or 
negative for αvβ6 were selected to be stained for the inflammatory cell 
markers.  
3.4.3 Scoring of inflammatory cell infiltrate in DCIS 
 
In order to investigate the relationship between αvβ6 expression and 
inflammatory cell infiltrate, the sections were scanned and scored using 
Process Image software as described in section 2.5.3. 
3.4.4 Matrigel assay  
A group of C57/Blk6 normal mice were used in this study. β4 cells and β6 
myoepithelial cells were suspended in Matrigel then injected separately into 
opposite flanks of the mice. B16 mouse tumour was used as positive control. 
After 9 days when the tumour became palpable the mice were sacrificed and 
Matrigel with the surrounding tissue was extracted. The Matrigel plugs were 
processed for staining for the inflammatory cell markers as described in section 
2.3.
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3.4.5 Scoring of inflammatory cell infiltrate in Matrigel 
plugs  
  
The numbers of cells positive for different inflammatory cells markers were 
scored using Imagescope software (section 2.5.4). 
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3.5Results 
3.5.1 Selection of DCIS cases 
 
To investigate the relationship between myoepithelial expression of αvβ6 and 
inflammatory cell profile in the DCIS microenvironment, 47 cases of DCIS 
were stained for αvβ6.  Sixteen cases of αvβ6-positive and 15 cases of αvβ6-
negative DCIS were selected for characterisation of the inflammatory cell 
infiltrate (figure 3.1).  
               
Figure 3.1 Representative images of DCIS with myoepithelial cells homogenously 
negative (A) or positive (B) for αvβ6 integrin.   
These cases were selected for staining for inflammatory cells markers.  
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3.5.2 Inflammatory cell infiltrate in DCIS in relation to 
altered myoepithelial cell phenotype 
 
3.5.2.1 CD69+ve cells in DCIS in relation to αvβ6 expression 
 
CD69 is a membrane receptor transiently expressed on activated T 
lymphocytes and not detected in resting lymphocytes (Sancho, Gomez et al. 
2005).  CD69 antibody was first optimised for use on human tonsil tissue as a 
positive control and when specific staining was achieved, the antibody was 
applied to the DCIS tissue samples. Immunohistochemistry staining for CD69 
antigen was performed on 15 cases of DCIS where the myoepithelial 
compartment was homogenously positive for αvβ6 and 15 cases homogenously 
negative for αvβ6, but only 4 cases of αvβ6-negative and 14 cases of αvβ6-
positive were scored as other cases had insufficient peri-ductal stroma around 
the DCIS for evaluation. The cases were scored on a duct-by-duct basis. 
Images of whole ducts were scanned using NDP software, exported to JPG 
image format, and analysed using Process Image software (section 2.8.2).  At 
least 4 ducts in each case were analysed, counting the number of cells in a 
100µm perimeter around each duct, and the relationship between density of 
CD69+ve cells and myoepithelial αvβ6 status was determined using the Mann 
Whitney test. CD69+ve cells were distributed around the ducts in the stroma, 
within ducts and at the edge of the ducts.  The purpose of this study was to 
investigate the peri-ductal inflammatory cell infiltrate, therefore, only CD69 
+ve cells around the ducts were counted. The number of CD69+ve cells around 
the ducts varied between 0 and 47 in both groups of DCIS cases.   
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 However, DCIS ducts positive for αvβ6 showed significantly higher numbers 
of CD69 +ve cells compared to αvβ6–ve cases (p=0.0001) (figures 3.2 & 3.3).  
This suggests that T cell infiltrate in αvβ6 +ve DCIS is more activated.  
 
          
 
Figure 3.2 Representative images of CD69 staining in DCIS cases 
 
DCIS cases homogenously positive or negative for αvβ6 were stained for CD69 and the 
number of CD69+ve cell around each duct in a 100µm perimeter was quantitated. Higher cell 
density was detected in the peri-ductal areas of αvβ6-positive ducts (B) compared to αvβ6-
negative ducts (A).  
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Figure 3.3 CD69+ve cells in DCIS in relation to myoepithelial αvβ6 status  
 
DCIS cases where the myoepithelial compartment was either homogenously positive or 
negative for αvβ6 were stained for CD69.  Cells positive for CD69 were counted in a region of 
100µm around the duct. A total of 4 ducts for each case were scored. Significantly more 
CD69+ve cells were present around ducts positive for αvβ6 (p=0.0001). The four ducts that 
showed the highest number of CD69 postive cells are derived from two different cases. 
However, the both cases also include ducts with very low CD69 counts. This suggests the 
nature of the peri-dcutal environment is locally determined varying between ducts in the same 
case.  
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3.5.2.2 CD4+ve cells in DCIS microenvironment  
 
The same series of DCIS samples was stained for CD4 and human tonsil tissue 
was used as a positive control. Nine cases of αvβ6-negative and 12 cases of 
αvβ6-positive DCIS had sufficient peri-ductal stroma for scoring. CD4+ve 
cells were also scattered within the ducts, around the ducts and at the edge of 
the ducts and only the number of the positive cells around the ducts was 
counted.  In each case, at least 4 ducts have been analysed using Process 
Images software, counting the number of cell in a 100 µm perimeter around 
each duct. The number of CD4+ve cells in αvβ6-positive cases ranged from 0 
to 207 and in αvβ6-negative cases ranged from 0 to 160. However, a higher 
number of CD4 positive cells was detected around ducts positive for αvβ6 
compared to the negative ducts (p=< 0.01) (figures 3.4 & 3.5).  
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Figure 3.4 Representative images of CD4 staining in DCIS cases 
 
DCIS cases positive or negative for αvβ6 were stained for CD4. Positively stained cells are 
indicated by arrows. A higher infiltrate was present around αvβ6-positive ducts (B) compared 
to αvβ6-negative ducts (A).                        
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Figure 3.5 Quantification of CD4+ve cells around DCIS ducts in relation to αvβ6 
expression 
 
The number of CD4 positive cells in a 100µm perimeter around DCIS ducts positive or 
negative for αvβ6 was quantitated. This showed significantly higher number of CD4+ve cells 
in αvβ6-positive DCIS cases (p=<0.01). The five highest scoring datapoints in αvβ6-positive 
samples are all derived from a single case. However, this case also contained many ducts with 
low scoring counts, again indicating the very heterogeneous nature of the samples, even within 
a case. 
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3.5.2.3 FOXP3+ve cells in DCIS microenvironment 
Since FOXP3+ve Treg cells have been implicated as having a role in the 
progression of breast cancer, their presence in DCIS was investigated. 15 cases 
of αvβ6 positive and 15 cases of αvβ6 negative DCIS were stained with 
monoclonal antibody to FOXP3 antigen, using human tonsil tissue as a positive 
control. Three cases of αvβ6-negative and 14 cases of αvβ6-positive DCIS had 
sufficient peri-ductal stroma for scoring. At least 4 ducts in each case were 
analysed, counting the number of cells in a 100µm perimeter around each duct 
using Process Image software. FOXP3+ve cells were also scattered inside the 
ducts, around the ducts and at the edge of the ducts, but only peri-ductal cells 
were counted. The level of FOXP3+ve cells varied between αvβ6-negative 
cases and αvβ6-positive cases. The number of FOXP3+ve cells in the peri-
ductal area of αvβ6-negative cases ranged from 0 to 13 while in αvβ6-positive 
cases ranged from 0 to 57. However, αvβ6 negative cases showed a lower 
density of FOXP3+ve cells compared to αvβ6 positive cases (figure 3.6). The 
positive correlation between αvβ6 +ve myoepithelial cells and the number of 
FOXP3+ve cells was significant (p=<0.01) (figure 3.7).  
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Figure 3.6 Representative images of FOXP3+ve cells in DCIS cases 
 
DCIS samples with myoepithelial cells positive or negative for αvβ6 were stained for FOXP3. 
This demonstrated a higher number of FOXP3+ve cells around ducts positive for αvβ6 (B) 
compared to those negative for αvβ6 (A). Positively stained cells are indicated by arrows.   
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Figure 3.7 FOXP3+ve cell density in DCIS microenvironment in relation to αvβ6 
expression  
 
The number of FOXP3+ve cells in a 100µm perimeter of DCIS ducts positive or negative for 
αvβ6 was quantitated and showed significantly more FOXP3+ve cells in αvβ6-positive cases 
(p=<0.01). 
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3.5.2.4 CD8 cytotoxic T cell density in DCIS cases 
 
CD8 antibody was tested for use on human tonsil tissue as a positive control 
and when specific staining was achieved, the antibody was applied to DCIS 
samples. Three cases of αvβ6-negative and 7 cases of αvβ6-positive DCIS had 
sufficient peri-ductal stroma to allow scoring. At least 4 ducts per cases were 
analysed using Process Image software. The number of CD8+ve cells varied 
from 0 to 74 in both groups of DCIS cases. However, the analysis 
demonstrated a lower number of CD8 positive cells around ducts positive for 
αvβ6 compared to the negative ducts (p=0.0003) (figures 3.8& 3.9).  
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Figure 3.8 Representative IHC images of CD8+ve cells in DCIS  
 
DCIS cases with myoepithelial cells positive or negative for αvβ6 were stained with CD8 
antibody. Positive cells are indicated with arrows. This showed a higher number of CD8+ve 
cells around ducts negative for αvβ6 (A) compared to those positive for αvβ6 (B) 
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Figure 3.9 CD8+ve cell density in DCIS in relation to αvβ6 expression 
 
The number of CD8 positive cells in a 100µm perimeter around DCIS ducts positive or 
negative for αvβ6 was quantitated. This showed significantly lower numbers of CD8 +ve cells 
in αvβ6-positive DCIS samples (p=0. 0003). 
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3.5.2.5 DCIS-associated CD45RO+ve cells 
 
CD45RO antibody was optimised for use on human tonsil tissue as a positive 
control and when the specific staining was achieved, the antibody was applied 
to DCIS samples. Five cases of αvβ6-negative and 5 cases of αvβ6-positive 
DCIS contained sufficient peri-ductal stroma for scoring. At least 4 ducts in 
each case were analysed using Process Image software. The number of positive 
cells in a region of 100 µm around the duct was counted and the proportion 
ranged from 0 to 145 in both groups of the DCIS cases. Comparing the density 
of CD45RO+ve cells, no difference was identified between the two groups of 
DCIS cases (p=0.2) (figures 3.10 & 3.11).  
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Figure 3.10 Representative IHC images of CD45RO in DCIS  
 
A series of cases of DCIS with myoepithelial cells homogenously positive or negative for αvβ6 
were stained for CD45RO. Positive cells are indicated by the arrows. The microenvironment of 
αvβ6 postive (B) and αvβ6 negative (A) cases showed no difference in the number of CD45RO 
+  cells.  
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Figure 3.11 CD45RO+ve cell density in DCIS microenvironment in relation to αvβ6 
status 
 
The number of positive cells in a 100µm perimeter around DCIS ducts positive or negative for 
αvβ6 was quantitated. Comparing the proportion of CD45RO+ve cells, no difference was 
identified between the two groups of DCIS cases (p= 0.2).  
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3.5.2.6 MHC-II+ve cells in DCIS  
 
 Macrophages dominate tumour microenvironments where they play a key role 
in tumour growth (Balkwill, Charles et al. 2005).  Typically, the M1 
macrophage phenotype is associated with up-regulation of MHC class II 
(Quiding-Jarbrink, Raghavan et al. 2010).  
 In order to investigate the presence of M1 macrophages in DCIS stroma in 
relation to αvβ6 expression, the same DCIS samples with myoepithelial cells 
positive or negative for αvβ6 were stained for MHC-II.  The antibody was 
tested on human tonsil as a positive control. Five cases of αvβ6-negative and 
15 cases of αvβ6-positive DCIS were analysed. At least 4 ducts in each case 
were analysed using Process Image, and the number of positive cells in a 
region of 100µm around the duct was counted. The level of MHC-II+ve cells 
varied between αvβ6-positive cases and αvβ6-negative cases. The number 
of MHC-II+ve cells in αvβ6-positive cases ranged from 0 to 33 while in 
the αvβ6-negative cases was from 0 to 87. This demonstrated a higher number 
of MHC-II+ve cells around ducts negative for αvβ6 compared to the positive 
ducts (p= < 0.0001) (figures 3.12 & 3.13).  
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Figure 3.12 Representative images of MHCII+ve cells in DCIS microenvironment in 
relation to αvβ6 status 
 
DCIS cases where the myoepithelial compartment was either homogenously positive or 
negative for αvβ6 have been stained with MHC-II antibody.  Positive cells are indicated by 
arrows. A higher infiltrate was present around αvβ6 negative ducts (A) compared to αvβ6 
positive ducts (B). 
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Figure 3.13 MHC-II+ve cell in DCIS microenvironment in relation to αvβ6 status  
 
A series of DCIS cases homogenously positive or negative αvβ6 were stained for MHC class II 
antigen and the number of positive cells in the peri-ductal region was counted. This showed 
significantly more MHC-II+ve cells around ducts negative for αvβ6 (p=< 0.0001). 
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3.5.2.7 CD74+ve cell infiltrate in DCIS microenvironment  
 
CD74 is expressed on antigen-presenting cells, including B cells, monocytes, 
dendritic cells and macrophages (Greenwood, Metodieva et al. 2012).  CD74 
acts as the high-affinity receptor for the pro-inflammatory cytokine 
macrophage migration inhibitory factor (MIF) (Leng, Metz et al. 2003).  
CD74 was optimised for use on human tonsil tissue and when specific staining 
was achieved, the antibody was applied to DCIS samples, with three cases of 
αvβ6-negative and 5 cases of αvβ6-positive DCIS being appropriate for 
scoring. Whole sections were scanned using NDP scanner, and each duct 
image exported to JPG format. CD74+ve cells were distributed within the 
ducts, around the ducts and at the edge of the ducts, but only peri-ductal cells 
were counted.  At least 4 ducts in each case were analysed using Process Image 
software, and the number of positive cells in a region of 100 µm around the 
duct was counted. The number of positive cells ranged between 0-44 in both 
groups of DCIS cases, with no significant difference between αvβ6-positive 
and negative ducts (p=0.1) (Figures 3.14 &3.15).  
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Figure 3.14 Representative images of CD74+ve cell in DCIS cases 
 
DCIS cases where myoepithelial cells are homogenously positive or negative for αvβ6 were 
stained for CD74. Positive cells are indicated by arrows. The microenvironment of αvβ6 
postive and αvβ6 negative cases showed no difference in the number of CD74+ve  cells.  
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Figure 3.15 CD74+ve cell infiltration in DCIS microenvironment in relation to αvβ6 
expression  
 
The number of CD74+ve cells in a region of 100 µm around DCIS ducts was counted as 
described. No difference was identified between the two groups of DCIS cases (p=0.1).  
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3.5.2.8 CD68+ve cells in DCIS cases 
 
The presence of CD68+ve macrophages in breast cancer has been associated 
with higher tumour histological grade (Naukkarinen and Syrjanen 1990, Lee, 
Happerfield et al. 1997, Volodko N 1998). To investigate the relationship with 
altered myoepithelial phenotype, the CD68 antibody was tested on human 
tonsil tissue as a positive control and when specific staining was achieved, the 
antibody was applied to the same series of DCIS cases positive or negative for 
αvβ6. Five cases of αvβ6-negative and 13 cases of αvβ6-positive DCIS had 
sufficient peri-ductal stroma for analysis. At least 4 ducts in each case were 
analysed using Process Image, and the positive cells in a 100µm perimeter 
were quantitated. The number of CD68+ve cells ranged between 0 and 110 in 
the peri-ductal area of αvβ6-negative cases while in αvβ6-positive cases ranged 
between 0 and 270. Comparing the number of CD68+ve cells, no difference 
was detected between αvβ6 positive and αvβ6 negative cases (p=0.5) (figures 
3.16 & 3.17). 
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Figure 3.16  Representative images of CD68+ve cells in DCIS stroma in relation to αvβ6 
status  
 
The microenvirnment of  αvβ6 postive and αvβ6 negative cases showed no difference in the 
number of CD68+ve  cells. Postively stained cells was indicated by arrows.  
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Figure 3.17 CD68+ve cells in DCIS microenvironment in relation to αvβ6 expression 
 
A series of DCIS cases homogenously positive or negative for αvβ6 were stained for CD68 
antigen and the number of positive cells in the peri-ductal region was counted as described. . 
Comparing the proportion of CD68+ve cells, no difference was identified between the two 
groups of DCIS (p=0.5).  
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3.5.2.9 Arginase-1+ve cells in DCIS microenvironment  
 
It has been reported that M2 macrophages express arginase-1(El Kasmi, Qualls 
et al. 2008), therefore, in order to investigate M2 macrophages in DCIS stroma 
in relation to αvβ6 status, arginase-1 antibody was optimised on normal human 
liver as a positive control and when specific staining was achieved, the 
antibody was applied to the same series of DCIS cases. Seven cases of αvβ6-
negative and 12 cases of αvβ6-positive DCIS were appropriate for analysis. 
Whole sections were scanned using NDP scanner, and each duct image 
exported to JPG format. At least 4 ducts per case were analysed using Process 
Image, and the number of arginase-1 positive cells in a 100µm perimeter 
around the duct was counted. The number of arginase-1+ve cells ranged 
between 0 and 47 in αvβ6-postive cases and between 0 and 10 in αvβ6-
negative cases.  Interestingly, the peri-ductal microenvironment in αvβ6 +ve 
cases showed a higher number of arginase-1 +ve cells compared to the αvβ6-ve 
cases (p=0.0001) (figures 3.18 &3.19), suggesting that αvβ6 expression in 
DCIS is associated with M2 macrophage infiltration.  
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Figure 3.18 Representative images of arginase-1+ve cells in DCIS stroma in relation to 
αvβ6 status  
 
The microenvironment of αvβ6 positive DCIS cases (B) showed a higher number of arginase-
1+ve cells compared to the negative cases (A).  Positive cells are indicated by arrows.   
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Figure 3.19 Arginase-1+ve cells in DCIS microenvironment in relation to αvβ6 expression 
 
The number of arginase-1 positive cells in a region of 100µm around DCIS ducts was counted. 
This demonstrates significantly higher numbers of arginase-1+ve cells in αvβ6-positive DCIS 
cases compared to the αvβ6-negative ducts (p=0.0001).   
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3.5.3 Inflammatory cell profile in relation to αvβ6 status 
 
In order to gain a picture of the relative levels of the different inflammatory 
cell types in αvβ6–positive and αvβ6-negative DCIS, the mean of each cell 
type in all the αvβ6 positive ducts and αvβ6 negative ducts was calculated, and 
then the different cell types were expressed as a percentage of the total 
inflammatory infiltrate (figure 3.20). This demonstrated that CD4+ve cells 
were the most dominant cell in αvβ6-positive DCIS cases while MHC-II+ve 
cells were the dominant population in αvβ6-negative DCIS cases (figure 3.20 
A& B).   Although the relative number of FOXP3+ve cells was small, they 
made up 3% of the population in αvβ6-positive cases and only 2% in αvβ6-
negative cases. In contrast, CD8+ve cell number was nearly three-fold in the 
cases negative for αvβ6 compared to αvβ6-positive cases (figure 3.20 A).  
CD45RO+ve cells were the second dominant cell type in the microenvironment 
of αvβ6 negative cases (figure 3.20 A), while they represent only 5% of 
inflammatory cell infiltrate in αvβ6 positive DCIS cases (figure 3.20 B). 
FOXP3+ cells and arginase-1 + cells represent a minor component of the 
inflammatory cell population in both groups of DCIS cases (figure 3.20 A). 
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Figure 3.20 Percentage of inflammatory cell populations in the peri-ductal 
microenvironment of DCIS in relation to αvβ6 status 
   
CD4 + cells are the dominant cell in αvβ6-positive DCIS cases while MHC-II+ve cells are the 
dominant population in αvβ6-negative DCIS cases. CD8+ cells represent 13% in negative 
cases (A) and 5% in positive cases (B).  FOXP3+ cells and arginase-1 + cells are a minor 
population in both DCIS groups.  Numbers of CD45RO +ve cells are very low in the αvβ6- 
positive cases (B), but represent the second dominant population in the αvβ6-negative cases 
(A).  
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3.5.4 Analysis of the inflammatory cell infiltrate in 
relation to myoepithelial αvβ6 status in-vivo  
 
The immunohistochemical analysis of DCIS samples for peri-ductal 
inflammatory cell infiltrate suggests that expression of αvβ6 in DCIS-
associated myoepithelial cells correlates with a higher Treg cell and M2 
macrophage infiltrate.  To test this more directly, the second part of this 
chapter aimed to study the relationship between αvβ6 status and the 
inflammatory cell infiltrate using an in-vivo assay. 
Matrigel plugs containing either β6 (αvβ6-positive) or β4 (αvβ6-negative) 
myoepithelial cells were injected into the flanks of 6 mice. B16 mouse 
melanoma cells were used as a positive control. After 9 days when the tumours 
became palpable, the mice were sacrificed, and Matrigel with the surrounding 
tissue was extracted. The gels were formalin fixed and paraffin embedded and 
sections were stained for inflammatory cell markers. Matrigel plugs without 
myoepithelial cells were used as negative controls.  
3.5.4.1 Quantitation of CD4+ve T cells in Matrigel plug assays 
 
CD4 antibody was optimised on normal mouse spleen tissue and when specific 
staining was achieved, the antibody was applied to Matrigel plugs containing 
either β4 or β6 myoepthelial cells (section 2.3). Whole sections were scanned 
using NDP software and analysed using Imagescope software (section, 
2.9.2.1). The scoring scheme parameters specifying the staining intensity 
threshold of CD4 were set up and the software was run to count the cells 
positive for CD4 over the entire section. The result was exported to an Excel 
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file and the number of CD4+ve cells per mm
2
 was calculated, and plotted on 
graph using prism software. This showed a higher number of CD4+cells in 
Matrigel plugs containing β6 cells compared to Matrigel plugs containing β4 
cells (p=0.005) (figures 3.21 & 3.22).   
               
 
Figure 3.21 Representative images of CD4+ve cells in Matrigel plugs 
  
The number of CD4+ve cells in Matrigel plugs containing either β4 or β6 cells was analysed 
using Imagescope software. Matrigel plugs containing β6 cells (B) showed a higher number of 
CD4+ve cells per unit area compared to those plugs containing β4 cells (A). Positively stained 
cells are indicated by arrows.  
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Figure 3.22 CD4+ve cells in Matrigel plugs containing myoepithelial cells 
   
The number of CD4+ve cells in Matrigel plugs containing either β4 or β6 myoepithelial cells 
was analysed as described. This showed more CD4+ve cells were present in Matrigel plugs 
containing β6 cells compared to Matrigel plugs containing β4 cells (p=0.005).   
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3.5.4.2 Density of FOXP3+ve cell in Matrigel plugs  
 
 The same series of Matrigel plugs containing myoepithelial cells were stained 
for FOXP3 and normal mouse spleen tissue was used as a positive control. 
Whole sections of Matrigel plugs were scanned using NDP and the number of 
FOXP3+ve cells was analysed using Imagescope software. Appropriate scoring 
parameters detecting the specific staining of FOXP3 were set up and the 
Imagescope software was run to count cells positive for FOXP3 over the entire 
section. The result was exported to an Excel file and the number of FOXP3+ve 
cells per mm
2
 was calculated and plotted on a graph. This demonstrated a 
higher number of FOXP3+ ve cells in Matrigel plugs containing  β6 cells 
compared to Matrigel plugs containing β4 cells (p=0.007) (figures 3.21 & 
3.22).   
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Figure 3.23 Representative images of FOXP3+ve cells in Matrigel plugs 
 
The same series of the Matrigel plugs containing myoepithelial cells were stained for FOXP3. 
Positive cells are indicated by arrows. FOXP3+ve cells were counted using Imagescope 
software and significantly more FOXP3+ve cells were present in Matrigel plugs containing β6 
cells (B) compared to those plugs containing β4 cells (A).  
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 Figure 3.24 Distribution of FOXP3+ve cells in Matrigel plugs containing myoepithelial 
cells   
 
The number of FOXP3+ve cells in Matrigel plugs containing either β4 or β6 myoepithelial 
cells was analysed using Imagescope software.  Significantly more FOXP3+ve cells were 
present in Matrigel plugs containing β6 cells compared to the Matrigel plugs containing β4 
cells (p=0.007). 
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3.5.4.3 Density of CD8+ve T cells in Matrigel plugs 
 
CD8 antibody was optimised for use on normal mouse spleen tissue as a 
positive control and when specific staining was achieved, the antibody was 
applied to the same series of Matrigel plugs containing myoepithelial cells. The 
sections from Matrigel plugs were scanned using NDP software and the 
number of CD8+ve cells was analysed using Imagescope software. The scoring 
scheme parameters detecting the specific staining of CD8 were set up and the 
Imagescope software was run to count cells positive for CD8 over the entire 
section. The result was exported to an Excel file and the number of CD8+ve 
cells per mm
2
 was calculated and plotted on a graph using prism software. 
Comparing the number of CD8+ve cells, no difference was identified between 
Matrigel plugs containing β4 cells and Matrigel plugs containing β6 
myoepithelial cells (p=0.6) (figures 3.25 & 3.26).  
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Figure 3.25 Representative images of CD8+ve cells in Matrigel plugs 
 
The same series of Matrigel plugs containing myoepithelial cells was stained for CD8. The 
number of CD8+ve cells was quantitated using Imagescope software. This demonstrated no 
difference between the number of CD8+ve cells in Matrigel plugs containing β4 cells (A) and 
Matrigel plugs containing β6 cells (B). Positive cells indicated by arrows.  
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Figure 3.26 Distribution of CD8+ve cells in Matrigel plugs 
 
The number of CD8+ve cells in Matrigel plugs containing either β4 or β6 myoepithelial cells 
was counted using Imagescope software. This showed no difference between the two groups of 
Matrigel plugs (p=0.6). 
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3.5.4.4 Quantitation of CD74+ve cells in Matrigel plugs  
 
The same series of Matrigel plugs containing myoepithelial cells was stained 
for CD74 and normal mouse spleen tissue was used as a positive control. The 
slides were scanned using NDP software. Each section from the Matrigel plugs 
was opened in Imagescope software, appropriate scoring parameters to detect 
the specific staining of CD74 in the cells were set up and the software was run 
to count the cells positive for CD74 in the total area of the section. The result 
was exported to an Excel file and number of CD74+ve cells per mm
2 
was 
calculated, and plotted on a graph using prism software. This showed no 
difference between Matrigel plugs containing β4 cells and Matrigel plugs 
containing β6 myoepithelial cells (p=0.9) (figures 3.27 & 3.28).   
  Chapter 3 Inflammatory cell infiltrate in DCIS 
149 
 
 
                  
 
 
Figure 3.27 Representative images of CD74+ve cells in Matrigel plugs assays 
 
The same series of Matrigel plugs containing either β4 or β6 myoepithelial cells was stained 
for CD74. The number of CD74+ve cells was counted using Imagescope software. This 
showed no difference between the number of CD74+ve cells in Matrigel plugs containing β4 
cells (A) and Matrigel plugs containing β6 cells (B). Positive cells are indicated by arrows. 
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Figure 3.28 Density of CD74+ve cell in Matrigel plugs 
  
Matrigel plugs containing either β4 or β6 myoepithelial cells were stained for CD74 and the 
number of CD74+ve cells was scored using Imagescope software as described. Comparing the 
proportion of CD74+ve cells, no difference was identified between the two groups of Matrigel 
plugs containing myoepithelial cells (p=0.9).  
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3.5.4.5 Distribution of Arginase-1+ve cells in Matrigel plugs 
assays 
Arginase-1 antibody was optimised for use on normal mouse liver tissue and 
when specific staining achieved, the antibody was applied to the same series of 
Matrigel plugs containing myoepithelial cells. The sections were scanned using 
NDP software. Each section from the Matrigel plugs was opened in 
Imagescope software, appropriate scoring parameters to detect the specific 
staining of arginase-1 set up and the software was run to count cells positive 
for arginase-1 in the total area of the section. The result was exported to an 
Excel file and number of arginase-1+ve cells per mm
2 
was calculated, and 
plotted on a graph using prism software. Comparing the number of arginase-
1+ve cells, no difference was detected between Matrigel plugs containing β4 
and Matrigel plugs containing β6 myoepithelial cells (p=0.4) (figures 3.29 & 
3.30).  
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Figure 3.29 Representative images of arginase-1+ve cells in matrigel plugs 
 
The same series of Matrigel plugs containing either β4 or β6 myoepithelial cells were stained 
for arginase-1. The number of positive cells was quantitated using Imagescope software. This 
showed no difference between the two groups of Matrigel plugs.  Positively stained cells 
indicated by arrows.  
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Figure 3.30 Density of arginase+ve cell in Matrigel plugs  
 
The number of arginase+ve cells in Matrigel plugs containing myoepithelial cells was counted 
using Imagescope. No difference was identified between the two groups of Matrigel plugs 
(p=0.4). 
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3.6 Discussion  
 
There is growing evidence for a role of the microenvironment in modulating 
tumour cell behaviour.  In DCIS, the microenvironment is complex with 
myoepithelial cells forming a unique component. Myoepithelial cells play a 
role in suppression of breast cancer cell growth, invasion and angiogenesis 
through expression of protease inhibitors and other factors (Alpaugh, Lee et al. 
2000), though it is not clear if this function is retained in DCIS. In fact, Allinen 
et al (2004) showed that myoepithelial cells in DCIS exhibit multiple changes 
in gene expression, with loss of anti-angiogenic factors and up-regulation of 
certain chemokines (Allinen, Beroukhim et al. 2004). The epithelial-specific 
integrin αvβ6 is not normally detected on normal adult epithelia but is highly 
expressed during tissue remodelling including wound healing and 
carcinogenesis (Breuss, Gallo et al. 1995). We previously identified de novo 
up-regulation of αvβ6 on myoepithelial cells in a subset of DCIS with almost 
universal expression in DCIS associated with invasive disease (Allen, Thomas 
et al. 2014). In addition, αvβ6 appears to play a critical role in the induction of 
tumour tolerance as a recent study has shown that there is a direct relationship 
between the number of infiltrating Treg cells and the level of αvβ6 expression 
in colorectal cancer (Yang, Du et al. 2012). αvβ6 integrin also can convert the 
precursor TGFβ to the active form of TGFβ in dendritic cells (DCs), which 
converts immature DCs to tolerogenic DCs (Chen, Yao et al. 2011). In turn, 
tolerogenic DCs generates Treg cells (Li, Guo et al. 2008). 
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Moreover, down-regulation of αvβ6 results in inflammation by impairing the 
immune-suppressive activity of Treg cells (Munger, Huang et al. 1999). 
Suppression of the β6 integrin in mice results in down regulation of 
inflammation in skin and respiratory tract (Huang, Wu et al. 1996). 
Together, these data imply a relationship between αvβ6 and the inflammatory 
environment. We therefore hypothesised that this altered myoepithelial 
phenotype, with up-regulation of αvβ6, may also modulate the inflammatory 
infiltrate in the DCIS microenvironment and so contribute to disease 
progression. To address this, the relationship between the peri-ductal 
inflammatory infiltrate in DCIS and myoepithelial expression of αvβ6 integrin 
was analysed by immunohistochemistry, quantitating the peri-ductal infiltrate 
on a duct-by-duct basis. This demonstrated significantly higher infiltration of 
Treg cells, as determined by CD4 and FOXP3 expression, in αvβ6-positive 
DCIS cases as compared to αvβ6-negative cases (P=0. 01). CD69, a marker of 
activated T cells was detected at a higher level in αvβ6-positive cases 
compared to the αvβ6-negative cases (p=<0.0001). Higher levels of arginase 
expression, a marker of tumour associated macrophages (TAMs), also was 
identified in αvβ6-positive DCIS compared to αvβ6-negative DCIS cases 
(P=0.0001), whereas a higher number of M1 macrophage, as detected by 
MHC-II was present in αvβ6-negative cases compared to αvβ6-positive cases 
(P=<0.0001). 
TAMs and Treg cells have been shown to exert a tumour-promoter action, and 
these data suggest therefore that expression of αvβ6 on myoepithelial cells in 
DCIS may be associated with a more tumour-promoter inflammatory infiltrate. 
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In invasive breast cancer, the number of CD45RO +ve cells is associated with 
an increased risk of recurrence and poor survival (Scholl, Pallud et al. 1994). 
However, this study demonstrated that the microenvironment of αvβ6 positive 
and αvβ6 negative showed no difference in the number of CD45RO +ve cells. 
This may reflect the difficulties of using a single marker, which is not specific 
to one cell type, since it will not adequately reflect more subtle differences in 
immune cell populations, or may be a consequence of study size. Expanding 
the number of cases analysed may help clarify this. 
In addition, CD4+ve cells are the dominant inflammatory cell population in 
αvβ6-positive DCIS microenvironment and MHC-II+ve cells are the dominant 
population in the αvβ6-negative DCIS microenvironment. FOXP3+ve cells and 
arginase-1+ve cells were the least abundant inflammatory cell population in 
DCIS microenvironments.  
To investigate the hypothesis in vivo, a group of 12 female C57/Blk6 normal 
mice, 4 weeks old were used in this study. β4 cells and β6 cells were suspended 
in Matrigel then injected into mice flanks separately. B16 mouse Lewis lung 
cancer cells were used as a positive control and Matrigel alone as a negative 
control. After 9 days mice were sacrificed, and Matrigel with the surrounding 
tissue was extracted. These Matrigel plugs were formalin-fixed and paraffin- 
embedded then sections stained for inflammatory markers CD4, FOXP3 
(Treg), CD8 (cytoxic T cell), CD74 (MIF receptor) and arginase (M2 
macrophage). It was difficult to quantity the positive cells in the Matrigel plugs 
sections because of the level of background staining, and care was taken to 
apply stringent thresholds on the software to identify what represented true 
staining over background levels.  
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Within the limitations of the study and confidence of interpretation, the in vivo 
assays demonstrated a positive correlation between β6+ve myoepithelial cells 
and CD4+ve cells (p=0.005) and FOXP3+ve cells (P=0.007). This confirms the 
human tissue study and further supports the concept that the altered 
myoepithelial phenotype can directly modulate the nature of the inflammatory 
cell infiltrate. 
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3.7 Conclusion  
 
These studies have shown a correlation between the inflammatory infiltrate in 
DCIS and expression of αvβ6 integrin by myoepithelial cells. This work has 
demonstrated higher infiltration of regulatory T cells, as determined by CD4 
and FOXP3, in αvβ6+ve DCIS cases as compared to αvβ6-negative cases. It 
also has shown that the β6+ve DCIS cases are associated with higher numbers 
of TAMs compared to β6-ve DCIS cases.  
Overall, DCIS tissue data also have suggested that the DCIS microenvironment 
contains high infiltration of CD4+ve T cells. The number of FOXP3 + cells 
and arginase-1+ cells indicates they are a minor inflammatory cell population 
in DCIS, whilst MHCII cells numbers are very low in αvβ6 +ve cases but 
represents the second dominant cell population in αvβ6 -ve cases. Despite 
difficulties with interpretation, the in-vivo study is valuable in demonstrating a 
more direct link between myoepithelial phenotype and inflammatory infiltrate 
and showed a positive correlation between the numbers of CD4 and FOXP3 
cells and up-regulation of αvβ6.  In conclusion, this work indicates that there is 
variation in the extent and nature of the inflammatory infiltrate in DCIS and 
this is influenced by myoepithelial cell phenotype.   
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4.1 Introduction  
4.1.1 Progression of DCIS to invasive disease  
There are major limitations in understanding the natural history of progression 
DCIS to invasive breast cance. One study by Page et al, reports on the follow-
up of a group of women in whom the diagnosis of DCIS was missed, such that 
these women received no treatment following biopsy. In the most recent report, 
extended follow-up data are provided on the original cohort of 28 women over 
a total of 46 years, with a median follow-up of 31 years for women who did not 
develop carcinoma. (Sanders, Schuyler et al. 2005). This demonstrated that 
eleven of 28 women developed invasive breast carcinoma (IBC), all in the 
same breast and quadrant from which their low-grade DCIS biopsy was taken 
(Sanders, Schuyler et al. 2005). Whilst clearly this study is very much biased 
towards low grade disease, it does indicate that not all DCIS will progress to 
invasive disease, even over a very extended time period.  
A major diagnostic factor that can be used to distinguish DCIS from invasive 
breast cancer is the presence of an intact basement membrane and 
myoepithelial cell layer (Polyak and Kalluri 2010). The importance of 
myoepithelial cells in DCIS progression is supported by several lines of 
evidence. Toussaint et al analyzed the expression profile of DCIS with clinical 
follow-up and demonstrated that decreased expression of CD10, a 
differentiated myoepithelial cell marker, was associated with decreased 
disease-free survival (Toussaint, Durbecq et al. 2010).  
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Work in our laboratory has identified a novel and functionly relevant change in 
DCIS-associated myoepithelial cells: up-regulation of the integrin αvβ6. We 
show that this leads to a switch in myoepithelial cell function from tumour 
suppressor to tumour promoter (Allen, Thomas et al. 2014). We previously 
have shown that normal myoepithelial cells can influence breast fibroblast 
function (Jones, Shaw et al. 2003) but the potential impact of αvβ6-modified 
myoepithelial cells on the peri-ductal microenvironment has not been explored. 
      
                                                                                                          
Chapter 4 Role of T lymphocytes in progression of DCIS   
 
 
162 
 
4.2 Hypothesis  
 
 In chapter 3, this study has shown that expression of αvβ6 on DCIS- 
associated myoepithelial cells is associated with an altered peri-ductal 
inflammatory microenvironment that would contribute to a pro-tumour 
phenotype. A key step in progression of DCIS is loss of the myoepithelial cell 
layer. We hypothesise that one mechanism by which the inflammatory 
infiltrate may promote tumour progression is through induction of 
myoepithelial cell apoptosis, possibly through release of tumour necrosis 
factors (TNF).  Since the immunohistochemical analysis suggests that αvβ6 
expression correlates with increased Treg cells, and a key cytokine released by 
these cells is the pro-apoptotic molecule TRAIL, we hypothesise that loss of 
the myoepithelial layer could be mediated by TRAIL-induced apoptosis, and 
that αvβ6-positive myoepithelial cells may be more susceptible to this effect 
than their negative counterparts.   
The objectives are to: 
 Co-culture primary T cells and Jurkat T cells with β4 myoepithelial 
cells or β6 myoepithelial cells and measure induction of TRAIL. 
 Analyse expression of the TRAIL receptors, DR4 & DR5, in 
myoepithelial cells by RT-PCR, Western blot and flow cytometry. 
 Analyse directly the sensitivity of myopithelial β4 and myopithelial β6 
cell populations to TRAIL-induced apoptosis using recombinant 
TRAIL. 
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 To further substantiate the clinical relevance of apoptosis in DCIS 
tissues using caspase-3 as a marker.  
4.3 Methods and Materials 
4.3.1 Measuring TRAIL levels in T cells  
 
Primary T cells and Jurkat T cells were co-cultured with β4 and β6 
myoepithelial cells for 48 hrs (section 2.8.10). After this, T cells were 
harvested and protein isolated and assayed for TRAIL by ELISA as described 
in section 2.20. 
4.3.2 Measuring TRAIL receptors in myoepithelial cells 
 
The levels of DR4 and DR5 TRAIL receptors in β4 and β6 myoepithelial cell 
lines were analysed by qPCR (section 2.17). Western blot and Flow cytometry 
techniques to measure the protein level of both receptors was unsuccessful as 
the antibodies could not be optimised. 
4.3.3 Analysing the susceptibility of myoepithelial cell 
lines to apoptosis 
 
 β4 and β6 myoepithelial cells were treated with recombinant 
TRAIL for 2,4 and 8 hrs (section 2.9) then the level of cleaved 
PARP (apoptosis marker) was detected by Western blot as 
described in section 2.10. 
      
                                                                                                          
Chapter 4 Role of T lymphocytes in progression of DCIS   
 
 
164 
 
 Both myoepithelial cell lines were treated with etoposide 
chemotherapy for 4, 6, 8 and 48 hrs to induce apoptosis (section 
2.9). Serial images of the cells were taken during the treatment time 
course in order to assess morphological changes relating to 
apoptosis. 
4.3.4 Detection of apoptosis in DCIS-associated 
myoepithelial cells by immunohistochemistry 
 
A set of DCIS cases positive for αvβ6 and showing high infiltration with Treg 
cells was stained with cleaved caspase-3 antibody as described in section 2.4.  
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4.4 Results 
4.4.1 Impact of myoepithelial cells on T-cell derived 
TRAIL  
 
Primary T cells and Jurkat T cells were co-cultured with β4 or β6 myoepithelial 
cells for 48 hrs, and then levels of TRAIL in primary T cell and Jurkat T cell 
lysates measured  by ELISA (Enzyme-Linked Immunosorbent Assay) (section 
2.20). The co-culture experiment was repeated a minimum of three times 
(section 2.8.10). Lysates of primary T cells and Jurkat T cell from the three 
independent experiments were  loaded, in  duplicate, onto the ELISA plate.    
At the 48hrs time point, there was no difference in TRAIL levels in Jurkat T 
cells co-cultured with either β4 myoepithelial cells or  β6 myoepithelial cells 
(figure 4.1, p=0.1). However, at the same time point, higher levels of TRAIL 
were detected in primary T cells following co-culture with β6 myoepithelial 
cells compared to T cells co-cultured with β4 myoepithelial cells (figure 4.1, 
p=0.02). 
There was no significant proliferation of either Jurkat T cells or primary T cells 
following co-culture with myoepithelial cells, as determined by cell counts at 
the endpoint of the experiment.  
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Figure 4.1  Measurment of TRAIL levels in Jurkat T cells and primary T cells co-
cultured with β4 or β6 myoepithelial cells for 48 hrs 
 
Both T cells populations  (primary and Jurkat cells) were  co-cultured with β4 or β6 
myoepithelial cells for 48 hrs and lysates of T cells  then harvested and TRAIL levels  
measured by ELISA . Jurkat cells co-cultured with  β6 cells show no significant difference in 
TRAIL levels compared to those cultured with β4 myoepithelial cells (p=0.1). However, 
primary T cells co-cultured with β6 myoepithelial cells show higher levels of TRAIL compared  
to those  co-cultured with β4 myoepithelial cells (p=0.02). Results represent three independent 
experiments.  
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4.4.2 Expression of TRAIL receptors DR4 & DR5 in 
myoepithelial cell populations  
 
Expression of DR4 and DR5 RNA was analyzed in myoepithelial cell 
populations using RT-PCR. GAPDH was used to normalize DR4 and DR5 
expression levels. HeLa cells were used as a positive control for TRAIL 
receptors. This demonstrated β6 myoepithelial cells express higher levels of 
DR4 RNA compared to β4 myoepithelial cells (figure 4.2, p=0.002). β6 
myoepithelial cells also express higher levels of DR5 RNA compared to β4 
myoepithelial cells (figure 4.3, p=0.03).  Using Hela cells as a positive control 
DR4 and DR5 monoclonal antibodies failed to be optimised in order to 
investigate expression of DR4 and DR5 at the protein level in myoepithelial 
cells by Western blot. FITC conjugated antibodies to DR4 and DR5 were also 
tested in flow cytometry but this was unsuccessful as the antibodies could not 
be optimised.  
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Figure 4.2 RNA expression of DR4 in myoepithelial cells 
 
RT-PCR showed β6 myoepithelial cells express higher levels of DR4 RNA compared to β4 
myoepithelial cells (p=0.002). Error bars=SD. Bars represent the mean of triplicate 
experiments. 
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Figure 4.3 RNA expression of DR5 in myoepithelial cells 
 
DR5 RNA levels were analysed by RT-PCR. This demonstrated β6 myoepithelial cells express 
higher levels of DR5 RNA compared to β4 myoepithelial cells (p=0.03). Error bars=SD. Bars 
represent the mean of triplicate experiments.     
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4.4.3 Detection of apoptosis in TRAIL-treated 
myoepithelial cell lines 
 
(i) Detection of cleaved PARP 
Apoptosis was assessed in TRAIL-treated β4 and β6 myoepithelial cells by 
Western blot using an antibody to cleaved PARP. β4 and β6 myoepithelial cells 
were exposed to recombinant TRAIL at 500ng/ml concentration for 2, 4 and 8 
hrs (Figure 4.4A). Cells were grown under control conditions (vehicle only) 
over the same time periods (Figure 4.4 B). At the appropriate time point the 
cells were harvested, protein extracted and Western blot carried out for cleaved 
PARP to determine the level of apoptosis. Experiments were repeated a 
minimum of three times. β4 myoepithelial cells showed very low levels of 
cleaved PARP at all the time points (Figures 4.4 A&B). However, β6 
myoepithelial cells exhibited stronger bands for cleaved PARP compared to β4 
myoepithelial cells, with maximum levels being observed between 4-8 hrs 
(Figures 4.4 A&B). This suggests that β6 myoepithelial cells may be more 
sensitive to TRAIL-induced apoptosis compared to β4 myoepithelial cells.  
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Figure 4.4 A: Detection of apoptosis by cleaved PARP in β4 and β6 myoepithelial cells 
exposed to TRAIL   
 
 β4 and β6 myoepithelial cells were treated with recombinant TRAIL (500ng/ml) at 37 °C for 
2, 4 and 8hrs. Apoptosis was analysed by immunoblotting for the presence of cleaved PARP.  
β6 myoepithelial cells exhibit higher levels of cleaved PARP compared to β4 myoepithelial 
cells at all time points (A). β- actin was used as a loading control. The results also were 
analysed via ImageJ integrated density (B).  Relative density of Cleaved PARP for non-treated 
β4 cells versus β4 cells treated with TRAIL for 2, 4 and 8 hrs was 1:0.90, 1:1 and 1: 0.97, 
respectively. While, relative density of Cleaved PARP for non-treated β6 cells versus β6 cells 
treated with TRAIL for 2, 4 and 8 hrs was 1: 3.3, 1:4 and 1:3, respectively. 
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Figure 4. 4 B: Detection of apoptosis by cleaved PARP in β4 and β6 myoepithelial cells 
exposed to TRAIL   
 
 β4 and β6 myoepithelial cells were treated with recombinant TRAIL (500ng/ml) at 37 °C for 
2, 4 and 8 hrs. Apoptosis was analysed by immunoblotting for the presence of cleaved PARP. 
β4 myoepithelial cells showed low level of cleaved PARP compared to β6 myoepithelial cells 
(C), and β6 myoepithelial cells exhibit the highest level after 4 hrs (C). β- actin was used as a 
loading control. The results also were analysed via ImageJ integrated density (D). Relative 
density of Cleaved PARP for β4 cells treated with TRAIL for 2, 4 and 8 hrs versus β4 cells 
were grown under control conditions (vehicle only) over the same time periods was 2.4:1, 2.2:1 
and 1.8: 1, respectively. While, relative density of Cleaved PARP β6 cells treated with TRAIL 
for 2, 4 and 8 hrs versus non treated β6 cells were grown over the same time periods was 6:1, 
5.2:1 and 12.1:1, respectively. 
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(ii) Morphological changes   
In order to investigate susceptibility to apoptosis in both myoepithelial cell 
lines, the lines were exposed to etoposide chemotherapy (1μM/ml) for 4, 6, 8 
and 48 hrs.  After 4, 6 and 8 hrs, neither cell line showed a response to the 
treatment (figure 4.5A), however, by 48hrs β6 myoepithelial cells started to 
display changes in morphology with reduction in the cell number. The cells 
showed contraction, blebbing of the cell membrane and phase bright 
appearance (Figure 4.5B & C). In contrast, the majority of β4 myoepithelial 
cells look healthy with just occasional cells becoming phase bright (Figure 
4.5B). 
 
Figure 4.5 A: Induction of morphological changes in β4 and β6 myoepithelial cell lines on 
exposure to etoposide chemotherapy   
 
Control cells, exposed to vehicle only, appear healthy, and both cell lines remained healthy at 4 
hrs post-treatment.  
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Figure 4.5B: Induction of morphological changes in β4 and β6 myoepithelial cell lines on 
exposure to etoposide chemotherapy 
   
Both cell lines remained healthy at 6hrs and 8 hrs after treatment. However, by 48hrs, whereas 
β4 myoepithelial cells (left panel) still look healthy with only occasional cells becoming phase 
bright (late stage, brown arrow), β6 myoepithelial cells (right panel) showed a change in 
morphology, with reduced cell numbers. The cells displayed extensive plasma membrane 
blebbing (green arrows), contracted morphology (early stage, red arrow) and phase-bright 
appearance (late stage, brown arrow).  
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Figure 4. 5 C Induction of morphological changes in β6 myoepithelial cell lines on 
exposure to etoposide chemotherapy.   
 
Both cell lines were treated with 1μM/ml etoposide for different time periods as indicated. 
After 48 hrs, β6 myoepithelial cells showed changes in their morphology, with a reduced cell 
number and extensive plasma membrane blebbing (green arrows), contracted (early stage, red 
arrow) and phase-bright (late stage, brown arrow) morphology. 
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4.4.4 Detection of cleaved caspase-3 as a marker of 
apoptosis in DCIS  
 
The above data suggests that acquisition of αvβ6 by myoepithelial cells in 
DCIS may make them more susceptible to apoptosis and contribute to their loss 
in DCIS.  
In this study we propose that myoepithelial cells may be lost through apoptosis 
generated by signals from inflammatory cell mediators. To investigate the 
hypothesis that myoepithelial cell apoptosis may be taking place in-vivo, a 
preliminary analysis of 6 cases of DCIS positive for αvβ6 and showing high 
infiltration with Treg cells were selected and stained for cleaved caspase-3. 
Immunohistochemistry demonstrated staining for cleaved caspase-3 in 
myoepithelial cells in some of the DCIS ducts (Figure 4.6.). This provides 
some support for the hypothesis that myoepithelial cells may be lost through 
apoptosis however further work is needed to provide definitive evidence. 
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Figure 4.6  Representative example of caspase-3 immunohistochemistry staining in αvβ6 
+ve DCIS case with high peri-ductal infiltration of Treg cells.  
 
Staining for cleaved Caspase-3 was evident in myoepithelial cells of DCIS, as indicated by 
arrows (A). Apoptotic tumour cells (together with necrotic debris) inside the ducts of DCIS 
showed strong positive staining with casapase-3 and served as an internal positive control, as 
indicated by arrow (B). 
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4.5 Discussion 
 It is well documented that disruption of the myoepithelial layer (ME) and 
basement membrane (BM) is a prerequisite for breast cancer invasion (Clarke, 
Brunner et al. 1989, Sheikh, Garcia et al. 1994). Moreover, it has been shown that 
the stromal tissue surrounding mammary ducts that exhibit disruption of the 
ME layer is often highly vascular and highly infiltrated with inflammatory cells 
(WBCs) when compared to the stroma around ducts with an intact ME layer 
(Man, Tai et al. 2003). White blood cells (WBCs) release protolytic enzymes 
that are capable of degrading the BM and alter host cells in vivo and in vitro 
(Zhang, Schiller et al. 1998, Yakirevich, Izhak et al. 1999). In addition, WBCs 
can freely cross over the ME and BM barrier, (Chen, Yang et al. 1997, Correa, 
Plunkett et al. 2003), and tumours with or without WBC infiltration have been 
shown to have a different clinical course and outcome (Menard, Tomasic et al. 
1997, Hartveit 1998). Yousefi and his colleagues demonstrated that mammary 
ducts with focal disruption of the myoepithelial cell layer showed a higher 
frequency of WBC infiltration than ducts without myoepithelial cell layer 
disruption. They also pointed out that WBCs were often located at or close to 
the centre of myoepithelial cell layer disruptions, raising the possibility that 
inflammatory cells may be involved in disruption of myoepithelial cell layer 
(Yousefi, Mattu et al. 2005). Furthermore, a study has reported that patients 
with a lymphocytic infiltrate at the tumour edge have a significantly poorer 
short-term prognosis compared to patients with lymphocytic infiltration in 
other locations (Hartveit 1998), suggesting a direct interaction between tumour  
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cell behaviour and inflammatory cells. Tumour necrosis factor- related 
apoptosis-induced ligand (TRAIL) is expressed by peripheral T lymphocytes  
(Salehi, Vodjgani et al. 2007) and induces apoptosis  in a variety of cancer cell 
lines, including breast cell lines (Keane, Ettenberg et al. 1999, Walczak, Miller 
et al. 1999, Chinnaiyan, Prasad et al. 2000).Furthermore, activated Treg cells 
express TRAIL in vivo (Ren, Ye et al. 2007) but whether this may be involved 
in mediating loss of myoepithelial cells in DCIS has yet to be established. 
WBCs may have a direct or indirect influence on the integrity of the structure 
of ME cells and the BM layer, and therefore play a key role in mediating the 
transition of DCIS to invasive disease. Since a positive correlation was 
identified between myoepithelial expression of αvβ6 and peri-ductal Treg cell 
infiltration, the study aimed to address two main questions: firstly, to develop 
an in-vitro model system to determine whether expression of αvβ6 on 
myoepithelial cells actually induces higher levels of TRAIL in T cells, and 
secondly to investigate whether TRAIL can disrupt the myoepithelial cells 
barrier through induction of myoepithelial cells apoptosis. 
We first have examined the levels of TRAIL in Jurkat and primary T cell 
populations following co-culture with β4 or β6 myoepithelial cells for 48 hrs. 
Primary T cells, but not Jurkat T cells, were found to express higher levels of 
TRAIL when they were co-cultured with β6 myoepithelial cells than when co-
cultured with β4 myoepithelial cells. The lack of response in the established 
cell line may be a reflection of its immortalisation, and the lack of ‘plasticity’ 
in a cell line, in comparison to primary cells.  TRAIL has been shown to be 
induced in activated T cells (Jeremias, Herr et al. 1998, Sato, Nuki et al. 2010). 
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CD69 is considered to be an early marker of T cell activation (Sancho, Gomez 
et al. 2005), and in the immunohistochemical study on DCIS tissues, we 
demonstrated higher numbers of CD69-positive T cells in the peri-ductal 
environment of αvβ6-positive myoepithelial cells compared to αvβ6-negative 
ducts. Thus, it is possible that up-regulation of αvβ6 can lead to T cell 
activation. Co-culture studies followed by a detailed phenotypic analysis of T 
cells could address this. Similar studies in our laboratory have shown that 
αvβ6-positive myoepithelial cells can modulate macrophage phenotype and 
activation (M Allen, personal communication), making this a plausible theory. 
TRAIL mediates its actions through specific TRAIL receptors, DR4 and DR5. 
These receptors have been deteced on breast cancer cells and high DR5 
expression is strongly correlated with decreased survival (McCarthy, Sznol et 
al. 2005). The aim, therefore, was to measure the levels of TRAIL receptors 
(DR4& DR5) in the myoepithelial cell populations. Both DR4 and DR5 were 
detected on the myoepithelial cell lines, with significantly higher levels of 
mRNA expression for both receptors in the β6 myoepithelial cells compared to 
β4 myoepithelial cells. Unfortunately attempts to measure DR4 and DR5 at the 
protein level were unsuccessful as the antibodies could not be optimised.  
To investigate more directly the effect of TRAIL on ME apoptosis, β6 and β4 
myoepithelial cells were treated with recombinant TRAIL for 2, 4 and 8 hrs, 
after which the cells were analysed for expression of cleaved PARP, as a 
marker of apoptosis. 
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This demonstrated enhanced apoptosis in the β6+ve myoepithelial cell line 
compared to the β6–ve myoepithelial cells at each time point. The results also 
showed that apoptosis reached peak levels at 4hrs post- treatment in both cell 
lines. This provides early evidence that ME positive for β6 integrin may be 
more susceptible to the effect of Treg cells, but this requires further 
investigation. In addition, exposure of both myoepithelial cell lines to 
Etoposide-induced apoptosis has shown that β6+ve myoepithelial cells were 
more susceptible to apoptosis compared to β6–ve myoepithelial cells. 
Therefore, the effect is not specific to TRAIL.  
As a preliminary approach to evaluate the clinical relevance of these findings, a 
small series of DCIS samples was assessed for the presence of apoptosis, 
specifically relating to the myoepithelial compartment. A set of DCIS cases 
showing αvβ6+ve myoepithelial cells and high levels of infiltration with Treg 
cells were stained with an antibody against caspase-3 antigen, as a marker of 
apoptosis. Immunohistochemistry demonstrated staining for caspase-3 in 
myoepithelial cells in some of the DCIS ducts.  This provides some support for 
the hypothesis that myoepithelial cells may be lost through apoptosis however 
further work is needed to provide definitive evidence, including analysis of 
DCIS ducts negative for αvβ6, and normal breast ducts, as a comparison.  
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4.6 Conclusion  
 
Up-regulation of β6 in DCIS-associated myoepithelial cells influence primary 
T cells to express higher levels of TRAIL, and β6 myoepithelial cells express 
higher levels of TRAIL receptor mRNA compared to β6-ve myoepithelial 
cells. Furthermore, expression of β6 by myoepithelial cells appears to increase 
their sensitivity to TRAIL induced apoptosis.  
This may represent one mechanism whereby the myoepithelial cell population 
in DCIS may be lost, so promoting progression to invasive disease. 
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5.1 Introduction  
 
5.1.1 Galectin-7 expression in myoepithelial cells   
  
In the normal breast, it has been shown that galectin-7 is highly expressed by 
the myoepithelial cells (Demers, Rose et al. 2010).  In breast cancer, High 
expression levels of galectin-7 were restricted to high-grade breast carcinoma 
(Demers, Rose et al. 2010). Its over-expression has been shown to be 
associated with metastasis to the lung and bone. It has been suggested that 
galectin-7 has the ability to render mammary epithelial cells more resistant to 
apoptosis (Demers, Rose et al. 2010).  
Moreover, galectin-7 has been described both as pro-apoptotic (Bernerd, 
Sarasin et al. 1999, Kuwabara, Kuwabara et al. 2002), and anti-apoptotic 
(Gendronneau, Sidhu et al. 2008, Demers, Rose et al. 2010).  
5.2 Hypothesis 
 
Galectin-7 is a molecule highly expressed by normal myoepithelial cells and is 
down- regulated in low-grade invasive breast cancer and up-regulated in high 
grade invasive cancer. Evidence suggests that galectin-7 modulates cellular 
apoptotic response, but in some situations it appears to protect against 
apoptosis and others promote apoptosis. The expression of galectin-7 in DCIS 
has not previously been reported, however, given the multiple phenotypic 
changes in DCIS-associated myoepithelial cells, we hypothesise that this 
important regulatory protein may also be altered in DCIS, and this may alter 
the susceptibility of myoepithelial cells to apoptotic signals. 
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5.2.1 Aims of this chapter  
 To determine the expression of galectin-7 in DCIS-associated 
myoepithelial cells. 
  Analyse its relationship with αvβ6 expression. 
 Analyse the relationship between galectin-7 and αvβ6 with clinical 
characteristics of DCIS 
 Investigate expression and relationship of galectin-7 and αvβ6 in 
myoepithelial cell lines and primary populations 
 To examine the influence of galectin-7 expression on myoepithelial 
apoptosis using recombinant TRAIL.  
5.3 Methods and Materials 
5.3.1 Investigation of galectin-7 and αvβ6 expression in 
DCIS  
 
Galectin-7 and αvβ6 antibodies were applied to 47 cases of DCIS and a series 
of 294 core biopsies with a pre-operative diagnosis of DCIS (section 2.4). 
5.3.2 Analysis of the relationship between galectin-7 and 
αvβ6 in DCIS 
 
47 cases of DCIS were scored duct-by-duct for expression of galectin-7 and 
αvβ6 as described in section 2.5. The core biopsies were scored for overall 
amount of staining for both markers and not on a duct-by-duct basis (section 
2.5). 
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5.3.4 Measurement of galectin-7 in myoepithelial cells 
 
Protein and mRNA levels of galectin-7 in β4 and β6 myoepithelial cells were 
measured using Western blot and PCR as described in sections 2.10 and 2.16. 
5.3.5 Knockdown of galectin-7 in primary myoepithelial 
cells and β4 myoepithelial cell line 
 
In order to investigate the impact of knockdown of galectin-7 on αvβ6 
expression, primary myoepithelial cells were treated with galectin-7 siRNA or 
control siRNA for 24, 48 and 72hrs as described in section 2.11, and galectin-7 
and β6 expression was measured by Western blot.  In addition, galectin-7 was 
knocked down in β4 cells then cells were exposed to TRAIL or etoposide 
(section 2.9) to study the effect on apoptosis by measurement of cleaved PARP 
by Western blot (2.10).  
5.3.6 Measuring duct size  
 
Duct size was measured in 47 cases of DCIS and related to expression of 
galectin-7 and αvβ6 using NDP software as described in section 2.6. 
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5.4 Results  
 
5.4.1 Expression of galectin-7 in control tissues  
The Galectin-7 antibody was first optimised for use on normal breast tissue and 
skin tissue as positive controls and when specific staining of the appropriate 
cell compartment was achieved, the antibody was applied to the breast tissue 
samples. Initial staining of normal human breast tissue sections showed 
staining of cytoplasm and nuclei of myoepithelial cells with sparing of the 
luminal cell population (Figure 5.1A), consistent with the previous study 
reporting galectin-7 as a marker of myoepithelial cells (Demers, Rose et al. 
2010). In skin there was extensive staining of the epidermis (Figure 5.1C) as 
has been reported in previous studies describing galectin-7 as a marker of 
stratified epithelium (Madsen, Rasmussen et al. 1995, Magnaldo, Bernerd et al. 
1995). 
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Figure 5. 1Galectin-7 expression in normal mammary gland and skin tissue  
 
Immunohistochemical analysis of human normal tissues demonstrates specific expression of 
galectin-7 in myoepithelial cells. Luminal epithelial cells and stroma are clearly negative 
(panels A & B), and strong positive staining is seen in stratified epithelium of skin (panel C). 
Normal mammary myoepithelial cells show no staining with rabbit IgG, which was used as 
negative control (panel D). (Magnification A&C 5X; B&D 20X). 
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5.4.2 Galectin-7 expression in DCIS cases and its 
correlation with αvβ6  
 
To examine the expression of galectin-7 in DCIS and its relationship to αvβ6 
expression, paraffin-embedded tissue sections were selected from 47 patients 
with DCIS and stained for both markers.  Rabbit IgG was used as negative 
control. After staining, the sections were scanned using Nanozoomer software 
and then scored on a duct-by-duct basis for each marker on serial sections.  
The number of ducts positive for the two markers varied greatly between 
samples. The majority of ducts positive for αvβ6 were negative for galectin-7, 
with 70% of galectin-7 positive ducts being β6 negative compared to 30% 
being β6 positive (Figure 5.2 & 5.3). This demonstrated an inverse relationship 
between the two proteins (p= 0.001). In some cases, myoepithelial cells were 
positive for both proteins or negative for both markers, though this was less 
common (Figure 5.2 & 5.3).  
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Figure 5. 2 Immunohistochemical staining of DCIS for Galectin 7 and αvβ6 
 
 Paraffin-embedded sections from DCIS specimens were stained with antibodies to galectin-7 
and αvβ6. The specimens have been scored duct by duct for galectin-7 and αvβ6 expression. 
The study showed that the majority of ducts of DCIS that express αvβ6 are negative for 
galectin- 7. 
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Figure 5. 3 Immunohistochemical staining of DCIS for Galectin 7 and avβ6  
 
The pattern of staining varied between cases and in a minority of cases myoepithelial cells 
were negative for both markers (panel B) or were positive for both markers (panel C). Some 
cases were positive for galectin-7 and negative for αvβ6 (D). 
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Figure 5.4 Analysis of galectin-7 and αvβ6 expression in DCIS cases  
 
There was a significant inverse relationship between expression of β6 and Galectin-7 in DCIS-
associated myoepithelial cells, with 70% of Galectin-7 positive ducts being β6 negative 
compared to 30% being β6 positive (p=0.001 using one way ANOVA test). It can also be seen 
that a minority of DCIS ducts showed expression of both markers or were negative for both 
Galectin-7 and αvβ6. 
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5.4.3 Galectin- 7 expression in myoepithelial breast cell 
lines  
 
To determine the levels of galectin-7 in relation to αvβ6 expression in 
myoepithelial cells, and to provide the basis for future functional studies, two 
cell lines have been selected; β4 myoepithelial cells that are negative for αvβ6, 
and β6 myoepithelial cells that over-express β6 integrin. The level of galectin-7 
protein and mRNA in both cell lines was analysed by Western blot and PCR, 
respectively. β4 myoepithelial cells exhibited higher levels of expression of 
galectin-7 protein compared to β6 myoepithelial cells (Figure. 5.5A). Similarly, 
mRNA expression analysis demonstrated that galectin-7 is expressed at higher 
levels in β4 myoepithelial cells compared to β6 myoepithelial cells (Figure 
5.5C). The MDA MB 468 breast cancer cell line was used as a positive control 
for Western blot (Figure 5.5A), while primary myoepithelial cells were used as 
positive control and primary luminal epithelial cells as negative control for 
PCR (Figure 5.5C).  
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Figure 5. 5 Analysis of Galectin- 7 in myoepithelial cell lines  
 
(A) Western blot analysis for galectin-7 in β4 and β6 myoepithelial breast cell lines. β4 
myoepithelial cells show a higher level of galectin-7 (14 KDa) compared to β6 myoepithelial 
cells. HSC70 was used as a loading control. MDA MB 468 breast cancer cell line was used as 
positive control. (B) The results also were analysed via ImageJ integrated density and show 
relative density of galectin-7 for β4 myoepithelial cells versus MDA MB 468 cells was 1.86:1. 
The relative density of β6 cells versus MDAMB 468 cells was 0.14: 1. (C) Galectin-7 mRNA 
level in β4 and β6 myoepithelial cell lines was determined by PCR relative to the steady-state 
expression of GAPDH. β6 myoepithelial cells expressed very low levels of galectin-7 mRNA 
compared to β4 myoepithelial cells. Primary myoepithelial cells ware used as positive control 
and primary luminal epithelial cells as a negative control for the PCR. 
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5.4.4 Impact of galectin-7 knockdown on αvβ6 
expression 
 
Immunohistochemical analysis of DCIS tissues demonstrated an inverse 
correlation between myopeithelial galectin-7 and αvβ6 expression. In order to 
investigate this further, galectin-7 was knocked down in the β4 myoepithelial 
cell line and in primary myoepithelial cells for 24, 48 and 72 hrs, and β6 
expression was measured by Western blot.  Galectin-7 knockdown in primary 
myoepithelial cells was achieved at both 24 hrs and 48 hrs time points (figure 
5.6 & 5.7) as detected by Western blot. Western blot on these cells for β6 
demonstrated up-regulation of β6 in myoepithelial cells treated with galectin-7 
siRNA for 48hrs compared to those treated with Control siRNA for the same 
time point (figure 5.8). The experiments were repeated on the β4 myoepithelial 
cell line and whilst knockdown of galectin-7 was achieved, there was no 
change in the level of β6 expression (data not shown). 
 
Figure 5. 6 Knockdown of galectin-7 in primary myoepithelial cells  
(A) Galectin-7 knockdown in primary myoeithelial cells was achieved at both 24 hrs and 48 
hrs time-point as detected by Western blot.  Two samples of non-treated myoepithelial cells 
were used as controls. (B) The results also were analysed via ImageJ integrated density. The 
relative density of in gal-7 siRNA 24hrs versus CsiRNA for same time point was 0.61:1.2 
respectively. The relative density of gal-7 siRNA 48hrs versus CsiRNA at 48 hrs was 0.17: 
0.89.  
 
                                                            Chapter 5 Galectin-7 in relation to αvβ6  
   
195 
 
 
 
 
 
Figure 5.7 Knockdown of galectin-7 in primary myoepithelial cells at extended time-
points  
 
(A) Galectin-7 knockdown in primary myoeithelial cells was achieved at 48 hrs time as 
detected by Western blot.  Non-targeting siRNA (CsiRNA) and non-treated myoepithelial cells 
were used as controls. The cells were also analysed following 72hrs knockdown, however, no 
difference in the level of galectin-7 was evident. (B) The results also were analysed via ImageJ 
integrated density. The relative density for galectin-7 in cells treated with gal-7 siRNA for 
24hrs versus cells treated with CsiRNA at the same time point was 0.64:0.58. The relative 
density for gal-7 in cell treated with siRNA for 48hrs versus CsiRNA treated cells at the same 
time point was 0.30: 0.68. At 72 hrs the relative density for gal-7 in cells treated with siRNA 
for 72hrs versus CsiRNA treated cells at the same time point was 1.2: 1.2. 
 
 
Figure 5.8 Analysis of β6 expression following knockdown of galectin-7 in primary 
myoepithelial cells  
 
(A) Galectin-7 knockdown in primary myoeithelial cells was achieved at 24 hrs and 48 hrs 
time-points.. Western blot for β6 was carried out on these cell lysates and demonstrates up-
regulation of β6 in myoepithelial cells treated with gal-7 siRNA for 48hrs compared to those 
treated with CsiRNA at the same time point. (B) The results also were analysed via ImageJ 
integrated density. The relative density for β6 in cells treated with gal-7 siRNA for 24hrs 
versus CsiRNA for the same time point was 0.76:0.58. The relative density for β6 in cells 
treated with gal-7 siRNA for 48hrs versus CsiRNA for the same time point was 0.62: 0.27. At 
72 hrs the relative density for β6 in gal-7 siRNA treated cells versus CsiRNA treated cells was 
1.2: 0.88. 
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5.4.5 Relationship between Galectin-7 expression and 
apoptotic response  
 
(i) Detection of cleavage PARP  
In earlier experiments, treatment of myoepithelial cells with TRAIL led to 
induction of apoptosis in β6 cells but not in β4 cells. Furthermore, we 
demonstrated an inverse relationship between β6 expression and galectin-7 in 
human DCIS tissues. Galectin-7 has been implicated in apoptosis, having both 
pro-apoptotic and anti-apoptotic functions. We therefore investigated whether 
loss of galectin-7 in β4 cells would make these cells more sensitive to TRAIL-
induced apoptosis. Thus, we knocked down Galectin-7 in β4 myoepithelial 
cells. RT-PCR for galectin-7 RNA and immunoblotting for galectin-7 protein 
was undertaken to assess knockdown efficiency (Figure. 5.9, 5.10, 5.11 and 
5.12). Optimal knockdown was reached by 48 hrs. Galectin-7 knockdown cells 
and non-targeting control cells were then exposed to recombinant TRAIL for 2, 
4 and 8 hours. Apoptosis was assessed by detection of cleaved PARP by 
Western blot. Knockdown of Galectin-7 appeared to enhance apoptosis in β4 
myoepithelial cells. The time-course study indicates that there is no difference 
in cleaved PARP levels between the non-targeting control cells and galectin-7 
knockdown cells after 2 hrs of treatment, whereas high levels of cleaved PARP 
were detected after 4 hrs of exposure to TRAIL in β4 galectin-7 knock down 
cells compared to control cells. By 8 hrs, the same level of cleaved PARP was 
detected in galectin-7 knockdown cells and non-targeting control cells (Figure 
5.13). 
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Figure 5.9   Knockdown of galectin-7 in β4 cells for 24hrs 
 
RT-PCR results showed significant down-regulation of galectin-7 RNA in gal -7 knockdown 
β4 cells at the 24 hrs time point compared to CsiRNA and non-treated counterparts (p=0.0001). 
There also was reduction of galectin-7 RNA in CsiRNA cells compared to non-treated controls.  
Error bars=SD. Bars represent triplicate experiments. 
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Figure 5.10 Knockdown of galectin-7 in β4 cells for 48hrs 
 
Galectin-7 was knocked down in β4 myoepithelial cells for 48 hrs. This showed significant 
down-regulation of galectin-7 RNA in β4 cells treated with Gal-7siRNA compared to the cells 
treated with CsiRNA and non treated cells  (p=0.0002). Error bars=SD. Bars represent 
triplicate experiments. 
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Figure 5.11Knockdown of galectin-7 in β4 myoepithelial cells at 24 hrs  
 
(A) Galectin-7 knockdown β4 in myoepithelial cells was achieved at 24 hrs as detected by 
Western blot. Both CsiRNA and non-treated β4 myoepithelial cells were used as controls. (B) 
The results also were analysed via ImageJ integrated density. The relative density for galectin-
7 in cells treated with gal-7 siRNA for 24hrs versus cells treated with CsiRNA for the same 
time was 0.68:1.  
 
 
Figure 5.12  Knockdown of galectin-7 in β4 myoepithelial cells at 48 hrs  
 
(A) Optimal knockdown of galectin-7 in β4 myoepithelial cells was reached by 48 hrs as 
detected by Western blot.  Cells treated with CdiRNA and non-treated β4 myoepithelial cells 
were used as controls. (B) The results also were analysed via ImageJ integrated density. The 
relative density for galectin-7 in cells treated with gal-7 siRNA for 48hrs versus cells treated 
with CsiRNA treated cells was 0.30:0.89.  
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Figure 5. 13 Detection of apoptosis by cleaved PARP in β4 cells exposed to TRAIL 
following knockdown of galectin-7  
 
(A) Cells treated with non-targeting siRNA or galectin-7 siRNA were exposed to recombinant 
TRAIL at 500 ng/ml for 2, 4 and 8 hrs. Apoptosis was analysed by Western blot using an 
antibody to cleaved PARP. By 4 hrs, galectin-7 knockdown β4 cells exhibit increased PARP 
cleavage compared to non-targeting control cells. There is no difference in cleaved PARP 
between galectin-7 knockdown β4 cells and non-targeting control cells at 2 hrs or 8 hrs post-
treatment. (B) The relative density of cleaved PARP in gal-7 siRNA cells treated with TRAIL 
for 2 hrs versus CsiRNA cells at the same time point was 1:1.2. In contrast, the relative density 
of cleaved PARP in gal-7 siRNA cells treated with TRAIL for 4 hrs versus CsiRNA cells at the 
same time point was 11: 2.8. The relative density of cleaved PARP in gal-7 siRNA cells treated 
with TRAIL for 8 hrs versus CsiRNA cells at the same time point was 8.6: 9.5. 
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(ii) Morphological changes 
 To further investigate whether loss of galectin-7 enhances apoptosis in 
myoepithelial cells, β4 cells treated with control siRNA (CsiRNA) or galectin-
7 siRNA (G7siRNA) were exposed to etoposide chemotherapy at 1μM/ml for 
48 hrs. After 48 hrs, galectin-7 knockdown cells showed morphological 
changes suggestive of early apoptosis such as blebbing of the cell membrane, 
contraction and bright phase appearance, compared to the non-targeting control 
cells (Figure 5.14). 
 
 
 
 
Figure 5.14 Induction of morphological changes in β4 cells treated with G7 siRNA (A) or 
control siRNA (B) on exposure to etoposide  
 
β4 cells were treated with G7siRNA or CsiRNA and exposed to 1μM/ml etoposide for 48 hrs. 
(A) Galectin-7 knockdown cells exhibit morphological changes suggestive of early apoptosis 
indicated by plasma membrane blebbing (green arrows), contracted morphology (early stage, 
red arrow) and phase-bright appearance (late stage, brown arrow). (B) Less marked changes 
are seen in β4 cells treated with control siRNA. 
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5.4.6 Relationship between galectin-7 and αvβ6 
expression and DCIS duct size  
 
On analysis of DCIS tissues it was clear that the size of involved ducts was 
variable. It may be postulated ducts become more expanded by neoplastic cells 
as the disease progresses. In order to assess whether there is a correlation 
between DCIS duct size and myoepithelial cell phenotype, the DCIS ducts 
were measured using NDP software (section 2.6). In the 47 cases of DCIS 
analysed, 268 ducts were positive for galectin-7 and 206 ducts were negative 
for galectin-7, and 521 ducts positive for αvβ6 and 69 ducts negative for αvβ6. 
Data was plotted on a graph using prism software. Two-tailed T- test was used 
to measure the p value.  
In general, the size of galectin-7 positive ducts was significantly smaller than 
the negative ducts (p=0.0001) (figure 5.15). Whereas, the size of αvβ6 positive 
ducts was larger compared to the αvβ6 negative ducts (p=0.0006) (figure 5.16).  
The ducts positive for galectin-7 and negative for αvβ6 were significantly 
smaller than ducts positive for both markers (p=<0.0001), ducts negative for 
both (p=0.02) and ducts negative for galectin-7 and positive for αvβ6 
(p=<0.0001) (figure 5.17).  
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 Figure 5.15  Measurement of the area of ducts in DCIS cases where the ducts are positive 
or negative for galectin-7 
 
47 DCIS cases were stained for galectin-7 and αvβ6. 268 ducts positive for galectin-7 and 206 
ducts negative for galectin-7 were measurable in these cases. The size of the ducts was 
measured using NDP software. DCIS ducts negative for galectin-7 was significantly larger than 
the galectin-7 positive ducts (p=0.0001).  
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Figure 5.16 Measurement of area of ducts in DCIS cases where the ducts are positive or 
negative for αvβ6 
 
From 47 DCIS cases, 521 ducts positive for αvβ6 and 69 ducts negative for αvβ6 were 
measureable. The size of the ducts was measured using NDP software. DCIS ducts negative for 
αvβ6 were significantly smaller compared to the αvβ6 positive ducts (p=0.0006).  
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Figure 5.17 Measurement of size of ducts in DCIS cases where the ducts are positive or 
negative for both galectin-7 and αvβ6 or positive for one and negative for the other 
 
From 47 cases ducts where they are positive or negative for both Galectin-7 and αvβ6 or 
positive for one marker and negative for the other one were measured for the size of ducts. This 
demonstrated that the size of ducts positive for galectin-7 and negative for αvβ6 is significantly 
smaller than the ducts are negative for both (p=0.02), ducts positive for both markers 
(p=<0.0001) and ducts negative for galectin-7 and positive for αvβ6 (p=0.0001).  
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5.4.7 Relationship between galectin-7 and αvβ6 
expression and clinical outcome 
 
In order to address whether expression of αvβ6 and galectin-7 could act as 
predictors of progression to invasion, a second cohort of samples were 
analysed. This cohort included tissues from pre-operative diagnostic core 
biopsies showing DCIS in 294 patients, some of whom had invasive disease 
present on their surgical excision specimen. These samples were therefore 
stained and scored for galectin-7 and for αvβ6 integrin. This was done blind of 
the final histology and the scores returned to Prof Westenden to reconcile with 
clinical data. Some of the core biopsies showed invasive disease and these 
were excluded from the analysis, resulting in interpretable staining being 
available on 225 cases. The clinical and pathological features of these cases is 
summarised in Table 2.2. 
 
Table 5.1: Summary of case numbers with interpretable staining and other continuous 
attributes 
 
Factor Number with 
known status 
Mean (SD) 
Size of DCIS (mm) 141 24 (20) 
ER % 215 69 (44) 
Galectin 7 hscore 225 93 (95) 
αvβ6 hscore 224 75 (85) 
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Table 5.2 : Categorical pathological data relating to core biopsies with interpretable 
staining 
 
 
 
Factor Category No (%) 
Grade of core 1 26 (11) 
2 47 (21) 
3 132 (59) 
NK 20 (9) 
Invasive tumour 
present? 
No 55 (24) 
Yes 170 (76) 
 
 
There was no significant positive or negative association between galectin-7 
hscore and αvβ6 hscore (Spearman correlation coefficifient = 0.08, p=0.2). No 
significant association with presence of invasion was noted for either galectin-7 
(p=0.4) or αvβ6 (p=0.5). The only significant association with galectin-7 was 
with grade of core biopsy, with increasing galectin-7 levels with poorer grade 
(p=0.002; data not shown). The only significant associate of αvβ6 was ER 
status (p=0.001), with decreasing αvβ6 levels with increasing ER score- that is, 
αvβ6 is associated with ER negativity (Table 5.3) 
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Table 5.3 Relationship between αvβ6 and ER 
 
ER  Mean (SD) αvβ6 hscore 
0  102 (97) 
>0, <50  123 (97) 
50-90  76 (84) 
>90  61 (74) 
Missing  57 (100) 
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5.5 Discussion  
 
The results in chapter 4 provide early evidence that myoepithelial cells positive 
for β6 integrin may be more susceptible to the effect of T-cells, though this 
requires further investigation in co-culture models. Many changes could 
influence the response of myoepithelial cells to TRAIL. It has been shown that 
normal myoepithelial cells express galectin-7 and its expression is altered 
during breast cancer progression (Demers, Rose et al. 2010). One of the major 
biological roles played by galectin-7 relates to its modulatory effects on 
apoptosis; while it seems to display pro-apoptotic activity in some tumour cell 
lines (Bernerd, Sarasin et al. 1999, Kuwabara, Kuwabara et al. 2002), other 
studies have suggested that galectin-7 may display anti-apoptotic effects 
(Gendronneau, Sidhu et al. 2008, Demers, Rose et al. 2010). With respect to 
the pro-apoptotic roles played by galectin-7, the Kuwabara group reported that 
ectopic expression of Galectin-7 in HeLa cells and in the colon carcinoma cell 
line DLD-1 renders them more susceptible to apoptosis induced by 
actinomycin D and UVB (Kuwabara, Kuwabara et al. 2002). Similarly, an 
increase in galectin-7 expression has been demonstrated in apoptotic 
keratinocytes of human skin explants exposed to UVB (Bernerd, Sarasin et al. 
1999). In contrast, exposure of skin from wild type (wt) or galectin-7-/- adult 
mice to UVB revealed a twofold increase in apoptotic cells in galectin-7-/- 
compared with wt epidermis at 6 hrs (Gendronneau, Sidhu et al. 2008).  A 
study by Demers and colleagues suggests that galectin-7 has the ability to 
render mammary cells more resistant to apoptosis. They demonstrated that the 
mouse breast cancer cell line 4T1, when transfected with galectin-7, become 
more resistant to apoptosis when exposed to epigallocatechin galatte, a 
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pharmacological agent known to induce apoptosis in 4T1 cells (Demers, Rose 
et al. 2010). Thus, it appears from the literature that galectin-7 certainly has a 
role in apoptosis, and whereas most evidence suggests it is pro-apoptotic some 
models suggest it may be anti-apoptotic, and this is context-dependent. The 
next aim therefore was to determine whether there was any change in galectin-
7 expression in DCIS-associated myoepithelial cells, and whether this could 
influence their response to apoptosis-inducing stimuli.  
Therefore, galectin-7 expression was examined in a series of DCIS tissue 
samples, in conjunction with αvβ6 expression in order to investigate the 
relationship between these molecules. In keeping with previous reports 
galectin-7 expression was found to be limited to myoepithelial cells in normal 
breast. In DCIS cases there was more variable expression of galectin-7. Some 
ducts entirely lacked expression, others retained myoepithelial cell expression 
whilst in others the pattern of staining was heterogeneous. When compared to 
αvβ6 status, there was an inverse relationship between the two markers, thus 
positivity for αvβ6 on myoepithelial cells was associated with loss of galectin-7 
(p= 0.001). To further investigate the relationship between αvβ6, galectin-7 and 
susceptibility to apoptosis, β4 and β6 myoepithelial cells were examined for 
expression of galectin-7. This showed reduced expression of galectin-7 in the 
β6 cells. To determine whether galectin-7 has the ability to protect 
myoepithelial cells from apoptosis, galectin- 7 was knocked down in β4 cells, 
which were then exposed to recombinant TRAIL and the level of apoptosis 
measured using cleaved PARP. This demonstrated that the β4 cells appeared to 
be more sensitive to TRAIL when galectin-7 levels were reduced compared to 
non-target control cells.  
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In order to investigate whether galectin-7 and αvβ6 could be used to predict 
progression to invasive disease, a cohort of DCIS core biopsies was analysed, 
and expression related to final surgical pathology, where some cases were pure 
DCIS and others had areas of invasion. This analysis did not show a significant 
relationship between galectin-7 expression and αvβ6, and was not related to the 
presence or absence of invasive disease in the final surgical excision. It is not 
clear why the inverse relationship between galectin-7 and αvβ6 identified on 
the initial DCIS set was not evident in this larger sample series. However, it 
may relate to the method of analysis of the staining. In the original DCIS 
sample set, staining for each marker was assessed on a duct-by-duct basis, 
whereas in the core biopsy series, a score of percentage staining for each 
marker was made. This may be too coarse a method of analysis to capture the 
relationship between the two markers, however time precluded the much more 
labour-intensive duct-by-duct analysis on the core biopsies, though this will be 
done as future work. It also is possible that the level of heterogeneity within a 
sample makes analysis on core biopsy too unreliable. The relationship between 
presence of myoepithelial αvβ6 and negative ER status of DCIS cells is 
interesting and may reflect the more advanced stage of αvβ6-positive DCIS. 
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5.6Conclusion 
 
The work in this chapter has shown s that αvβ6 expression in myoepithelial 
cells is associated with lower levels of galectin-7 expression in vitro and in 
vivo. Furthermore, it demonstrates that knockdown of galectin-7 expression in 
myoepithelial cells in vitro results in enhanced susceptibility to TRAIL-
induced apoptosis. 
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6.1 Introduction 
6.1.1 Cytokines expressed in normal breast and 
breast cancer 
 
There is evidence for a change in cytokine profile in both invasive and pre-
invasive DCIS. An early report showed that the cytokine High in normal- 1 
(HIN-1) expression is significantly down regulated in 94% of human breast 
carcinomas and 95% of pre-invasive lesions, such as DCIS (Krop, Sgroi et al. 
2001).  
 In contrast, IL-1α is highly expressed in DCIS and invasive breast cancer 
compared to benign tumours (Kurtzman, Anderson et al. 1999), and promotes 
tumour growth (Kumar, Kishimoto et al. 2003). Moreover, IL-5 is inducing 
CD4 T cells (Hogan, Koskinen et al. 1998). IL-16 has a role in recruitment of 
Treg cells (McFadden, Morgan et al. 2007). 
Since we have demonstrated a relationship between altered myoepithelial cell 
phenotype and inflammatory infiltrate it is possible that the altered phenotype 
results in an altered cytokine signature to influence the inflammatory 
population. 
                                                  Chapter 6: Myoepithelial cell – T cell interactions 
 
215 
 
6.2 Hypothesis 
 
The immunohistochemical analysis in this study demonstrates a correlation 
between the nature of the inflammatory cell infiltrate and myoepithelial cell 
phenotype. It is unclear from this tissue study whether there is a functional 
interaction between myoepithelial cells and the inflammatory infiltrate. 
Therefore, this chapter aimed to study the interaction between myoepithelial 
cells and inflammatory cells in vitro using the Jurkat T cell line and primary T 
cells. The specific aims are to:  
 Co-culture Jurkat and primary T cells with β4 (αvβ6-ve) or β6 
(αvβ6+ve) myoepithelial cells and measure the levels of CD4 and 
CD8 in the T cells.  
 Investigate the profile of cytokines released by both myoepithelial cell 
populations (β4 & β6) using condition medium. 
 Investigate how myoepithelial cell – T cell interactions may impact on 
cytokine release by co-culture of Jurkat T cells with both β4 and β6 
myoepithelial cell lines.  
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6.3 Methods and Materials 
6.3.1 Co-culture of myoepithelial cells with T cells  
 
β4 and β6 myoepithelial cells were co-cultured with primary T cells and Jurkat 
T cells for 24, 48 and 72 hrs as described in section 2.8.10. 
6.3.2 Measurement of CD4 and CD8 in T cells co-
cultured with myoepithelial cells  
 
Levels of CD4 and CD8 were measured in primary T cells and Jurkat T cells 
co-cultured with β4 or β6 myoepithelial cells using flow cytometry technique 
(section 2.19). 
6.3.3 Investigation of cytokine levels in myoepithelial 
cells  
 
Cytokines released and expressed by β4 and β6 myoepithelial cells were 
measured using cytokine profile arrays, as described in 2.18.  
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6.4 Results  
 
6.4.1 Analysis of CD3 expression in Jurkat T cells  
 The Jurkat T cell line was assessed for CD3 expression prior to use to confirm 
their validity as a model of T cells. Jurkat cells were stained with Alexa Fluor 
488 anti-human CD3 antibody and analysed on FACS Calibur (BD) using 
Cellquest software.  At least 10000 cells were analysed and mouse IgG isotype 
was used as a negative control. The data acquisition threshold was set on a 
forward channel to exclude dead cells and debris with very low size. This 
revealed the percentage of CD3 expression in Jurkat T cells is 84.4% (figure 
6.1 A).  Jurkat cells were also investigated for expression of CD3 by Western 
blot, and were positive (figure 6.1, B). 
 
Figure 6.1 Expression of CD3 in Jurkat T cells 
  
Flow cytometry analysis of expression of CD3 in Jurkat T cells showed 83.4% of Jurkat T cells 
were positive (A) and Western blot analysis also demonstrate Jurkat cells were positive for 
CD3 expression (B).  
                                                  Chapter 6: Myoepithelial cell – T cell interactions 
 
218 
 
6.4.2 Analysis of CD3 expression in primary T cell 
 
Primary T cells isolated from Peripheral blood mononuclear cell (PBMC) of 
healthy donors were also stained for CD3.  Levels of CD3 were measured by 
flow cytometry. At least 10000 cells were analyzed using Cellquest software. 
This demonstrates that primary T cells were 74.4% positive for CD3 (figure 
6.2).   
 
          
 
Figure 6.2  Representative dot plot of CD3 expression in primary T cells  
 
Expression of CD3 in the primary T cells was measured by flow cytometry. Cells stained with 
isotype IgG control were used to set up the gate and at least 10000 cells were analyzed using 
Cellquest software. Primary T cells showed 74.4% positivity for CD3 expression. 
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6.4.3 Analysis of CD4 expression in primary T cells and 
Jurkat T cells  
 
Primary T cells isolated from Peripheral blood mononuclear cell (PBMC) of 
healthy donors and Jurkat T cells were analysed for expression of CD4 by flow 
cytometry. Both cell types were stained with Alexa Fluor 488 anti-human CD4 
antibody.  Cells stained with mouse IgG isotype were used to set up the gates.  
At least 10000 cells were quantified using Cellquest software. This revealed 
that 45% of the primary T cells were positive for CD4 (figure 6.3), while 
49.4% of Jurkat cells were positive for CD4 (figure 6.4).       
 
              
Figure 6.3 Expression of CD4 in the primary T cells 
 
Levels of CD4 expression was measured by FACS. Cells stained with matched isotype control 
were used to set up the gates and at least 10000 cells were analyzed using Cellquest software. 
Primary T cells showed 45% positivity for CD4 expression.  
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Figure 6.4 Representative dot plot of CD4 expression in Jurkat T cells 
 
Jurkat T cells were measured for expression of CD4 by flow cytometry. The gates were set up 
using cells stained with mouse IgG isotype.  At least 10000 cells were analyzed using Cellquest 
software. Jurkat T cells showed 49.4% positivity for CD4. 
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6.4.4 Analysis of CD8 expression in primary T cells and 
Jurkat T cells  
 
Primary T cells and Jurkat T cells were analysed for expression of CD8 by 
FACS. Cells labelled with matched isotype control were gated on, and at least 
10000 cells were quantified using Cellquest software. This revealed that 37.4% 
of primary T cells were positive for CD8 expression (figure 6.5) and 7.8% of 
Jurkat T cells were positive for CD8 expression (figure 6.6).   
       
Figure 6.5 Expression of CD8 in primary T cells  
 
CD8 levels were measured in primary T cells by FACS. At least 10000 cells analyzed using 
Cellquest software.  Primary T cells showed 37.4% of positivity for CD8 expression.   
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Figure 6.6 Expression of CD8 in jurkat T cells  
 
CD8 expression was measured in Jurkat T cells by flow cytometry. The same number of  the 
cells was quantified using Cellquest software.  This demonstrated 7.8%  of Jurkat cells were 
positive for CD8.  
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6.4.5 Effect of myoepithelial cells on expression of CD4 
in primary T cells 
 
Immunohistochemical analysis of DCIS tissues demonstrated lower numbers of 
CD4+ve cells and higher numbers of CD8+ve cells in ducts with αvβ6-
negative myoepithelial cells compared to those with αvβ6-positive 
myoepithelial cells. This suggests that αvβ6 expression in myoepithelial cells 
may play a role in driving T cells towards CD4+ve phenotype. To investigate 
this, primary T cells were co-cultured with β4 myoepithelial cells or β6 
myoepithelial cells, and the level of CD4 expression measured by flow 
cytometry.   
Primary T cells were co-cultured with β4 cells or β6 cells for 24, 48 and 72 hrs 
(see 2.8.10). Primary T cells were stained with anti-CD4 antibody and matched 
isotype was used as a negative control for each run. At least 10000 cells were 
evaluated for expression of CD4 using Cellquest software.  
At 24 hrs time point, CD4 level in primary T cells co-cultured with β4 cells 
was 51.7% while its level was 52.4% in those co-cultured with β6 
myoepithelial cells (figure 6.7), and after 48 hrs, T cells co-cultured with β4 
cells showed 55.2% positivity for CD4 expression and 52.3% positivity in 
those co-cultured with β6 cells (figure 6.8). At 72 hrs time point, CD4 levels 
were 52.9% and 52% with β4 and on β6 myoepithelial cells, respectively 
(figure 6.9). Thus, no significant difference was seen between the two 
myoepithelial cell lines. CD4 levels were up-regulated in primary T cells 
following co-culture under all conditions compared to T cells cultured without 
β4 or β6 cells (45%).  
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Figure 6.7 Representative dot plots of CD4 expression in primary T cells co-cultured with 
β4 or β6 myoepithelial cells for 24hrs  
 
Primary T cells were co-cultured with β4 or β6 myoepithelial cells for 24hrs. The primary T 
cells were then collected and stained for CD4. At least 10000 of cells were evaluated using 
Cellquest software. Matched isotype control was used instead of the primary antibody as a 
negative control.  51.7 % of primary T cells co-cultured with β4 cells were positive for CD4 
(A), and when co-cultured with β6 myoepithelial cells 52.4% were positive for CD4 (B). 
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Figure 6.8 Expression of CD4 in primary T cells co-cultured with β4 or β6 cells for 48 hrs  
 
Primary T cells were co-cultured with β4 or β6 myoepithelial cells for 48 hrs.  Primary T cells 
were collected and stained for CD4. At least 10000 cells were quantified using Cellquest 
software. This showed 55.2 % of primary T cells co-cultured with β4 cells were positive for 
CD4 (A) and 52.3% were positive for CD4 when co-cultured with β6 cells (B).  
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Figure 6.9 Expression of CD4 in primary T cells co-cultured with β4 or β6 cells for 72 hrs  
 
Primary T cells were co-cultured with β4 or β6 myoepithelial cells for 72 hrs. Gates were set 
up based on the cells labelled with IgG isotype control.   At least 10000 cells were quantified 
using Cellquest software.  T cells co-cultured with β4 cells showed 52.9 % positivity for CD4 
(A) and T cells co-cultured with β6 cells showed 52% positivity for CD4 (B).  
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6.4.6 Effect of myoepithelial cells on expression of CD4 
in Jurkat T cells 
 
Jurkat T cells were also co-cultured with β4 or β6 myoepithelial cells for the 
same time points as described above (24, 48 & 72hrs) (section 2.8.10).  After 
each time point, CD4 expression in Jurkat T cells was measured by flow 
cytometery.  
 Jurkat cells labelled with matched isotype control instead of the primary 
antibody were used for each run to set up the gates. The same number of cells 
was analyzed using Cellquest software.  CD4 expression level in Jurkat cells 
co-cultured with β4 cells for 24 hrs was 32.3%, while in those co-cultured with 
β6 cells was 33.8% (figure 6.10).  
 After 48 hrs a gradual decrease in the level of CD4 expression in Jurkat cells 
was observed in both groups of co-culture compared to non co-cultured cells: 
Jurkat cells co-cultured with β4 cells showed 20.4% positivity for CD4 and 
those co-cultured with β6 cells showed 21.8% positivity (figure 6.11). At 72 
hrs time point, CD4 levels in Jurkat cells co-cultured with β4 or β6 cells were 
31.8% and 32.7%, respectively (figure 6.12). Thus, no significant difference 
was seen between the two myoepithelial cell lines. The level of CD4 
expression in Jurkat cells was 49.4% without co-culture.  
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Figure 6.10 Representative dot plots of CD4 expression in Jurkat T cells co-cultured with 
β4 or β6 myoepithelial cells for 24hrs 
 
 Jurkat T cells were co-cultured with β4 or β6 myoepithelial cells for 24 hrs. Cells labelled with 
matched IgG isotype were used to set up the gates. At least 10000 cells were analyzed using 
Cellquest software. This demonstrated that CD4 level in Jurkat cells co-cultured with β4 cells 
is 32.3% (A) and in Jurkat cells co-cultured with β6 cells is 33.8% (B).   
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Figure 6.11 Expression of CD4 in Jurkat T cells co-cultured with β4 or β6 myoepithelial 
cells for 48 hrs 
 
Jurkat T cells co-cultured with β4 or β6 myoepithelial cells for 48 hrs were collected and 
stained for CD4. At least 10000 cells were evaluated using Cellquest software. This 
demonstrated CD4 expression in Jurkat cells co-cultured with β4 cells was 20.4% (A), and in 
those co-cultured with β6 cells were 21.8% (B).  
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Figure 6.12 Expression of CD4 in Jurkat T cells co-cultured with β4 or β6 myoepithelial 
cells for 72 hrs  
 
Jurkat T cells co-cultured with β4 or β6 myoepithelial cells for 48 hrs were collected and 
stained for CD4. Cells labelled with matched isotype control were used to gate on, and at least 
10000 cells were evaluated using Cellquest software. This showed the levels of CD4 
expression in Jurkat cells co-cultured with β4 cells was 31.8 % (A) and in those co-cultured 
with β6 cells was 32.7% (B).  
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6.4.7 Impact of myoepithelial cells on expression of CD8 
in primary T cells 
 
CD8 expression was analyzed in primary T cells co-cultured with β4 or β6 
myoepithelial cells for 24, 48 and 72 hrs (2.8.10) by FACS.  A negative control 
using matched isotype antibody instead of the primary antibody was used for 
each run.  At least 10000 cells were quantified using Cellquest software.   
At 24hrs time point, comparing the levels of CD8 in primary T cells co-
cultured with β4 or β6 cells showed no difference between the two groups, at 
30.2%, and 30% respectively (figure 6.13).  After 48 hrs of co-culture, CD8 
expression in primary T cells was slightly up-regulated but with no striking 
difference between the two groups, with 34.2 % positivity in those exposed to 
β4 cells and 31.9% positivity in those exposed to β6 cells (figure 6.14).  At 72 
time point, the level of CD8 expression was 32% in T cells co-cultured with β4 
cells and 31% in those co-cultured with β6 cells (figure 6.15). Each time point 
of the co-culture experiments was repeated at least three times. CD8 expression 
in primary T cells without co-culture was 37.4%. 
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Figure 6.13 Representative dot plots for expression of CD8 in primary T cells co-cultured 
with β4 or β6 myoepithelial cells for 24 hrs  
 
Primary T cells were co-cultured with β4 and β6 myoepithelial cells for 24 hrs then collected 
and stained for CD8. At least 10000 cells were evaluated using Cellquest software.  This 
showed CD8 level in T cells co-cultured with β4 cells is 30.2% (A) and 30 % when co-cultured 
with β6 cells (B).   
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Figure 6.14 Representative dot plots for expression of CD8 in primary T cells co-cultured 
with β4 or β6 myoepithelial cells for 48 hrs  
 
Primary T cells were co-cultured with β4 and β6 myoepithelial cells for 48 hrs then collected 
and stained for CD8. At least 10000 cells were analyzed using Cellquest software. This showed 
no difference between the two groups; 34% CD8 positivity in the presence of β4 cells (A) and 
31.9 % in those co-cultured with β6 cells (B).   
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Figure 2.15 Representative dot plots for expression of CD8 in primary T cells co-cultured 
with β4 or β6 myoepithelial cells for 48 hrs  
 
Primary T cells were co-cultured with β4 or β6 cells for 48 hrs  and analyzed for CD8 
expression. This demonstrated 32% of T cells co-cultured with β4 cells are positive for CD8 
(A), while 31% of T cells co-cultured with β6 cells are positive for CD8 (B).   
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6.4.8 Impact of myoepithelial cells on expression of CD8 
in Jurkat T cells  
 
Levels of CD8 expression were also measured in Jurkat T cells by flow 
cytometry following co-culture with β4 and β6 myoepithelial cells for 24, 48 
and 72 hrs (section 2.8.10).  At each time point Jurkat cells were collected and 
stained for CD8. Cells labelled with matched isotype control were used to gate 
on, and at least 10000 cells were quantified using Cellquest software.  
At 24hrs time point, the levels of CD8 in Jurkat T cells co-cultured with β4 or 
β6 cells showed no difference between the groups, at 12%, and 12.1 
respectively (figure 6.16), and at 48 hrs there was 10.1% positivity in those 
cultured with β4 cells and 10.7% positivity in those cultured with β6 cells 
group (figure 6.17).   
At 72 hrs time point, the levels of CD8 expression showed a slight decline, 
however, still there is no difference between the two groups. Jurkat cells co-
cultured with β4 cells showed 8.5% positivity for CD8 and Jurkat cells co-
cultured with β6 cells showed 7.1% positivity (figure 6.18). 
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Figure 6.16 Expression of CD8 in Jurkat T cells co-cultured with β4 or β6 myoepithelial 
cells for 24 hrs 
 
Jukat T cells were co-cultured with β4 and β6 myoepithelial cells for 24 hrs and then collected 
and stained for CD8.  Cells labelled with isotype control were used to gate on, and at least 
10000 cells were evaluated using Cellquest software.  This demonstrated CD8 level in T cells 
co-cultured with β4 cells at 12% (A) and 12.1% in those co-cultured with β6 cells (B).   
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Figure 6.17 Expression of CD8 in Jurkat T cells co-cultured with β4 or β6 myoepithelial 
cells for 48 hrs  
 
CD8 levels were measured by FACS in Jurkat T cells co-cultured with β4 or β6 myoepithelial 
cells for 48 hrs.  At least 10000 cells were evaluated using Cellquest software.  This showed 
CD8 level in T cells co-cultured with β4 cells of 10.1% (A) and 10.7% in those they co-
cultured with β6 cells (B).   
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Figure 6.18 Representative dot plots of expression of CD8 in Jurkat T cells co-cultured 
with β4 or β6 myoepithelial cells for 72 hrs  
 
T cells were co-cultured with β4 or β6 myoepithelial cells for 72 hrs and analyzed for CD8 
expression by FACS using Cellquest software. T cells co-cultured with β4 cells showed 8.5% 
positivity for CD8 (A), with 7.1% of positivity for CD8 when co-cultured with β6 cells (B).   
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6.4.9 Cytokine profile of myoepithelial cells 
 
Cells lysates from β4 and β6 myoepithelial cells were collected as described in 
section, 2.10.1. Cytokine profile arrays for both cells types were performed 
(section 2.18). the expression of each cytokine is represented by two dots on 
the membrane. The densities of these dots were analyzed by Image J software 
and then plotted on a graph using Microsoft Office Excel 2007. This 
demonstrates that β4 and β6 myoepithelial cells express 20 of the cytokines 
present on the arrays, including C5/C5a, CD40L , G-CSF,  GM-CSF,  GROa, 
I-309, SICAM-1, IFN γ, IL-1α, IL-1β,IL-1ra, IL-5, IL-13, IL-16, IL-23, IL-
25,MIF, MIP-1α, SerpinE1 and RANTES (figure 6.19).  β6 myoepithelial cells 
were shown to express relatively higher levels of interleukins including  IL-1α, 
IL-1β, IL-5, IL-13, IL-16, IL-23 and IL-25 compared to β4 myoepithelial cells 
(figure 6.19). IL-1ra is expressed more highly by β4 myoepithelial cells (figure 
6.19). Moreover, β6 myoepithelial cells showed relatively higher levels of 
MIF, Serpin E1 and C5/C5a compared to β4 myoepithelial cells. 
These observations suggest that up-regulation of αvβ6 expression on 
myoepithelial cells during DCIS may have an influence on the cytokine profile 
of myoepithelial cells, which may in turn influence their effect on the 
microenvironment.  
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Figure 6.19 Cytokines expressed in β4 and β6 myoepithelial cells 
 
Lysates of β4 and β6 myoepithelial cells were collected and cytokine arrays were performed.    
Each cytokine is represented by two dots on the array blot.   Densities of each cytokine dots 
was quantified using Image J software.  Then, the relative densities were plotted on a graph 
using Microsoft Office Excel 2007.  This shows that β6 myoepithelial cells express relatively 
higher levels of IL-1α, IL-1β, IL-5, IL-13, IL-16, IL-23, IL-25, MIF, Serpin E1 and C5/C5a 
compared to β4 myoepithelial cells. In contrast, IL-1ra is expressed more by β4 cells compared 
to β6 myoepithelial cells.  
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6.4.10 Cytokines released by myoepithelial cells 
 
Condition media (CM) from β4 and β6 myoepithelial cells were collected as 
described in section, 2.8.8.  The CM were incubated with cytokine array 
membranes to investigate the cytokine profile released from β4 and β6 
myoepithelial cells. As described, each type of cytokine is representative by 
two dots on the membrane, and the densities of the dots were quantified using 
Image J software. The relative density of signal was plotted on a graph using 
Microsoft office Excel 2007.  This demonstrated that β4 myoepithelial cells 
released 10 types of  cytokine including, GM-CSF, GROa, SiCAM-1, IL-
1a,IL-1ra, IL-6, IL-8, MIF, serpinE1 and RANTES (figure 6.20 ) while β6 cells 
released 16 of the cytokines present on the array, including G-CSF, GM-CSF, 
GROa, 1-309, SiCAM-1, IFNγ, IL-1α, IL-1ra, IL-6, IL-8, IL-10, IL-13, MCP-
1, MIF, serpinE1 and RANTES ( figure 6.20 ). β4 myoepithelial cells released 
higher levels of IL-8 and RANTES compared β6 myoepithelial cells.  Whereas 
GM-CSF, GROa, SiCAM-1, IL-1α, IL-1ra, IL-6, MIF and serpin E1 are 
released at higher levels by β6 myoepithelial cells compared to β4 cells.  in 
addition, G-CSF, I-309,   IL-10 and IL-13,   IFNγ, and MCP-1 were detected 
only in CM from β6 myoepithelial cells. These findings support the suggestion 
that up-regulation of αvβ6 integrin on myoepithelial cells influences the profile 
of cytokines released. 
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Figure 6.20 Cytokine profile released by β4 and β6 myoepithelial cells 
 
Cytokine array profiles were run for the condition media collected from β4 and β6 
myoepithelial cells. Each cytokine is representative by two dots on the array membrane, and 
the density of the signal from these dots was measured by Image J software and plotted on a 
graph using Microsoft Office Excel 2007. This demonstrates that some cytokines are released 
only by β6 myoepithelial cells, including G-CSF, I-309,   IL-10 and IL-13, IFNγ, and MCP-1. 
Morover, GM-CSF, GROa, SiCAM-1, IL-1α, IL-6, MIF and serpin E1 are released at a higher 
level β6 cells compared to β4 cells.  
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6.4.11 Influence of T cells on myoepithelial cytokine 
expression 
 
To determine the influence of T cells on myoepithelial cell cytokine 
expression, Jurkat  cells were used as a  model of  T cells and were co-cultured 
with either β4 or  β6 myoepithelial cell types for 24 hrs as described  in section, 
2.8.10.  Myoepithelial cell lysates were then collected and cytokine arrays were 
performed (section, 2.18).  
β4 and β6 myoepithelial cell cytokine profiles changed following co-culture 
with Jurkat T cells.  They lost  most of their  cytokines expression after they 
were co-cultured with jurkat cells. In addition, levels of  IFNγ, IL-1β, IL-1ra, 
MIF and serprinE1 were expressed relatively  more in β4 cells compared to  β6 
cells (figure, 6.21). 
These observations suggest that T cells may have a role in changing of  
myoepithelial cells cytokines profile in DCIS disease. However, this  
suggestion needs further investigations. 
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Figure 6.21 Influence of jurkat T cells on cytokines express on myoepithelial cells 
 Cytokines profiles have investigated in β4  and  β6 cells  co-cultured with jurkat T cells for 
24hrs.  Cytokines expressed on both myoepithelial cells changed after co-cultured with jurkat T 
cells as they lost the most of thier cytokines. Moreover, β4  cells relatively express more levels 
of of  IFNγ, IL-1β, IL-1ra, MIF and serprinE1 compared to β cells.  
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6.5Discussion 
 
Many studies have shown that inflammatory cell  infiltrate may play a role in 
cancer cells behaviour in DCIS, it has demonstrated that myoepithelial cells 
exhibit multiple changes in gene expression and up-regulation of certain types 
of chemokines (Allinen, Beroukhim et al. 2004). We previously have shown 
that up-regulation of   αvβ6 on myoepithelial cells in a subset of DCIS which is 
associated with invasive disease (Allen, Thomas et al. 2014). 
We also have observed in this study that there is a correlation between certain 
types of inflammation cell infiltrate in DCIS with the expression of αvβ6 on 
myoepithelial cells.  In DCIS microenvironments, expression of αvβ6 on 
myoepithelial cells is associated with a higher level of CD4+ve cells and a 
lower level of CD8+ cells. Therefore, this chapter was aimed to investigate the 
influence of αvβ6+ myoepithelial cells on the phenotype of inflammatory cells, 
also to investigate influence of T cells on myoepithelial cell cytokines.  
 β6 myoepithelial cells were used as a model of αvβ6+ve myoepithelial cells 
and β4 cells were used as a model of αvβ6–ve myoepithelial cells. Both types 
of myoepithelial cells were co-cultured with primary T cells and Jurkat T cells 
for 24, 48 and 72 hrs and the levels of CD4 and CD8 expression were 
measured in primary T cells and Jurkat T cells by flow cytometery. This 
demonstrated the levels of  CD4 expression in  two types of T cells  showed no 
different between  T cells co-cultured with β4 cells and those  co-cultured with  
β6 cells at all times points. Also there was no difference in the levels of CD8 
expression  in both types of T cells between T cells co-cultured with β4 cells 
and those co-cultured with β6 cells for all time points. 
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This is not consistent with the observations from the tissue study but is 
probably a limitation in the study design, since in-vitro there is no new 
recruitment of T cell populations.  In-vivo study has shown that Matrigel plugs 
containing β6 cells associated with higher numbers of CD4+ve cells compared 
to the Matrigel plugs containing β4 cells, and this supports the idea that the 
environment of β6+ve myoepithelial cells leads to effects on recruitment of T 
cell populations.  
In order to elucidate mechanisms that myoepithelial cells could effect the 
phenotypes of inflammatory cells infiltrate in DCIS stroma, cytokines of both 
phenotypes of myoepithelial cells were investigated with or without co-culture 
with T cells. 
 DCIS and invasive breast cancer express higher level of IL-1α compared to 
benign tumours (Kurtzman, Anderson et al. 1999)  and promotes tumour 
growth (Kumar, Kishimoto et al. 2003).  This is consistent with the cytokines 
array results that show β6 myoepithelial cells relatively expressed a higher 
level of IL-1α compared to β4 cells. In addition, β6 cells expressed higher level 
of IL-5 compared to β4 cells which induces CD4 T cells (Hogan, Koskinen et 
al. 1998).  β6 cells also expressed more of IL-16 which has a role in  induction 
recruitment T reg cells (McFadden, Morgan et al. 2007). 
 Therefore, upregulation of IL-5 and IL-16 in β6 cells is likely to be the 
explanation for the higher numbers of CD4+ve T and FOXP3+ve cells in αvβ6 
positive DCIS cases. However, cytokines arrays results need to be validated.  
                                                  Chapter 6: Myoepithelial cell – T cell interactions 
 
247 
 
6.6 Conclusion 
 
Expression of αvβ6 integrin in myoepithelial cells in DCIS has an effect in the 
cytokines expressed and released by myoepithelial cells. T cells may have also 
impact in types of cytokines expressed by myoepithelial cells.   
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7.0 Discussion 
7.1 Overview of the study aims 
 
 The transition of DCIS to invasive disease is a critical stage in the progression 
of breast cancer and is characterised by penetration and eventual loss of the 
myoepithelial cell layer and basement membrane. Myoepithelial cells play an 
important role in the regulation of normal breast function and have been shown 
to exhibit potent tumour suppressor function (Jones, Shaw et al. 2003). 
However, DCIS-associated myoepithelial cells appear to have an altered 
phenotype (Zhang men et al 2003), including up-regulation of the tumour-
promoting integrin αvβ6. The DCIS microenvironment is complex, composed 
of ECM and varied stromal cells types, including fibroblasts, blood vessels, 
adipocytes and immune cells (Polyak and Kalluri 2010).  Inflammatory cells in 
breast cancer have been described as having both pro-tumour and anti-tumour 
effects.  The aim of this project was  to investigate the influence of the change 
in myoepithelial phenotype that occurs during DCIS on the inflammatory 
microenvironment, and to characterize the inflammatory cell infiltrate in ductal 
carcinoma in situ (DCIS) and its potential role in DCIS progression using  a 
combination of immunohistochemistry, in-vitro and in-vivo techniques. 
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7.2 αvβ6 positive DCIS-associated myoepithelial 
cells and the inflammatory cell infiltrate  
 
In an immunohistochemical study, de-novo expression of αvβ6 on 
myoepithelial cells was confirmed in a subset of cases of DCIS.  
Different types of inflammatory cells populations were identified in the DCIS 
microenvironment, including CD4+ve, CD8+ve, CD45RO+ve, CD69+ve, 
FOXP3+ve, MHCII+ve, CD68+ve and arginase+ve cell types. The presence of 
αvβ6 on the myoepithelial cells was significantly correlated with higher levels 
of CD4+ve, FOXP3+ve, CD69+ve and arginase+ve cells, and with low 
numbers of MHCII+ve and CD8+ve cells. Together, these observations suggest 
that αvβ6 expression by DCIS-associated myoepithelial cells may play a role in 
modifying the immune infiltrate, driving it towards a Treg and M2 macrophage 
phenotype.  
To investigate the potential influence of myoepithelial cell expression of αvβ6 
on the inflammatory cell phenotype, two myoepithelial cell lines were used in a 
series of in-vivo and in-vitro models: β4 (αvβ6–ve) and β6 (αvβ6+ve) 
myoepithelial cells. Matrigel plug assays were used in female C57/Blk6 normal 
mice to assess the inflammatory infiltrate in response to β4 or β6 myoepithelial 
cells. Immunohistochemical analysis of these tissues showed that β6 
myoepithelial cells were associated with higher levels of CD4+ve cells, 
compared to β4 myoepithelial cells (p=0.007). The number of FOXP3+ve cells 
was also higher in plugs containing β6 cells compared to β4 cells (p=0.005), 
supporting the findings in human tissue samples.   
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7.3 Role of T cells in progression of DCIS 
 
Man and his colleagues (2007) have suggested that inflammatory cells play a 
role in transition of DCIS to invasive disease. They suggest that internal or 
external injuries such as trauma, inflammation or exposure to some chemicals 
results in disruption of the myoepithelial cell layer with subsequent infiltration 
of inflammatory cells. Thus, these inflammatory cells can lead to further 
degeneration of the myoepithelial cells and basement membrane, resulting in a 
gap that allows direct contact between the tumour tissue and stromal cells (Man 
2007), however the mechanisms by which myoepithelial cells may be lost is 
unclear. The current study has shown that expression of αvβ6 on DCIS-
associated myoepithelial cells is associated with an altered peri-ductal 
inflammatory microenvironment that would contribute to a pro-tumour 
phenotype. One potential mechanism of myoepithelial cell loss could be 
through apoptosis. Therefore, this study hypothesised that loss of the 
myoepithelial layer could be mediated by T-cell derived TRAIL-induced 
apoptosis, and that αvβ6-positive myoepithelial cells may be more susceptible 
to this effect than their negative counterparts.  
7.4 Increased expression of TRAIL 
 
TGF-β has been shown to up-regulate TRAIL expression in primary human 
hepatocytes (Herzer, Grosse-Wilde et al. 2008). It also has been demonstrated 
that TRAIL plays an important role in TGF-β–induced apoptosis in liver tumor 
cells (Herzer, Grosse-Wilde et al. 2008). 
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Therefore, co-culture experiments were performed to investigate whether 
myoepithelial cells could regulate TRAIL expression. The level of TRAIL was 
measured in Jurkat and primary T cell populations following co-culture with β4 
or β6 myoepithelial cells for 48 hrs. This demonstrated primary T cells, but not 
Jurkat T cells, express higher levels of TRAIL when they were co-cultured 
with β6 myoepithelial cells than when co-cultured with β4 myoepithelial cells. 
The lack of response in the established cell line may be a reflection of its 
immortalisation, and the lack of ‘plasticity’ in a cell line, in comparison to 
primary cells.  It has been shown that TRAIL is induced in activated T cells 
and CD69 is considered to be an early marker of T cell activation. In the 
immunohistochemical study on DCIS tissues, we demonstrated higher numbers 
of CD69-positive T cells in the peri-ductal environment of αvβ6-positive 
myoepithelial cells compared to αvβ6-negative ducts. Thus, it is possible that 
up-regulation of αvβ6 can lead to T cell activation. Co-culture studies followed 
by detailed phenotypic analysis of T cells, for example using FACS analysis, 
could address this. Similar studies in our laboratory have shown that αvβ6-
positive myoepithelial cells can modulate macrophage phenotype and 
activation (M Allen, personal communication), making this a plausible theory. 
7.5 Effect of TRAIL on DCIS-associated 
myoepithelial cells 
 
TRAIL mediates its actions through specific TRAIL receptors, DR4 and DR5. 
These receptors have been detected on breast cancer cells and high DR5 
expression is strongly correlated with decreased survival in patients with breast 
cancer (McCarthy, Sznol et al. 2005). The level of both receptors was 
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sigificantly higher in β6 myoepithelial cells compared to β4 myoepithelial 
cells. Unfortunately attempts to measure DR4 and DR5 at the protein level 
were unsuccessful as the antibodies could not be optimised. 
To investigate the effect of TRAIL on myoepithelial cell apoptosis, β6 and β4 
myoepithelial cells were treated with recombinant TRAIL for 2, 4 and 8 hrs, 
after which the cells were analysed for expression of cleaved PARP, as a 
marker of apoptosis. This demonstrated enhanced apoptosis in the β6+ve 
myoepithelial cell line compared to the β6–ve myoepithelial cells at each time 
point. This provides some indirect evidence that β6+ve myoepithelial cells may 
be more susceptible to the effect of Treg cells, but this requires further 
investigation. In addition, exposure of both myoepithelial cell lines to 
Etoposide also demonstrated that β6+ve myoepithelial cells were more 
susceptible to apoptosis compared to β6–ve myoepithelial cells. Therefore, the 
effect is not specific to TRAIL.  
A model for the involvement of altered myoepithelial cell phentoype and 
impact on inflammatory cell infiltrate and myoepithelial apoptosis is indicated 
below.
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7.6 Clinical relevance of myoepithelial cell 
apoptosis 
 
In order to evaluate the clinical relevance of myoepithelial cell apoptosis, a 
series of DCIS samples was assessed for the presence of apoptosis, specifically 
relating to the myoepithelial compartment. Cases were selected that were 
αvβ6+ve with high levels of infiltration with Treg cells, and were stained for 
caspase-3 antigen as a marker of apoptosis. This confirmed positive staining 
for caspase-3 in myoepithelial cells in some of the DCIS ducts.  This provides 
some very preliminary support for the hypothesis that myoepithelial cells may 
be lost through apoptosis however further work is needed to provide definitive 
evidence.  
7.7 Down-regulation of galectin-7 in 
myoepithelial cells and its relationship to αvβ6 
 
It has been shown that normal myoepithelial cells express galectin-7 and its 
expression is altered during breast cancer progression (Demers, Rose et al. 
2010). Therefore, galectin-7 expression was examined in a series of DCIS 
tissue samples, in conjunction with αvβ6 expression in order to investigate the 
relationship between these molecules. In keeping with previous reports, 
galectin-7 expression was found to be limited to the myoepithelial cells in 
normal breast tissue. In DCIS cases there was more variable expression of 
galectin-7. Some ducts entirely lacked expression, others retained 
myoepithelial cell expression, whilst in others the pattern of staining was 
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heterogeneous. When compared to αvβ6 status, there was an inverse 
relationship between the two markers, thus positivity for αvβ6 on myoepithelial 
cells was associated with loss of galectin-7 (p= 0.001). Thus this result may be 
proposed that progression of DCIS to invasive disease is a multi-step process.  
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7.8 Clinical impact of galectin-7 expression in 
DCIS-associated myoepithelial cells 
 
One of the major biological roles played by galectin-7 relates to its modulatory 
effects on apoptosis; while it seems to display pro-apoptotic activity in some 
tumour cell lines (Bernerd, Sarasin et al. 1999, Kuwabara, Kuwabara et al. 
2002), other studies have suggested that galectin-7 may display anti-apoptotic 
effects (Gendronneau, Sidhu et al. 2008, Demers, Rose et al. 2010). 
It has been reported that ectopic expression of Galectin-7 in HeLa cells and in 
the colon carcinoma cell line DLD-1 renders them more susceptible to 
apoptosis induced by actinomycin D and UVB (Kuwabara, Kuwabara et al. 
2002). Similarly, an increase in galectin-7 expression has been demonstrated in 
apoptotic keratinocytes of human skin explants exposed to UVB (Bernerd, 
Sarasin et al. 1999). On the contrary, exposure of skin from wild type (wt) or 
galectin-7-/- adult mice to UVB revealed a twofold increase in apoptotic cells 
in galectin-7-/- compared with wt epidermis at 6 h (Gendronneau, Sidhu et al. 
2008). In the breast, Demers and his colleagues (Demers, Rose et al. 2010) 
suggest that galectin-7 has the ability to render mammary cells more resistant 
to apoptosis. This study demonstrated that the mouse breast cancer cell line 
4T1, when transfected with galectin-7, becomes more resistant to apoptosis 
when exposed to epigallocatechin galatte, a pharmacological agent known to 
induce apoptosis in 4T1 cells (Demers, Rose et al. 2010). Thus, it appears from 
the literature that galectin-7 certainly has a role in apoptosis, and whereas most 
evidence suggests it is pro-apoptotic some models suggest it may be anti-
apoptotic, and this is context-dependent. Therefore, this study aimed to 
investigate whether there was any change in galectin-7 expression in DCIS-
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associated myoepithelial cells, and whether this could influence their response 
to apoptosis-inducing stimuli.  
To further investigate the relationship between αvβ6, galectin-7 and 
susceptibility to apoptosis, β4 and β6 myoepithelial cells were examined for 
expression of galectin-7. This showed reduced expression of galectin-7 in the 
β6 cells. To determine whether galectin-7 has the ability to protect 
myoepithelial cells from apoptosis, galectin- 7 was knocked down in β4 cells, 
which were then exposed to recombinant TRAIL. This demonstrated that the 
β4 cells appeared to be more sensitive to TRAIL when galectin-7 levels were 
reduced compared to non-target control cells. This was measured by western 
blot for cleaved PARP, however, it recognised that further analysis is required.  
7.9 Putative mechanisms to explain the impact of 
αvβ6 on inflammatory cell phenotype  
 
7.9.1 Effect of αvβ6 on phenotype of T cells  
 
We previously have demonstrated up-regulation of αvβ6 on myoepithelial cells 
in a subset of DCIS which is associated with invasive disease (Allen, Thomas 
et al. 2014). We also have observed in this study that there is a correlation 
between the type of inflammatory cell infiltrate in DCIS and the expression of 
αvβ6 on myoepithelial cells.  Expression of αvβ6 on DCIS-associated 
myoepithelial cells is associated with a higher level of CD4+ve cells and a 
lower level of CD8+ cells. Therefore, we investigated the influence of αvβ6+ 
myoepithelial cells on phenotype of inflammatory cells and also investigated 
influence of T cells on myoepithelial cell cytokines.  
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β6 myoepithelial cells were used as a model of αvβ6+ve myoepithelial cells 
and β4 cells were used as a model of αvβ6–ve myoepithelial cells. Both types 
of myoepithelial cells were co-cultured with primary T cells and Jurkat T cells 
for 24, 48 and 72 hrs and the levels of CD4 and CD8 expression were 
measured in the T cells by flow cytometry. No difference in the levels of CD4 
and CD8 were identified between cells co-cultured with β4 cells and those co-
cultured with β6 cells at any time points. This does not reflect the observations 
from the tissue study but is probably a limitation in the study design, since in-
vitro there is no new recruitment of T cell populations. The matrigel plugs 
assays containing β4 cells were associated with lower numbers of CD4+ve 
cells compared to matrigel plugs containing β6 cells, and this supports the idea 
that the environment of β6+ve myoepithelial cells leads to effects on 
recruitment of T cell populations.  
7.9.2 Altered cytokine expression by myoepithelial cells 
 
Myoepithelial cells in DCIS differ from normal myoepithelial cells (Allinen, 
Beroukhim et al. 2004): SAGE (serial analysis of gene expression) was 
employed to identify differences between isolated normal and DCIS-associated 
cell populations and demonstrated that DCIS-associated myoepithelial cells 
exhibited the greatest change in gene expression of all cells in DCIS, including 
up-regulation of certain chemokines such as CXCL14 (Allinen, Beroukhim et 
al. 2004). In order to address whether myoepithelial cells influence the 
inflammatory infiltrate through altered cytokine release, the cytokine profile of 
β6 and β4 myoepithelial cells with or without co-culture with T cells was 
analysed.
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This demonstrated that β6 myoepithelial cells expressed a higher level of IL-1α 
compared to β4 cells. β6 cells also expressed higher levels of IL-5 compared to 
β4 cells, which has been shown to induce CD4 T cells (Hogan, Koskinen et al. 
1998). In addition, β6 cells expressed more of IL-16, which has a role in the 
induction and recruitment of Treg cells (McFadden, Morgan et al. 2007). 
Thus, up-regulation of IL-5 and IL-16 in β6 cells may be one of the 
mechanisms leading to the higher numbers of CD4+ve and FOXP3+ve T cells 
in αvβ6 positive DCIS cases. The cytokine analysis also demonstrated that β6 
cells expressed and released more IFNγ compared to β4 cells, which previously 
has been shown to augment TRAIL-induced apoptosis (Park, Seol et al. 2004). 
These are promising results but ideally the cytokine arrays should be confirmed 
by ELISA and the functional relevance of these cytokines confirmed in co-
culture assays with knockdown. 
7.10 Strengths and Weaknesses of the Study 
 
The strength of this study is that the hypothesis is based on observations made 
in human DCIS tissue, that is, that there is a change in myoepithelial phenotype 
in a subset of DCIS cases, and this correlates with an increased periductal 
inflammatory infiltrate. Also, access to primary cell populations, both 
myoepithelial and T cell, as well as cell lines allowed results to be assessed in 
physiologically relevant systems. 
The study used different approaches to address the same question, in order to 
achieve robust results. Thus, the assessment of inflammatory cell populations 
in human tissues was cross-referenced to in-vivo Matrigel plug assays. 
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Furthermore, the functional impact of molecules was analysed using both 
knock-down and over-expression systems, also providing more robust data. 
The main weakness of the study lies in sample numbers, and this should be 
addressed in future work. 
Also, the Matrigel plug assays, although a potentially powerful approach to 
directly measure the impact of myoepithelial phenotype on inflammatory 
populations, were very difficult to interpret owing to high levels of 
background. 
7.11 Recomondation  
 
One of the most challenging areas of the study was quantifying the number of 
positive inflammatory cells in the Matrigel plugs sections because of the 
background staining. Therefore, it will be recommended that considerable 
effort should be made to improve the Matrigel plug technique in order enhance 
staining.  
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8.0 Summary and Conclusion 
8.1 Influence of DCIS-associated myoepithelial 
cell phenotype on inflammatory cell infiltrate 
 
This study has shown that there is a correlation between the inflammatory 
infiltrate in DCIS and expression of αvβ6 integrin by myoepithelial cells. The 
important findings are summarised below.  
 It has shown higher infiltration of regulatory T cells, as determined by 
CD4 and FOXP3, in αvβ6+ve DCIS cases compared to αvβ6-negative 
cases.  
 It also has demonstrated that the αvβ6+ve DCIS cases are associated 
with higher numbers of TAMs compared to αvβ6-ve DCIS cases.  
 Overall, analysis of DCIS tissue suggests that the DCIS 
microenvironment contains high infiltration of CD4+ve T cells. The 
number of FOXP3 + cells and arginase-1+ cells indicates they are a 
minor inflammatory cell population in DCIS, whilst MHCII cells 
numbers are very low in αvβ6+ve but represents the second dominant 
cell population in αvβ6-ve cases.  
 In addition, the in-vivo study has also shown a direct link between 
myoepithelial phenotype and inflammatory infiltrate, as indicated by a 
positive correlation between the numbers of CD4 and FOXP3 cells and 
up-regulation of αvβ6.  
                                                                                  Chapter 8 Summary and Conclusion 
 
264 
 
In conclusion, this work demonstrated that there is variation in the extent and 
nature of the inflammatory infiltrate in DCIS and this is influenced by 
myoepithelial cell phenotype.   
8.2 Impact of up-regulation of β6 on DCIS-
associated myoepithelial cells on T cell TRAIL 
levels  
 
 This work has shown that up-regulation of β6 in DCIS-associated 
myoepithelial cells promotes enhanced TRAIL expression in primary T 
cells  
  β6 myoepithelial cells express higher levels of DR4 and DR5  (TRAIL 
receptors ) RNA compared to β6-ve myoepithelial cells.  
8.3 Role of T cells in progression of DCIS   
 
 Expression of β6 by myoepithelial cells appears to increase their 
sensitivity to TRAIL induced apoptosis.  
 Knockdown of galectin-7 in a myoepithelial cell line increases their 
sensitivity to apoptosis mediated by TRAIL.   
 Cleaved caspase-3, a marker of apoptosis, has been detected in 
myoepithelial cells of αvβ6 positive DCIS cases highly infiltrated with 
T cells. 
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8.4 Altered myoepithelial cell phenotype during 
DCIS  
 
 This study has demonstrated that galectin-7, expressed by myoepithelial 
cells in normal breast, is down-regulated in a sub-set of DCIS. 
 An inverse correlation is evident between galectin-7 and αvβ6 
expression in myoepithelial cells as demonstrated by duct-duct 
analysis.  
Thus it may be proposed that there is evolution of DCIS in a multi-step 
manner towards a phenotype likely to progress to invasive disease. 
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9.0 Future directions 
 Knockdown of galectin-7 and over-expression of αvβ6 in primary 
myoepithelial cells has been successfully achieved. These primary 
myoepithelial cells will be used as another model to investigate our 
hypothesis and extend the work beyond myoepithelial cell lines. 
  Specific caspase-3 staining has been detected in myoepithelial cells of 
αvβ6 positive DCIS cases. To assess the relationship between galectin-
7, αvβ6 expression and apoptosis of myoepithelial cells, double staining 
for galectin-7 and caspase-3 or αvβ6 and caspase-3 will be applied to a 
wider series of DCIS samples. 
 Further functional assays to establish the role of altered myoepithelial 
cytokine profile would be undertaken, specifically knockdown of IL-5 
and IL-16.  
 Finally, the study will be extended to include earlier stages of disease, 
including hyperplasia and atypical hyperplasia, in order to establish at 
what stage changes in galectin-7 and αvβ6 molecules occur and to 
investigate this multi-stage hypothesis of breast cancer. 
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Together, these experiments aim to determine some of the mechanisms 
involved in the disruption and loss of the myoepithelial cell population in DCIS 
that may promote progression to invasive disease. 
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                                   Appendix 1   
 
1.1 Mycoplasma PCR 
1) Culture Supernatant 
I. Collect supernatant and centrifuge. 
II. Discard excess and leave behind 500µl. 
III. Flick tube  resuspend debris. 
2) PCR  
(GPO1)  FWd 1 ACT CTT ACG GGA GGC AGC AGT A 
(GPO2) Fwd 2   CTT AAA GGA ATT GAC GGG AAC CCG  
(GPO3) Rev      TGC ACC ATC TGT CAT TCT GTT AAC CTC    
 
1 
ist  
Round – Band at 720bp 
Culture supernatant                                 1µl 
GPO1 Forward Primer 1 (10 uM)           1µl 
MGSO Reverse Primer (10 uM)             1µl 
Formamide                    0.5µl 
Megamix                     16.5µl 
 
Cycling condition 
              95
°
C X 30s 
              95
°
C X 30s  
              55
°
C X 30s                  35 cycles  
              72
°
C X 1 min   
              72
°
C X 1 min   
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2
nd
   Round- Band at 145bp    
 1 
ist  
Round  PCR product                        1µl 
GPO1 Forward Primer 1 (10 uM)           1µl 
MGSO Reverse Primer (10 uM)              1µl 
Formamide                     0.5µl 
Megamix                      16.5µl 
                                                                     
1.2  1X  RIPA Buffer 
20 mM Tris-HCl (pH 7.5) 
150 mM NaCl,  
1 mM Na2EDTA 
1 mM EGTA 
1% NP-40 
1% sodium deoxycholate 
2.5 mM sodium pyrophosphate 
1 mM b-glycerophosphate 
1 mM Na3VO4 
1 μg/ml leupeptin. 
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 1.3 SDS–polyacrylamide gel                                                            
                                                       8%                            12%  
22.2% Acrylamide/0.6% Bis                10.81 mls                            7.21 mls 
1M Tris/HCl pH=8.8                             7.5 mls                               7.5 mls      
Distilled water                                       1.38 mls                             4.99 mls 
10% SDS                                                 200µl                                200µl 
10% Ammonium Persulfate                   100µl                                  100µl 
TEMED                                                   10µl                                     10µl 
1.4 Stacking gel  
22.2% Acrylamide/Bisacrylamide           2.2ml 
Distilled Water                                           6.6ml 
1M Tris/HCl pH=6.8                                  1.25ml 
10% SDS                                                     100µl 
10% Ammonium Persulfate                        50µl 
TEMED                                                        50µl
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1.5 SDS-PAGE: Running buffer 
Contents                                         weight                                          final 
concentration  
TRIS base                                        15.15 g                                         25Mm 
Glycine                                             72g                                                192Mm 
SDS                                                    5g                                                 0.1% 
(w/v) 
Distilled water                                   5liters  
1.6 SDS- PAGE:  Transfer buffer 
Contents                                         volume                                     final 
concentration  
Triglycin                                           25 ml                                       8% 
Methanol                                          50ml                                         25% 
Distilled water                                 250ml                                
 
1.7 RNA extraction  
1. Cell pellet was collected by centrifugation and resuspended in 600 µl of 
ZR RNA Buffer.  
2. Then, the cell pellet was vortexed  for few seconds and transferred to 
Zymo-Spin III C column in a collection tube and centrifuged for  at 
12.000 rpm for 1 minute. 
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3. The flow- through was discarded and 400 µl RNA pre-wash Buffer was 
added to the column and centrifuged at 12.000 rpm for 1 minute.  
4. The flow-through was discarded and 700 µl of RNA wash Buffer was 
added and centrifuged at 12.000 rpm for 30 seconds. Then, the flow-
through was discarded and this step was repeated with 400 µl of RNA 
wash Buffer.  
5. Then, the column was placed in a new collection tube and centrifuged 
at 12.000 rpm for 2 minutes to ensure complete removal of the wash 
Buffer.  
6. The column placed into  an RNase-free tube, 35 µl of DNase/ RNase-
free water was added directly to the column and incubated at room 
temperature for 1 minute then centrifuged at high speed for 30 seconds. 
Eluted RNA was used immediately or stored at < 70
ο 
C    
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                               Appendix 2  
Source of reagents 
             Product  Source  
A   
Acetic acid  Sigma, UK 
Acrylamide  Invitrogen, UK 
Acrylamide gel  Invitrogen, UK 
Ammonium acetate Sigma, UK 
APC National Diagnostics, UK 
Avidin biotin complex (ABC) Dakocyomation, UK 
B  
β-actin Sigma, UK 
BioRad DC protein assay kit (Reagent 
A, Reagent B and Reagent C) 
BioRad, UK 
C  
C57/BlK6 mice Harlan 
Calcium chloride  Sigma, UK 
CD40L ELISA  R & D, UK 
Centrifuge tube  BD, UK 
Chemiluminescence  film Amersham, UK 
Coverslips CR-UK 
Cryotubes BD,UK 
D  
DAP Sigma, UK 
Distilled water ( dH2O) CR-UK 
                                                                                                             Appendices 
 
316 
 
DMEM Sigma, UK 
DMSO Laboratory supplies, UK 
DNAse (RNAse free water) Promega,UK 
DPX (Mountant) VWR International  
E  
ECL plus Western Blotting Detection 
System  
Amersham Bioscience, UK 
EDTA  Sigma, UK 
EGF Sigma, UK 
Eosin  Sigma, UK 
Ethanol Fischer Scientific, UK 
Etoposide chemotherapy Sigma, UK 
F  
FBS (heat inactivated) Marathon laboratories,UK 
Flow cytometery tube  BD, UK 
Formalin saline  CR-UK 
G  
L-glutamine CR-UK 
H  
H&E Sigma, UK 
Haemocytometer Fischer Scientific, UK 
Ham’s F12 Sigma, UK 
Hydrogen peroxidase Fischer Scientific,UK 
Hydrocotisone  Sigma, UK 
I  
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IgG isotype control antibody  Sigma, UK 
Insulin  Sigma, UK 
M  
Matrigel  BD, UK 
Methanol  Fischer Scientific, UK 
Milk powder  Marvel  
N  
Nitrocellulose filter  Pall Life Science, UK 
Nunc EASY Flask T75 (75cm
2)
 plastic 
culture flasks 
Sigma 
P   
PAP pen  Zymed,UK 
PBS  CR-UK 
PCR-grade water Sigma, UK 
Pepsin  Invitrogen, UK 
PI (propidium iodide) Calbiochem, UK 
Plates for culture  BD, UK 
Ponceau S solution  Sigma, UK  
Power Syber green PCR Master  Mix  Applied Biosystem  
Protease inhibitor cocktail Calbiochem, UK 
R  
Rabbit anti-mouse IgG Dyanbeads Invitrogen, UK   
Resolving buffer  National Diagnostics, UK 
Recombinant TRAIL  Peprotech,UK 
RIPA buffer  Millipore, USA 
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RPMI medium Sigma, UK 
S   
SDS  Qiage,UK 
Sodium chloride  Sigma, UK 
T  
TRAIL ELISA  R& D, UK  
TBS (TRIS-buffered saline ) CR-UK 
TEMED  National Diagnostics, UK 
Trypan  Blue Sigma, UK 
Trypsin/EDTA  CR-UK 
Tween  Sigma, UK 
W  
Whatmann paper / sponges Invitrogen, UK 
X  
X –ray film  GE healthcare,UK 
Xylene  Fischer Scientific, UK 
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                               Appendix3 
           Presentations 
 
1- Khairiya Ahmed, Michael Allen, John Marshall, J Louise Jones 
Changes in the microenvironment of DCIS: the relationship between 
altered myoepithelial cell phenotype and inflammatory infiltrate, 
William Harvey day 2010. 
 
2- Khairiya Ahmed, Michael Allen, Jenny Gomm, John Marshall, J Louise 
Jones 
Myoepithelial control of the inflammatory microenvironment promotes 
transition of DCIS to invasive disease, William Harvey day 2012. 
 
3- Khairiya Ahmed, Michael Allen, Jenny Gomm, John Marshall, J Louise 
Jones 
T regulatory cells in the DCIS microenvironment induce myoepithelial 
apoptosis: a role in transition of DCIS to invasive disease? Keystone 
Symposia conference (The Role of Inflammation during Carcinogenesis 
conference), Dublin, Ireland 2012. 
   
4- Khairiya Ahmed, Michael Allen, Jenny Gomm, John Marshall, J Louise 
Jones 
Myoepithelial control of the inflammatory microenvironment promotes 
transition of DCIS to invasive disease, ESMO, IMPAKT Breast Cancer 
conference Brussels, Belgium 2012.  
 
5- Khairiya Ahmed, Michael Allen, Jenny Gomm, John Marshall, J Louise 
Jones 
 Changes in the microenvironment of DCIS: the relationship between 
altered myoepithelial cell phenotype and inflammatory infiltrate, 
William Harvey day 2013. 
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